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CHAPTER I
Introduction to the Problem
Mild cognitive impairment (MCI) is a mild decline in a single domain or
multiple cognitive domains. Although MCI usually causes cognitive changes that are
noticeable by the individual and/or caregivers, the global cognition and activities of
daily living (ADL) usually remain intact. However, the cognitive changes associated
with MCI are generally not severe enough to interfere with the daily life and
independent functions o f the patient. While patients with MCI are more likely to
develop Alzheimer’s disease or other dementias than patients without MCI, a diagnosis
o f MCI does not always indicate that the patient will develop Alzheimer’s disease or
dementia. MCI may resolve, and the patient’s cognitive exam may return to normal
baseline or remain stable without progression. Symptoms o f MCI are classified based
on the thinking skills affected. MCI that affects memory is known as amnestic MCI. In
the case o f amnestic MCI, a patient may start to forget important information that he or
she could previously recall easily, such as appointments or recent conversations. MCI
that affects thinking skills other than memory is known as non-amnestic MCI. Thinking
skills possibly affected with this type o f MCI include the ability to make sound
decisions, judgment o f time, judgment o f the sequence to complete complex tasks, or
visual perception (Alzheimer’s Association, 2013). The most recently developed
diagnostic criteria for MCI is the pre-dementia phase o f Alzheimer’s disease.
Patients diagnosed with MCI usually have more difficulty and may take longer
than their normal counterparts in performing cognitively demanding instrumental ADL.
Activities that may be affected include shopping, driving, medication regimen, food

preparation, and handling finances. In older adults with MCI, even small subtle
declines in cognitive abilities are associated with decreased independence and safety,
increased caregiver burden, a decreased chance o f reverting to normal cognitive status,
and increased likelihood of developing dementia (Lin, Vance, Gleason, & Heidrich,
2012). Although the causes o f MCI are not completely understood, experts believe that
early screening and diagnosis slow disease progression.
Background of the Problem
More than 16 million people in the United States live with some form of
cognitive impairment. The greatest risk factor for cognitive impairment is age. As the
baby boomer’s generation passes the age of 65 years, the number o f people living with
cognitive impairments is expected to increase dramatically. With an estimated 5.1
million Americans who are diagnosed with Alzheimer’s disease and are 65 years o f age
or older, Alzheimer’s disease is the most common type and the most well-known form
o f cognitive impairment. The projected increase o f this disease incidence is 13.2
million by the year 2050 (CDC, 2011), resulting in a higher demand on the healthcare
setting. The increasing economic burden and growing demand for care related to
cognitive impairment will pose a serious challenge to the community, the state, and the
nation. Apart from increased societal economic burdens, higher numbers o f family
members aiding in the care o f the affected patients will experience greater demands—
causing caregiver burnout. Currently, over 10 million family members provide care to a
patient with a cognitive impairment.
Age is the primary risk factor for cognitive impairment. Other risk factors
include family history, brain injury, education level, and other chronic

conditions. Other possible causes o f MCI in older adults include medication side
effects, metabolic and/or endocrine disorders, depression, dementia, and Alzheimer’s
disease. While some o f these causes, such as medication side effects and depression,
can be reversed with treatment; others, such as Alzheimer’s disease, cannot be reversed.
However, with early detection and diagnosis, symptoms can be treated, and families can
be educated on the predictive cognition changes.
Patients who are developing cognitive impairment or who have dementia usually
do not receive a formal diagnosis. In a review of literature, one study indicated that
most primary care providers were unaware of cognitive impairments in more than 40%
o f their cognitive impaired patients. Another study revealed that > 50% o f patients with
dementia received no clinical cognitive screening by a primary care provider. The
failure to evaluate for cognitive complaints is more likely to hinder the treatment o f any
underlying disease and comorbid conditions as well as to prevent safety issues for the
patient and others. In most cases, cognitive impairment will worsen over time (National
Institute for Learning [NIA], 2014). Providers who conduct early screening on patients’
age 65 years or older are better able to identify emerging cognitive deficits, pinpoint
possible causes, and develop an appropriate plan o f care. Identifying patients who
exhibit signs of cognitive impairment and taking appropriate steps to address their
issues results in a positive impact on the patient, the community, and the state (NIA,
2014).
Recommendations for routine cognitive assessment screenings in older adults
vary and continue to evolve. The U.S. Preventive Services Task Force (USPSTF)
developed guidelines that recommend cognitive screening in asymptomatic patients.

since the overall benefits have been reflected to outweigh the overall cost and risk
(USPSTF, 2015). The USPTF identified screening tools that successfully identify
people with early stages o f dementia. Currently, the amount o f evidence-based research
is inadequate to determine whether screening all older adults is beneficial (see
Appendix B). However, minimal evidence was found to support any potential harm in
screening for cognitive impairment.
The Centers for Medicare and Medicaid Services (CMMS) recommends
including cognitive assessment screenings for early detection o f MCI as part o f the
requirements o f the annual wellness visit for older adults age 65 years or greater. Even
though the CMMS recommends cognitive screenings annually, it does not specify what
screening approach to use. The Alzheimer’s Association recommends brief assessment
tools o f cognition that involve memory as well as formal interviews (see Appendix C).
Patients who test positive for cognitive impairments are referred for a more
comprehensive evaluation. The evaluation can be at a subsequent visit with a primary
care provider or specialty clinician (Grober, Wakefield, Ehrlich, Mabie, & Lipton,
2017).
Routine cognitive assessment will eventually become the standard o f care as a
screening strategy to improve and better manage effective treatment regimens.
Treatment and other preventive measures, as they emerge, will be integrated into
primary care clinics where much o f the older adult population receives their healthcare.
Screening tools and case findings will be essential in implementing treatment regimens,
thereby allowing adults to benefit from early detection and diagnosis (Grober et al.,
2017). The overall evidence of routine cognitive screenings is insufficient. However,

several important reasons exist to screen and identify early mild cognitive impairments.
Early detection has the potential to help patients make treatment decisions, including
the treatment o f reversible causes o f dementia and the management o f comorbid
conditions. Early detection o f mild cognitive impairments allows primary care
providers to anticipate problems that the patient may have in understanding and
adhering to recommended treatment regimens. Early detection also gives caregivers
and family members the opportunity to begin planning for future problems that may
result from the progression o f cognitive impairment. Even though the overall evidence
concerning routine screening is insufficient, providers should always remain aware of
the early signs and symptoms o f cognitive impairment and should evaluate for
treatment.
The National Institute o f Aging (NIA) has educational information available on
the screening and detection o f mild cognitive impairments for patients and primary care
providers. This educational information includes a database o f detection tools to screen
and help detect mild cognitive impairments. This collection o f statistical data,
guidelines, recommendations, and objectives accentuates the fact that MCI is a
progressive cognitive disease with the potential to adversely affect both the health o f the
patient and the overall healthcare system. Primary care providers, including nurse
practitioners and advanced practice nurses, have the potential to take an aggressive
approach to MCI detection and treatment by adhering to USPSTF recommendations.
Statement of the Problem
Dementia affects from 2.4 to 5.5 million Americans. Dementia’s prevalence
increases with age by 5% in persons aged 71-79 years, 24% in those aged 80-89 years.

and 37% in those older than 90 years o f age. Mild cognitive impairment is different
from dementia in that mild cognitive impairment is not severe enough to interfere with
instrumental ADLs. Various forms of cognitive impairment differ in their impact on the
daily functions o f older adults. To ensure and maintain the patient's ability to perform
independent ADLs, routine testing for declining mental functions must be completed
and is mandated by the U.S. Government. The lack o f consistent cognitive screenings
increases the patient’s chances o f late diagnosis as well as possible detrimental effects
and/or events.
Purpose of the Study
The purpose o f this study was to determine primary care providers’ adherence to
USPSTF (2015), and the Alzheimer’s Association’s (2013) recommendations and
guidelines advocating annual cognitive impairment screening on patients ages 65 years
and older. The Alzheimer’s Association issued an algorithm for detecting cognitive
impairment in older adults; this cognitive assessment algorithm was accepted and
mandated by U.S. Centers for Medicare and Medicaid Services during annual wellness
visits o f patients 65 years and older. In addition to the Alzheimer’s Association,
USPSTF acknowledges the increasing prevalence of cognitive impairment and the
benefits o f early detection. However, USPSTF argues a lack o f research and
information on the subject; to which, the current study attempted to aid the increasing
data on cognitive screening in older adults (USPSTF, 2014). This study examined the
amount o f primary providers’ compliance in completing cognitive impairment
screenings o f older adults, probable barriers decreasing provider adherence of
implementing annual cognitive testing o f older adults, and the preferred methods and

tools utilized for cognitive impairment screening o f those adults ages 65 years and
older.
Significance of the Research Project
With increasing advances in healthcare, people are living longer, but ironically
their quality o f life is diminishing. Over 5.1 million Americans over the age o f 65 years
are estimated to be living with some form o f cognitive impairment— not including
undiagnosed individuals. Along with other comorbidities commonly accompanying the
geriatric population, cognitive impairment (i.e., Alzheimer’s disease, mild cognitive
impairment, and other forms o f dementia) heavily burdens patients, patients’ families,
caregivers, the healthcare system, and the U.S. Government. In 2007, the U. S.
Department o f Health and Human Services, the CDC found approximately $647 million
as the average cost for a government-funded (i.e., Medicaid) nursing facility to
adequately care for an individual with Alzheimer’s disease (Wiese & Williams, 2015).
Wanting to prevent future federal bankruptcy and improve the quality o f life for
individuals diagnosed with age-related dementias, as well as their families and
caregivers, the U.S. Government mandated cognitive screenings o f older adults during
annual wellness visits (CDC, 2011).
In 2011, the CDC, the Centers for Medicare and Medicaid Services, the Agency
for Healthcare Research and Quality, and the Administration on Aging branch o f the
United States Department o f Health and Human Services collaborated to combat the
overwhelming burden o f age-related dementias (Wiese, Williams, & Tappen, 2014).
With efforts to increase early diagnosis and treatment o f age-related dementias, the U.S.
government initiated the National Alzheimer’s Project Act, which required routine
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cognitive screening o f adults over the age of 65 years (Wiese, Williams, & Tappen,
2014). Over 5 years after the initiation o f new guidelines warranting cognitive
screening o f older adults over 65 years, three questions justified investigation:
1. Do primary healthcare providers in Mississippi conduct mild cognitive
impairment screenings on older adults, and, if so, how often?
2. What provider-generated barriers may decrease the likelihood of cognitive
impairment screening in older adults during visits with primary care
providers?
3. What screening methods do primary care providers use to detect mild
cognitive impairments?
The current study attempted to answer these questions. Guided by Nola
Pender’s theoretical framework and concepts as proposed in her Health Promotion
Model, this study surveyed numerous primary care providers to discern the prevalence
o f adequate screening for detection o f cognitive impairment in older adults. The current
study also raised awareness and promoted the necessity o f annual cognitive screening o f
patients ages 65 years and older.
The CDC, the Alzheimer's Association, the Centers for Medicare and Medicaid
Services, and the Administration on Aging Branch o f the United States Department o f
Health and Human Services collaborated to produce the Healthy People 2020 initiative,
which specifically addresses the need for improvement in the detection and treatment o f
cognitive impairment in older adults (Wiese & Williams, 2015). With a lack o f nursing
research studies comparable to the current study, no recent evidence documented the

number of primary-care providers screening older adults to increase early detection of
cognitive impairment in older adults.
Wiese and Williams (2015) composed a literature review to inform nurses o f the
current policies, tools, and benefits o f annual cognitive assessments for older adults.
From licensed practical nurses to advanced practice nurses, many nurses are unaware of
the national screening guidelines and the benefits regarding cognitive assessments of
the geriatric population. Many nurses are also unaware that such screening is within
their scope o f practice. The results o f the current research study contributed to an
increase in nursing knowledge o f age-related dementia screening and nursing education
in the importance o f annual cognitive screening in older adults. These results promoted
additional nursing research o f early cognitive impairment detection in older adults and
identified the most valid cognitive screening tools.
Conceptual Framework
Nola Pender's Health Promotion Model (HPM) served as the guideline for the
theoretical framework for the research o f the annual cognitive screenings in older
adults. Presented in the 1980s, Pender integrated psychological, educational, and
nursing concepts and theories to formulate her Health Promotion Model. The HPM is
similar to Becker’s Health Belief Model in the promotion of disease prevention.
However, the HPM differs fi-om Becker’s model in that it does not include negative
factors, such as fear or threat, as a source o f motivation for health behavior. Pender’s
desired outcome from the HPM is that a person will have health-promoting behaviors,
which will affect overall health, fimctional ability, and quality o f life. The HPM theory
notes patients have a unique set o f experiences and characteristics that directly affect
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their behaviors related to health. Pender takes a holistic view o f not only the physical
health o f the patient, but also the surrounding factors that might influence the outcome
o f the patient’s well-being. As a nursing-based theory, Pender’s theoretical framework
integrates key concepts o f the nursing metaparadigm: person, health, environment, and
nursing. Pender defined the concept o f person as the focal point o f the HPM
(McCutcheon, Schaar, & Parker, 2016). Pender defined environment as the physical,
social, and cultural surrounding, which can be manipulated to facilitate healthpromoting behaviors. Health is described as a subjective, evolving experience
throughout an individual’s lifespan. The HPM considers nursing responsible for linking
the person and environment to promote behavior changes leading to optimal health
(Pender, 2011). Pender incorporated these fundamental nursing concepts to formulate
the proposition and assumptions o f the HPM.
The HPM suggests behaviors affecting positive or negative health promotion
and outcomes are controlled by various internal and external factors (Sakraida, 2014).
In Pender’s article explaining the HPM and its application to healthcare, she discussed
the major theoretical conceptions o f the HPM. The following key terms are defined for
the purposes o f understanding the HPM in relation to the present study:
1. Health-promoting behavior - an action directed towards promoting and
maintaining positive health outcomes.
2. Prior-related behavior - the fi-equency o f a past behavior that directly or
indirectly affects health-promoting behaviors.
3. Personal factors - sociocultural, psychological, and biological characteristics
(i.e., age, race, socioeconomic status, etc.) influencing healthy behaviors.
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4. Perceived benefits o f action - an anticipated benefit o f accomplishing a
behavior.
5. Perceived barriers to action - perceptions or actual blocks inhibiting
performing health-promoting behaviors.
6. Perceived self-efficacy - personal confidence in successfully performing a
behavior.
7. Activity-related affect - subjective feelings o f negativity or positivity
proceeding, during, or following a health-promoting behavior; and directly
affects perceived self-efficacy in that an individual is less likely to be
confident in a behavior with subjective feelings o f negativity.
8. Interpersonal influences —the views, expectations, support, etc. received
from family, healthcare providers, peers, etc. which influence an individual’s
perception o f a particular healthy behavior.
9. Situational influences —personal thoughts and perceptions o f an impending
behavior regarding aesthetics, additional options, and current environmental
demands.
10. Commitment to a plan o f action - personal dedication to initiation o f a
health-promoting behavior.
11. Immediate competing demands and preferences - various responsibilities or
personal demands, which an individual may have greater or lesser amount of
control over, that affects completing a health-promoting behavior (i.e.
healthy diet, employment responsibilities). (Pender, 2011, p. 12).
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In one o f her first research studies on the correlation o f behavior to enhancing
health promotion, Pender found that many individuals would utilize preventative and
health-promoting services when made available in their community. In her study,
Pender surveyed hundreds o f men and women between the ages o f 20 and 90
concerning their thoughts on utilizing preventative and health-promoting services
administered by a nurse practitioner. Although the research focus was on the behavioral
influences affecting the utilization o f nurse practitioners as opposed to physicians, the
study found most o f the sample population agreed to partake in health-promoting
services when offered by any healthcare provider (Pender & Pender, 1980). This
finding would later become the HPM ’s theoretical claim stating, “Families, peers, and
healthcare providers are important sources o f interpersonal influence that can increase
or decrease commitment to and engagement in health-promoting behaviors” (Pender,
2011, p. 5). The current research study addressed the significance o f healthcare
provider commitment to and engagement in positive healthcare outcomes, especially
regarding cognitive screening in older adults.
Many nursing researchers have based and tested their studies with Pender’s
HPM. McCutcheon et al. (2016) integrated the HPM into their study o f college-aged
males’ behaviors in preventing human papillomavirus (HPV). McCutcheon et al.
(2016) suggested most health preventive models were deficient and focused on fear as
an incentive, whereas Pender’s HPM emphasized positive methods to initiate and
maintain health-promoting behaviors.
The HPM’s theoretical claims and basis in advancing human potential closely
align with the present study o f early detection o f cognitive impairment in older adults.
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The HPM theoretical statements suggest individuals are more likely to increase desired
behaviors when perceived beneficial or deemed efficient— allowing the individual to be
perceived as competent (Pender, 2011). For primary healthcare providers, the perceived
benefit to action would be earlier diagnosis and treatment o f age-related dementias, to
which the provider would enhance his or her competency in secondary preventative and
health-promoting services. For primary providers not performing cognitive screenings,
the perceived barriers to action may include various forms o f activity-related effects,
such as inexperience with using cognitive screening tools, length o f examination, lack
o f time to perform cognitive screening in addition to other exams, or inadequate
reimbursement for cognitive screenings. These activity-related effects, as stated in the
HPM, are directly affected by the providers’ perceived self-efficacy. By surveying the
frequency o f cognitive screening o f older adults in the primary care setting and
surveying the primary care provider’s perspective on the lack o f cognitive impairment
screening, this study attempted to identify the perceived barriers and perceived selfefficacy to promote a positive behavioral change. As recommended in Pender’s HPM,
primary healthcare providers were allowed to observe the data identifying the lack of
and importance o f cognitive screening in older adults, to which implementation o f
routine cognitive screenings would begin to increase.
This current study utilized the HPM as a guide to identifying the perceived
barriers to action and perceived self-efficacy o f primary providers’ non-adherence to the
national guidelines requiring annual cognitive screening o f older adults. Through
surveying primary care providers, this study incorporated the theoretical assumptions
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and propositions o f the HPM to promote compliance with the national standard of
routine cognitive screening in the geriatric population.
Research Questions
In order to guide data collection regarding primary care providers’ adherence to
screening recommendations and guidelines, the following research questions were
formulated:
1. Do primary care providers in Mississippi conduct mild cognitive impairment
screenings on older adults; if so, how often?
2. What provider-generated barriers may decrease the likelihood o f cognitive
impairment screening in older adults during visits with primary care
providers?
3. What screening methods do primary care providers use to detect cognitive
impairments?
Definition of Terms
Primary care providers
Theoretical: Primary care providers are healthcare professionals who serve as
the first contact a patient makes with the healthcare delivery system and act as the
principal point o f continuing care for established patients by coordinating specialty care
and other services a patient may need (American Academy o f Family Physicians
[AAFP], 2014).
Operational: For the purpose o f this study, primary care providers are
physicians, nurse practitioners, physician assistants, or other medical practitioners who
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render primary care to older adults over the age o f 65 years and respond to the webbased survey.
Mild cognitive impairment
Theoretical: Mild cognitive impairment is an intermediate stage between the
expected cognitive decline o f normal aging and the more serious decline o f dementia
("Mayo Clinic," 2016).
Operational: For the purpose o f this study, mild cognitive impairment is defined
as a mild decline in a single domain or multiple cognitive domains, and it indicates a
significant risk o f progression to dementia or Alzheimer’s disease in patients older than
65 years.
Older adult
Theoretical: Any patient that is > 65 years o f age who receives medical
treatment (“Patient,” 2016).
Operational: For the purpose o f this study, the older adult is defined as a selfidentified person over the age o f 65 years who receives care from a primary care
provider choosing to participate in this study by responding to the web-based survey.
Screening method
Theoretical: Screening is defined as a preliminary procedure, such as a test or
examination, to detect the most characteristic sign or signs o f a disorder that may
require further investigation (“Screening,” n.d). A method is defined as means or
manner o f procedure, especially a regular and systematic way o f accomplishing
something ("Method," n.d.).
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Operational: For the purpose o f this study, screening methods included any
documented evidence o f mild impairments including, but not limited to, written
questionnaires, oral questions, health history, screenings, or electronic medical records
(EMR).
Provider-Generated Barriers
Theoretical: Provider is defined as any individual, institution, or agency that
provides health services to healthcare consumers (“Mayo Clinic,” 2016). Generated is
defined as brought into existence, produced, or originated (“Generated,” 2018).
Barriers is defined as a factor that tends to restrict the free movement, mingling, or
interbreeding o f individuals or populations (“Barriers,” 2018).
Operational: For the purpose o f this study, provider-generated barriers are any
factors originating with the provider that restrict the likelihood that the provider will
screen for mild cognitive impairments in older adults.
Assumptions
For the purpose o f this study, the following assumptions were made:
1. Due to the anonymity o f the survey, the researchers assumed participants
were honest about their current practices and thoughts regarding cognitive
impairment screening o f older adults.
2. In utilizing healthcare providers (i.e., physicians, nurse practitioners, and
physician assistants) within the primary care setting, the researchers
assumed all participants had adequate and equivalent professional and
educational competencies regarding healthcare within the geriatric
population
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3. Participants who agreed to participate in the current study were not coerced
or awarded incentives to encourage participating in this research study.
4. The researchers assumed the sample population of primary care providers
assessed a uniform number o f older adults in each o f their facilities.
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CHAPTER II
Review of Literature
The purpose o f this study was to determine primary care providers’ adherence to
the recommendations established by the United States Preventive Services Task Force
(USPSTF) (2014) and the guidelines published by the Alzheimer’s Association (2013).
The USPSTF is an independent group o f national experts in evidence-based practice
and prevention measures that work to improve health by making evidence-based
recommendations about clinical preventive services, such as screenings for the early
detection o f mild cognitive impairment. According to the USPSTF, “This
recommendation applies to universal screening with formal screening instruments in
community-dwelling adults in the general primary care population who are older than
age 65 years and have no signs or symptoms o f cognitive impairment” (USPSTF, 2014,
p. 1). The Centers for Medicare and Medicaid Services (CMS) amended its
recommendations for annual wellness visit (AWV) effective January 1, 2011. The
amendment included guidelines for what is included in the AWV. According to the
CMS website, “the following services to an eligible beneficiary by a health professional
. . . detection o f any cognitive impairment that the individual may have” (CMS, 2011, p.
2). With cognitive screening covered in the AWV, the Alzheimer’s Association
published the Cognitive Assessment Toolkit (see Appendix E) as a guideline to help
providers assess mild cognitive impairment quickly and efficiently {Cognitive
Assessment Toolkit^ n.d.). This chapter introduces the theoretical framework, presents a
review o f literature in reference to the present study, and further includes
summarizations o f work by Nola Pender and other research based on the HPM.
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Theoretical Framework
According to Nola Pender, her Health Promotion Model is driven by the desire
to increase well-being to foster human potential (Pender, 1996). Using the HPM as a
guideline for the present study was advantageous, as it aligned the researchers to focus
on the overall well-being and potentiality o f patients with mild cognitive impairment.
At the start o f the study, there was no cure o f MCI, but there was opportunity to prevent
further losses through medication, lifestyle, and behavioral modification. In
recognizing MCI earlier, rather than later, providers were better able to prepare the
patient and family for the advancement o f the disease and for the modifications to the
patient’s environment and treatment. In so doing, the provider helped create the best
possible outcome for all affected. For example, early in diagnosis, the provider might
have connected the family to resources to help enhance the patient’s nutrition through
education o f meal planning and preparation, daily caloric goals, and ease o f availability
o f food and services. If the patient and family would have had a nutritional plan in
place as the disease progresses, the patient would experience overall better health and
wellness due to his or her optimal nutritional status. By using the HPM as a guideline
to the study, the researchers were able to use a holistic view o f the patient and healthpromoting strategies to formulate appropriate assumptions and create effective methods
o f study to promote early recognition o f MCI and anticipate difficulties that could
hinder understanding and adherence to a treatment program.
Kelley, Sherrod, and Smyth (2009) conducted a research study in fall 2009.
This study utilized a retrospective chart review o f 250 charts. The population included
males and females within the clinic who had a history o f smoking and coronary artery
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disease (CAD) (Kelley et al., 2009). O f the 250 charts reviewed, only 150 patient
charts met the parameters o f the study. Data were obtained utilizing a “smoking
cessation chart review form” (Kelley et al., 2009, p. 87). The following research
questions were addressed in the study:
1. Is smoking cessation therapy being implemented with known coronary artery
disease patients who smoke with clinical diagnosis o f acute coronary
syndrome?
2. What timeframe (including prior diagnosis up to one year after diagnosis) is
smoking cessation addressed with known coronary artery disease patients
who smoke with a clinical diagnosis o f acute coronary syndrome? (Kelley et
al., 2009, p. 85)
The coneeptual framework o f the study was based on Pender’s theory o f the
HPM. The results o f the study revealed that 68.7% o f the patient sample did receive
smoking cessation teaching prior to or up to one year o f the diagnosis o f coronary artery
disease (Kelley et al., 2009, p. 89). According to Kelley et al.,
Pender’s HPM addresses many o f these factors from the patient perspective by
accounting for various characteristics that determine why one person may quit
smoking while another will not, even with identical smoking cessation
intervention. However, the most relevant HPM construct for this study was
interpersonal influences. (Kelley et ah, 2009, p. 90)
The major limitation o f the study was the small scale with which it was carried
out. Another limitation seen was only 150 of the charts accessed met criteria for the
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study. Finally, the last limitation listed was that the data collection tool had no validity
or reliability for its usefulness established (Kelley et ah, 2009).
Mehrabbeik, Mahmoodabad, Khosravi, and Fallahzadeh (2017) conducted a
study entitled Breahfast Consumption Determinants Among Female High School
Students o f Yazd Province Based on P ender’s Health Promotion Model. Their work
consisted o f a cross-sectional study examining 200 high school female students utilizing
a researcher-made questionnaire based on Nola Pender’s Health Promotion Model.
Cluster sampling method was utilized in selecting the students. According to the study,
the “children and adolescence” growth and development stage requires more nutrients
to sustain normal growth patterns. However, the stage is also the most crucial period
for correction o f dietary pattern. With this correction, breakfast is described to have the
most positive effects on nutrition and cognitive function. Thus, the purpose o f the study
was to promote the importance o f breakfast and its effects on physical and cognitive
development. Mehrabbeik et ah found 23% o f students ate breakfast every day, and 3%
never ate breakfast. Few students (11.3%) stated eating a variety o f cakes or cookies as
breakfast. One limitation o f this study included using a specific demographic rather
than a variety o f ages and gender. Contrary to this, a strength found in this study was
the utilization o f Pender’s HPM as the theoretical guideline. Mehrabbeik et ah provided
in-depth insight to the following five components o f the HPM: (a) positive activityrelated effect, (b) interpersonal influences, (c) prior related behavior, (d) perceived
barriers o f action, and (e) self-efficacy. Because Mehrabbeik et ah designed and
implemented the study based on Pender’s HPM, they concluded, “that Pender’s Health
Promotion Model is a good predictive model for breakfast consumption among student.
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Given that its components predicted 33% o f breakfast consumption, in planning
educational interventions, special attention to these components would be very helpful”
(Mehrabbeik et ah, 2017, p. 5065).
Pender’s Health Promotion Model was used in two very important facets o f the
current research. First, Pender’s model was used as a focus for the questions in the
survey. The current research was considered whether or not primary care providers
were routinely screening for mild cognitive delays in patients over the age o f 65 years.
The survey questions intended to include several questions aimed at why providers may
not be screening adequately or at all. These questions used Pender’s model as a base to
examine what barriers exist to adequate screening. Secondly, Pender’s model was used
to help shape follow-up teaching that was indicated with providers. Pender believed
that personal, self-initiated changes are essential to true and lasting change. The key to
making a difference, as it was found that the screening was not being done on an
adequate level, was based on the learner seeing a positive benefit in the suggested
changes. In the current research, the change increased the knowledge for a need o f
routine and early screening with a future benefit o f better healthcare outcomes for
patients and their families.
Review of Related Research
Malmstrom et al. (2015) implemented the following two studies: (a) to examine
the use o f The Rapid Cognitive Screen (RCS) to test for mild cognitive impairment and
dementia by primary care physicians and (b) to examine the ability o f the RCS to detect
MCI and dementia in an outpatient clinic setting/primary care setting. According to
Malmstrom et al., one in nine persons aged 65 years or older and 32% o f persons over
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85 years o f age are estimated to have Alzheimer’s disease, and the CDC’s expectation is
that this number will triple by 2050. Primary care physicians frequently do not properly
identify persons with cognitive dysfunction, and no gold standard screening tool
currently exists to detect cognitive dysfunction. Because dementia and cognitive
impairment interfere with patients’ ADLs, the lack o f consistent cognitive screening
decreases the chance o f early diagnosis and possibly increases the likelihood of
detrimental effects and/or events. The Diagnostic and Statistical Manual o f Mental
Disorders (4* edition; DSM-IV) criteria were used to make the diagnosis o f mild
cognitive impairment or dementia in this study, and there was no theoretical framework
for the study identified.
Malmstrom et al. (2015) identified the following three objectives for Study 1:
Examine the RCS sensitivity and specificity for MCI and dementia, evaluate the RCS
predictive validity for nursing home placement and mortality, and compare the RCS to
the Clock Drawing Test (CDT) plus recall. Study 1 utilized the RCS, which included
three items from the Veterans Affairs’ Saint Louis University Mental Status (SLUMS)
exam. Malmstrom et al. were testing the ability of the RCS to differentiate between
variables o f normal cognition, MCI, and dementia as noted in the DSM-IV. The patient
was to recall five words, perform a clock-drawing test, remember a story, and recall the
fact that Chicago was located in the state o f Illinois (insight). The RCS was scored on a
scale from 0-10 with zero being the worst and 10 being the best. The patient could
score a total o f 5 points for memory, 4 points for clock drawing, and 1 point for the
story recall. In 2003, the Malmstrom et al. began recruiting from the Saint Louis
Veterans Affairs Medical Center hospitals. The sample population included 702 male
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participants ranging from 65-92 years o f age. Dementia was present in 12% (ji = 82) o f
the participants, and MCI was present in 26% {n = 180). Scores from the study were
evaluated against the DSM-IV criteria for diagnosis of mild neurocognitive disorder or
dementia. Malmstrom et al. also performed a follow-up evaluation 7.5 years later to
evaluate the association o f RCS scores with nursing home placement and mortality. O f
the 702 participants studied, Malmstrom et al. were able to follow up with 533
participants with no changes in demographic data. Due to changes in primary care
providers, incorrect contact information, or inactive electronic medical records, some
participants were unable to be located.
The only objective for Study 2 was to examine the ability o f the RCS to detect
dementia and MCI in an outpatient setting. The sample population included 168
participants ranging from 60-90 years o f age. In 2013, the researchers began recruiting
participants from the Saint Louis University Geriatric Medicine and Geriatric
Psychiatry outpatient clinics. The study participants included 104 females and 64 males,
out of which 71 were o f African American decent and 92 o f Caucasian decent. In this
study, 36% (M = 61) o f participants were diagnosed with MCI and 44% {n = 74) of
participants with dementia.
Malmstrom et al. (2015) analyzed data using IBM SPSS Statistics, version 22
(Somers, NY) and SAS, version 9.2 (SAS Institute, Inc., Cary, NC) for Receiver
Operating Characteristic (ROC) contrasts. Statistics were reported as means, standard
deviations (SD), or percentages. Scores from RCS (0-10) and CDT plus recall (0-5)
were used for ROC curves for MCI and dementia. Sensitivity and specificity were
calculated using a standard approach. Results from ROC contrasts were computed to
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“compare the total areal under the curve (UAC) o f the screening tests (RCS vs. CDT
plus recall) for MCI and for dementia on the DSM-IV” (Malmstrom et al., 2015, p.
742). Malmstrom et al. also reported odd ratios (ORs) and 95% confidence intervals
(CIs) adjusted for the age o f the participant reported for the logistic regression analysis.
According to the results o f Study 1, the RCS was superior to the CDT plus recall
in predicting both dementia and MCI. Study 2 also found that RCS was successful in
predicting dementia and/or MCI with the use o f the SLUMS exam in the outpatient
settings. Both tests were found to have good sensitivity for the detection o f dementia on
the DSM-IV, with optimal scoring for dementia to be < 5 for RCS and < 2 for CDT plus
recall. When testing for MCI, the RCS exhibited a higher specificity with an optimal
score o f < 7, while the CDT plus recall only had optimal scores o f < 3. Although there
was little difference in the two screening methods in reference to dementia, the RCS is a
better detector for MCI which led Mahnstrom et al. to find it as an overall better
screening method for predicting both dementia and MCI. In < 3 minutes, the RCS can
be administered in a primary care setting with preliminary results showing it superior to
CDT plus recall in detecting MCI. Further study o f the CDT plus recall as a tool alone
for detecting MCI would assist in solidifying these preliminary results. Because
participants whose scores detected dementia or MCI were less likely to expire or be in a
long-term care facility 7.5 years after screening, it would be advantageous to conduct
long-term research to study the effects o f predicting dementia and MCI through not
only the RCS but through the CDT plus recall as well.
One strength found in this study is the author's’ use o f RCS as a screening tool.
Regardless o f patient load and busy schedules, RCS can be administered and scored
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quickly in the primary care setting; and it could be widely available to providers as it is
not a copyrighted material. With a variety o f demographic data, this study offered a
fairly thorough assessment o f the use o f the RCS as an appropriate screening method for
MCI and dementia. However, a larger sampling from more than one region or setting
would give a more complete estimate o f sensitivity and specificity o f the screening
tools. Another issue that could be improved upon is for a complete follow-up for
patients as there was nearly a 25% loss o f patient follow-up in Study 1.
Muller, Perische, Heymann, Elbing, and Laske (2017) executed a study
comparing the diagnostic accuracy o f the digital CDT against the conventional CDT for
discrimination of patients in the early course o f Alzheimer’s disease from cognitively
healthy individuals. According to Muller et al., 50% o f cognitively impaired cases go
undiagnosed, with the number o f cognitively impaired individuals increasing
dramatically as the elderly population increases. Moreover, there is a considerable delay
in the diagnosis of dementia, which reduces the efficacy o f available treatments.
Current diagnostic standards o f dementia are time-consuming (including psychometric
testing), invasive (including spinal fluid testing), and expensive (including neuro
diagnostic imaging). There is a need to develop fast, easy noninvasive and inexpensive
diagnostic tools to accurately detect people with cognitive impairment and dementia.
Early diagnosis through fast and accurate screening is the key to starting medications
and treatments needed and allowing for careful planning o f financial and support
systems.
Muller et al. (2017) sought to study several areas identified in the study
including the following: (a) clinical and demographic characteristics o f the participants.
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performance on the CDT in patients with amnestic mild cognitive impairment (aMCI),
early dementia o f Alzheimer’s type (eDAT), and healthy individuals/healthy control
(HC); (b) screening value o f the CDT in patients with aMCI, eDAT, and healthy
individuals; performance on the CDT in patients with aMCI showing normal
conventional Clock Drawing Test (cCDT) scores and healthy controls; and (c)
screening value o f the CDT in patients with aMCI showing normal cCDT score and
healthy controls.
Out o f 70 participants included in this study, 34 were females and 36 were males
with the mean age 66.9 + 10.3 years. All participants included were right-handed and
had normal or corrected-to-normal visual acuity and sufficient hearing ability. No
participants were included with a physical handicap that affected his or her ability to
perform the tasks indicated. Muller et al. (2017) also conducted a depression exam
utilizing the Geriatric Depression Scale (GDS) to exclude symptoms o f depression that
could interfere with test results. Patients with aMCI or EDAT were recruited from the
Memory Clinic o f the Department o f Psychiatry and Psychotherapy at the University
Hospital o f Tubingen. All participants underwent physical, neurological, and
neuropsychological and psychiatric examinations. Neuropsychological assessment
included the use o f the Mini Mental Status Exam (MMSE) and the Trial Making Test
(TMT-a). The results from these tests were compared to the diagnostic criteria for
eDAT defined by the National Institute o f Neurological and Communicative Disorders
and Stroke Alzheimer’s Disease and Related Disorders Association. To qualify for
eDAT criteria, participants had to score 4 points on the Global Deterioration Scale.
Furthermore, the diagnosis o f aMCI was defined according to the Mayo criteria.
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including presence o f a memory complaint, objectively impaired memory function,
intact ADLs, and the absence o f dementia.
The CDT was performed using a Windows Surface Pro 4 digitizer and a
handheld stylus pen. The tablet assessed different patient movements including time-inair and time-on surface calculated in milliseconds according to their binary coding.
Total-time corresponded to the time-in-air plus time-on-surface. All participants
completed the cCDT on the tablet with a handheld stylus pen following the instruction
to draw a circle (clock face) with the numbers in the appropriate positions and to place
the hands on the clock representing “ 10 past 11 o’clock.” Scoring ranged from 1 point
(perfect) to 6 points (not representative o f a clock at all). A score > 3 was considered
impaired.
Muller et al. (2017) analyzed data using statistical software package (SPSS—
version 23). For all tests, the level o f statistical significance was set to p < 0.05. Data
were also analyzed using the Pearson chi-square test to detect group differences in
gender distribution. Kruskal-Wallis test was used to detect group differences in cCDt
and GDS scores. One-way analysis o f variance (ANOVA) was used to assess group
differences in age, education and global cognition (MMSE), Trial Making Test Part A
(TMT-a) and Part B, time-in-air, time-on-surface, and total-time. According to the
Muller et al., receiver operating characteristics (ROC) curves were established to
illustrate the specificity o f dCDT variables (i.e., time-in-air, time-on-surface, and total
time) as well as cCDT scores in relation to sensitivity in classifying Healthy Control
(HC) individuals and patients with aMCI.
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Muller et al. (2017) examined the influence o f aMCI and early dementia
development on alterations in movement execution. Muller et al. studied these
movements in comparison to the traditional CDT scoring. The traditional scoring
system reveals poor sensitivity but excellent specificity in discriminating aMCI patients
from healthy individuals. Even in aMCI patients with normal cCDT scores, usage o f in
air trajectories yielded excellent sensitivity and a very good specificity in discriminating
from healthy individuals. The proportion of aMCI patients with normal cCDT scores
was 80% o f all aMCI patients. It is inferred that these findings indicate that even if the
clock drawing falls into the range o f “normal” performance, it is not necessarily
implicative that the subject is cognitively normal. It is also found that digitalized
assessment o f one’s non-visible time-in-air movements can be used as supplementary
information in identifying participants in the pre-dementia stage o f Alzheimer’s disease.
Hessler et al. (2013) sought to determine the effectiveness of the Six Item
Cognitive Impairment Test (6CIT) when used to screen patients for cognitive
impairment or dementia in the primary care setting. Hessler et al. predicted that the
number o f people affected by dementia will double every 20 years. This statistic alone
is enough to warrant providers to diligently screen elderly patients and patients with risk
factors for cognitive impairment or dementia. Hessler et al. foimd that practitioners
were more likely to screen patients if they had access to tests that were easy to
administer and tests that provided effective and consistent results. The Six Item
Cognitive Impairment Test (6CIT) has an administration time o f 2 to 4 minutes, which
fits well with the busy schedule o f a general practitioner. The 6CIT is also thought to
be as reliable and consistent as the mini-mental state examination. The purpose o f this
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study was to determine if the 6CIT is a suitable screening tool for the primary care
setting as it has been used in previous studies but not specifically in the primary care
setting.
The previous studies conducted with the 6CIT were in controlled settings, such
as dementia and geriatric centers; therefore, Hessler et al. (2013) wanted to test the
validity and reliability in a non-controlled environment. This particular study was part
o f the large population-based intervention program referred to as INVADE
(Intervention Project on Cerebrovascular Disease and Dementia in the District of
Edersberg) that investigated the effects o f primary medical care interventions on the
incidence o f dementia. The INVADE trial studied prevention at the primary care level
in Barvaria, Germany. In order to participate in the study, the following criteria were
outlined: (a) the patient must belong to a specific health insurance company referred to
as AOK, (b) live in Edersburg, and (c) be 55 years or older. There were no outlined
exclusion criteria. The screening process took place from 2001 to 2003. From an
original selection o f 11,317 people, 3,908 patients signed informed consent and agreed
to participate in the study. To determine a baseline, the patients were given a 6CIT at
the initial examination. Patients were then examined at three follow-up exams: Exam I
at 2 years. Exam II at 4 years, and Exam III at 6 years. The test has a maximum score o f
28 with a cutoff o f 10 to 11 for a diagnosis o f dementia and a score o f 7 to 8 for milder
cases.
O f the 3,908 participants examined, 1,600 were male, 2,308 were female, and
the mean age was 67.7 years. Hessler et al. (2013) used 72 different general
practitioners to conduct the screenings. The mean 6CIT score was 2.7 (SD = 3.9).
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Patients remained in the study an average o f 72.1 months. Over the course o f the study,
528 (or 14%) o f the patients interviewed at baseline were diagnosed with dementia.
Considering all factors (i.e., user error, age, gender, etc.), patients with a 6CIT score
above the 7-8 cutoffs had a threefold to fourfold increased risk for dementia. The 6CIT
proved to be a stable test over a long period o f time and was able to identify most
patients without dementia. However, it failed to identify a large population o f patients
with dementia. Based on the findings stated above, Hessler et al. (2013) determined
that the 6CIT was not suitable for use as routine screening instrument in the primary
care setting as it simply has the potential to overlook too many cases o f dementia.
Some o f the strengths o f the 6CIT study were the focus on the test’s
functionality, specifically in the primary care setting. Hessler et al. (2013)
acknowledged prior 6CIT studies and their effectiveness in diagnosing dementia; but, to
their knowledge, this was the first 6CIT study designated to the primary care setting
only. This study was also able to test real-world suitability and validity over three
distinct time periods. The major weakness of the study was the inability o f the 6CIT to
conduct a thorough dementia assessment on nearly 4,000 total patients. The group
members instead were forced to use dementia diagnosis from insurance claims to
compare the reliability o f the 6CIT findings.
Fowler et al. (2015) conducted a 24-month cluster-randomized trial with two
parallel groups. The purpose o f this study was to determine if access to cognitive
reports altered physician screening practices and treatment methods. As the aging
population increases, the number o f patients with cognitive impairment will also
increase. Today, more patients are seeking medical treatment in the primary care
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setting instead o f going to a specialist; therefore, it is suggested that cognitive screening
should take place in the primary care setting even though cognitive screening can be
time-consuming and challenging. In January 2011, Medicare and Medicaid services
began covering the cost o f an annual wellness visit; and, when performed thoroughly,
these assessments can be very beneficial in early diagnosis o f cognitive impairment.
Fowler et al. (2015) sought to determine if identifying patients with mild cognitive
impairment could result in a change in the physicians’ approach to treatment or if an
early diagnosis could impact the progression o f cognitive decline.
Fowler et al. (2015) identified two hypotheses. The first hypothesis stated that
primary care physicians in the cognitive report group (CR) who received cognitive
reports based on neuropsychological testing would perform dementia screening test,
refer patients to specialists for diagnostic assessment, and prescribe anticholinesterase
inhibitors more frequently than providers in the treatment as usual group (TAU)
(Fowler et al., 2015). The second hypothesis was that the patients o f physicians in the
CR group would have a slower rate o f progression o f cognitive deficits over 2 years
than cognitively impaired patients in the TAU group (Fowler et al., 2015). This
hypothesis was based on the belief that cases o f reversible cognitive impairment would
see improvement due to spontaneous resolution or treatment o f the underlying cause. In
more serious cases, if the cause o f impairment was believed to be Alzheimer’s disease,
the prognosis would be improved by prescribing cognitive enhancing medication.
According to Fowler et al. (2015), the randomization o f the study was
accomplished by focusing on primary care practices rather than individual primary care
physicians (PCP) and patients. Randomization at the PCP level was thought to
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influence the results o f the study due to several factors. Those factors included
physicians calling upon a colleague to cover each other’s patients thereby possibly
sullying results between groups or patients sharing providers possibly causing flawed
results. The chosen practices were broken into two groups: control report (CR) and
treatment as usual (TAU). Twelve primary care practices from southwestern
Pennsylvania were chosen according to specific geographic locations, such as urban,
suburban, and rural. Two o f the 12 were defined as urban, and 2 as rural. Eight o f the
12 were suburban and were further classified based on the number o f physicians
participating in the study. Each site was randomly assigned to the CR and TAU groups
with 6 sites in each group. Practices were recruited from October 2005 to January
2006, and patients were recruited from January 2006 to January 2008. Physicians were
given freedom to select the patients themselves. Patients with a diagnosis o f dementia
on their medical record or with a mini-mental state exam (MMSE) score o f 18 or below
were excluded. Patients with complaints o f memory loss who did not have a diagnosis
o f dementia, however, were not excluded. A total o f 731 patients were referred for the
study, 183 declined participation, and a total o f 581 patients completed the baseline
assessment. Fifteen o f the patients were deemed ineligible related to not meeting the
mentioned criteria. The final sample included 533 patients; o f these, 423 returned for
the final 2-year assessment. The TAU group represented 169 of these patients, and the
CR group accounted for 254 patients. A total o f 110 patients were lost to follow-up due
to factors, such as primary care changes, lack o f interest, or expiration (Fowler et al.,
2015).
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Data were collected by means o f a structured chart abstraction tool and included
demographics, neuropsychological tests, self-related questionnaires, and electronic
medical records. Information was collected over four periods: 12 months before
baseline, baseline to 12 months after baseline, 13-24 months, and 25-30 months.
Participants were ultimately given the diagnosis o f normal, mild cognitive impairment,
or dementia, which was determined by guidelines set by the University o f Pittsburgh
Alzheimer’s Disease Research Center.
The mean age o f participants at entry to the study was 73.6 years. O f the
participants, 58.9% were male and 63.8% were married. There were no significant
baseline differences between the two study groups. The results o f the study by Fowler
et al. (2015) revealed no major difference in the way physicians treated the patients on
either side at the end o f the 24 months. Physicians who received cognitive reports,
however, were more likely to order further testing and prescribe medication than the
physicians in the treatment as usual group; but there was no significant improvement in
those patients with MCI or dementia in either control group. One theory is that most
physicians prefer a wait-and-see approach over aggressive therapy, especially if the
patient does not have complaints concerning their cognitive impairment symptoms. In
the future, researchers would like the physicians involved in this type study to be more
specific with their documentation and more focused with their cognitive screening
assessment.
Fowler et al. (2015) claimed that at the time o f their study there was no other
study that had been previously conducted in this manner. Many studies had been
published on screening for cognitive impairment, but no previous study had tested
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specifically the different behaviors o f primary care physicians in relation to the presence
or absence o f previous cognitive reports. Another one o f the strengths to this study was
the comprehensive cognitive function assessment that was utilized. Previous studies
have only implemented a brief neurological exam. Although the study had several
strengths, there were also some weaknesses. The major problem with Fowler et al.’s
study was the demographic breakdown—with a majority o f patients identifying their
race as white. Because physicians were able to choose the patient population, concern
arose that physicians may have targeted patients who were already known to have
cognitive impairment.
Fowler et al. (2015) constructed a very relevant and well-planned study. The
research group went to great lengths to keep the study neutral and eliminate as many
biases as possible. The population and sample were clearly identified as well as the
data collection methods and instruments used during the course o f this randomized trial.
Fowler et al. could have improved this study by requiring physicians to perform specific
cognitive screenings on every patient in both control groups. This change would have
provided more consistent and thorough results. The charting was also very minimal in
some cases since several physicians only mentioned “memory problems” in their
respective documentation.
Wiese, Williams, and Tappen (2014) completed a systematic literature review o f
peer-reviewed publications identifying modifiable barriers to cognitive screening in
rural areas in the U.S. In the U.S., cognitive impairment with regard to mild cognitive
impairment, Alzheimer’s disease, and dementia is rapidly increasing in correlation with
the rise in the older adult population. Wiese et al. (2014) suggested every 67 seconds
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one person develops Alzheimer’s disease in America, and 75% o f those individuals
diagnosed with Alzheimer’s disease live in long-term healthcare facilities by the age o f
80 years. An estimated 5.2 million Americans have yet to be diagnosed with
Alzheimer’s disease, and over 50% o f those undiagnosed live in rural regions of the
United States. Wiese et al. (2014) proved the significance of their study in alluding to
the U. S. government's acknowledgment o f the need for increasing the detection of
MCI, as proposed in the Healthy People 2020 initiative. In addition to Healthy People
2020 goals, Wiese et al. cited reputable organizations, such as the Alzheimer’s
Association, the Alzheimer’s Foundation o f America, and the 111* Congress Special
Committee on Aging, along with six peer-reviewed publications (2014). This review by
Wiese et al. (2014) focused on the barriers resulting in the lack o f cognitive screening in
rural regions o f the U.S. and offered resolutions to these barriers with the utilization o f
Carrillo and Carrillo’s Healthcare Access Barriers (HCAB) model. Carrillo and
Carrillo’s framework suggested three modifiable barriers: financial, structural, and
cognitive. Wiese et al. stated their research question as the following: What are the
barriers to cognitive screening in rural U.S. populations? Seeking to answer this
research question, Wiese et al. (2014) reviewed several recent studies that addressed
and correlated with modifiable barriers o f the HCAB model (2014).
The methodology o f this study was clearly defined. Wiese et al. (2014) utilized
current peer-reviewed publications to complete a literature review addressing the
barriers o f the HCAB model (i.e. financial, structural, and cognitive). Due to the
qualitative structure o f the study, there was no setting, sample, or independent and
dependent variables. Wiese et al., however, identified the population under study as
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rural residents in the U.S. and the variables o f interest as the three barriers identified in
the HCAB model.
Wiese et al.’s (2014) interpretations were depicted in a chart. The chart
included each peer-review publication, the original purpose and design o f each
publication, and the barriers that each publication identified. In addition, the chart
categorized each barrier listed into principal barriers o f the HCAB model. Wiese et al.
(2014) found that all six peer-reviewed publications recognized cognitive/emotional
barriers, specifically the lack o f knowledge. Wiese et al. specified that many o f the
publications addressed the barrier o f lack o f provider knowledge. Several o f the
publications described instances in which healthcare providers believe cognitive
impairment is a part o f the normal aging process and thought an early diagnosis o f
Alzheimer’s disease was futile (Wiese et al., 2014). Wiese et al.’s implications for
improving provider knowledge o f the need and the importance o f cognitive impairment
screening included the following:
1. Correct inappropriate responses o f primary healthcare providers due to
misconceptions and lack o f expertise in screening for cognitive impairment.
2. Educate healthcare providers on the benefits o f cognitive impairment
screenings.
3. Educate primary healthcare providers regarding the mandatory screening of
Medicare recipients during annual wellness exams (Wiese et ah, 2014).
Markwick, Zamboni, and de Jager (2012) conducted a comparative study on the
ability o f the Montreal Cognitive Assessment (MoCA) and the Mini-Mental State
Examination (MMSE) in the early detection o f mild cognitive impairment. The
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performance of the MoCA subtest was compared at the same cutoff score as the
MMSE. The cutoff score for the MoCA was < 26, and the cutoff score o f the MMSE
was > 27. The MoCA detected cognitive impairments not detected by the MMSE in the
majority o f the participants screened. The MoCA appeared to be a sensitive screening
test for the detection o f early cognitive impairments (Markwick et ah, 2012). Cognitive
impairments are considered a transitional state between normal aging and Alzheimer’s
disease and are typically indicated by the presence o f cognitive impairment in those
greater than the expected age in the absence o f dementia. The ability to be able to
detect cognitive impairments by using screening methods will help with the diagnosis o f
early dementia and management o f the disease.
The early identification o f cognitive impairments may be a precursor to
Alzheimer’s disease or other dementias and will possibly lead to improved patient care
o f those diagnosed with dementia or other cognitive disorders. Treatment is most
beneficial when the symptoms are mild and people are able to cope. It is recommended
that screening should be used on those who have an increased risk o f developing
cognitive impairments.
A review o f the screening methods in primary care revealed that the most
commonly used cognitive screening instrument for dementia is the MMSE. The MMSE
assesses cognition in five subtest areas. The subtest areas include orientation,
registration, recall, attention/concentration/calculation, and language. Despite its
popularity, the MMSE has several limitations. These limitations could possibly limit
the effectiveness o f this screening in different populations. Race, education, and
language ability affect the performance on the MMSE. The M M SE’s ability to
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differentiate between those with mild cognitive impairment and healthy subjects is
limited. The meta-analysis showed that across several studies, the results showed
sensitivity to detect MCI in 62.7%, a specificity o f 63.3%, and a positive predictive
value o f only 37%. The cutoff scores for the MMSE are as follows: < 26 is abnormal
interpretation, <21 has increased odds o f dementia, and > 2 5 has decreased odds of
dementia (Markwick et al., 2012). The MMSE was designed to screen for dementia in a
time when there was little research on mild cognitive impairments. Now there are
screens available that would be more sensitive in the detection o f mild cognitive deficits
and should be more widely used.
Another screening tool is the Montreal Cognitive Assessment (MoCA). This
tool assesses multiple aspects o f cognition, short-term memory, functioning, attention,
concentration, and orientation to place and time. The MoCA was designed specifically
for screening patients who present with mild cognitive difficulties and sensitive to
deficits in cognition. With a possible score o f 30 points, 73% o f those studied obtained
scores below the cutoff o f 26 points. Even though their scores on the MMSE fell within
the normal range, MoCA had a sensitivity o f 90% for detecting mild cognitive
impairment in the subgroups. It also revealed that the MoCA had a very high
consistency and retest reliability (Markwick et al., 2012).
Sensitivity results o f this population used a cutoff score o f 26. The MoCA had a
sensitivity o f 83% to detect MCI. The MMSE included the memory task which is
limited and does not include a cued recall component. Additionally, there is not any
test of executive function or working memory. Several attributes contributed to the
MoCA for their findings o f improved detection o f MCI when compared to the MMSE.
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The main purpose o f this study was to evaluate research in a group o f older adults to
utilize the benefits o f the MoCA, as opposed to the MMSE for the use o f detection o f
MCI in clinic settings (Markwick et al., 2012).
Participants were selected from a longitudinal memory and aging study (Oxford
Project to Investigate Memory and Aging=OPTIMA) and were older adults with no
medical history o f a stroke or vascular events. They had attended regular OPTIMA
appointments for over a year. These participants were assessed with a counter-balanced
method o f using MMSE and MoCA, followed by a full battery o f neuropsychological
tests covering cognitive domains. The OPTIMA assessment included medical history,
examination, brain imaging, and dementia screening blood test. Diagnosis was based
on the results and from the full assessment (Markwick et al., 2012).
The statistical analysis was carried out by using PASW statistics 18. The
univariate analysis o f variance (ANOVA) was used to test for age, gender, and
education on MMSE and MoCA scores. The sensitivity o f the MoCA was to detect
cognitive impairments with a cutoff score < 26 and then investigated and compared to
the MMSE score with a cutoff > 27. The cutoff score can distinguish between those
with MCI and cognitively normal subjects. If the scores were < 24 or 30, then it is
generally considered to be indicative o f dementia (Markwick et al., 2012).
There were 107 consecutive participants, male and female, with a mean age o f
76 years. There were no significant associations o f gender, age, or education with the
MMSE and MoCA. MMSE scores ranged from 24-30, and the MoCA scores ranged
from 13-30. The correlation between these two-screening tests was significant. This
study group had MoCA scores < 26, which indicated cognitive impairment. The
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MMSE used the cutoff > 27, and 33,7% still fell below the MoCA cutoff. The general
agreement o f the diagnosis included 79 controls, 20 MCI, 6 probable Alzheimer’s
disease, and two other dementia-related diagnoses. The MoCA scores that were below
26 included 18.6% with dementia, 37.2 with MCI, and 44.2% controls. This showed
80% sensitivity to MCI and 100% sensitivity to dementia. In this wide population, the
MoCA detected more participants with cognitive impairments than the MMSE.
In the elderly population, the MoCA detected more participants with cognitive
impairments than the MMSE. Results suggested that screening for cognitive
functioning, such as orientation to place and time, remains important. However,
screening with a broader range o f cognitive tasks, including those not represented in the
MMSE, would be important in identifying mild cognitive difficulties that might go
undetected. The findings did have implication for the choice o f screening instruments
used in clinic settings, especially for those with early cognitive impairments, where the
MMSE was not sensitive enough to detect the deficits. The MoCA is more suitable
than the MMSE in screening for mild cognitive impairments. In conclusion, the study
demonstrated that in an elderly population, the MoCA detected more subjects with
cognitive impairment than the MMSE. Also, the cognitive impairment was evident
across a variety o f cognitive tasks.
Fowler et al. (2012) performed a cross-sectional study to determine primary care
patients’ perceptions o f dementia screening and evaluate the possibility o f an
association between their perceptions and their willingness to undergo screening. The
study utilized the PRISM-PC, a questionnaire created by the researchers, to assess the
study participants’ perceptions o f dementia (Fowler et al., 2012). The Mini-Mental
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State Examination (MMSE) was used for dementia screening in the patients who agreed
to be screened for dementia after the PRISM-PC.
According to Fowler et al. (2012), dementia is a debilitating and degenerative
neurological condition that, at the time o f the study, affected about 4.5 million people in
the U.S. Fowler et al. theorized that an understanding o f patients’ perceptions o f the
benefits and harms o f dementia screening may help to show any possible barriers and
facilitators to implementing sufficient dementia screening programs in primary care.
Fowler et al. stated that this study and others like it are necessary because, according to
the USPSTF, the evidence to systematically screen for dementia in primary care is
insufficient due to a lack o f studies evaluating the efficiency, benefits, and harms o f
dementia screening in primary care (Fowler et al., 2012). There were no hypotheses in
the study.
The study was conducted from January 2008 to June 2009 at a community-based
primary care clinic. A face-to-face interview was utilized. Participants included men
and women ages 65 years and above. A total o f 554 people participated in the study
which included 388 females, 166 males, 313 African Americans, and 363 people ages
70 years or older. All interviews were conducted in the clinic, and privacy was ensured
before the interview. The questionnaire and subsequent screening— if the patient
agreed—were all conducted at the same time.
For this study, the PRISM-PC was used to determine the patient’s perceptions of
dementia screening during a face-to-face interview. The PRISM-PC was developed by
the researchers to examine the perceived harms and benefits o f dementia. In this
questionnaire, Alzheimer’s Disease, served as a proxy for “dementia” because early
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research revealed that people more readily understood this term (Fowler et al., 2012).
The PRISM-PC has a total o f 50 questions. Basic demographic data was established in
the first 12 questions, including age, sex, race, education, annual income, and living
situation. These initial questions also delved into the patient’s experience with
Alzheimer’s disease. Additionally, there are 38 questions that measured the patient’s
knowledge o f and attitudes toward the acceptability, benefits, and harms o f dementia
screening. The questionnaire was scored on a 1-5 point Likert scale. A selection o f 1
designated strongly agree, and a selection of 5 designated strongly disagree. After the
questionnaire, the participants who agreed to dementia screening were screened using
the MMSE. Fowler et al. (2012) stated that participants whose results were positive on
the MMSE were referred to the local memory clinic for a diagnostic assessment.
According to the Fowler et al. (2012), the majority o f participants (89.7%)
agreed to be screened for dementia upon completion o f the questionnaire. Study
participants’ beliefs about screening and the benefits and harms associated with it were
associated with their likelihood o f accepting dementia screening. Participants who were
more strongly in agreement with the questions on the PRISM-PC geared toward the
benefits o f knowing about dementia earlier were much more likely to agree to
screening. The odds o f refusing the screening were significantly higher in patients aged
70-74 years {OR = 5.65, p < 00) and mildly higher in patients aged 75-79 years {OR =
3.63, p = .01) than in the reference group o f patients aged 65-69 years. Further analysis
o f the data showed that the only significant sociodemographic difference between the
participants who accepted screening and those who refused was age. Race, sex,
education, annual income, and living situation did not have a measurable effect on the
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participant’s likelihood to accept screening. In summary, the younger patients, ages 6569 years, were most likely to accept screening; and the middle age range in the study,
ages 70-75 years, were least likely to accept screening.
Fowler et al. (2012) identified several weaknesses in their study. First, there
was an inherent selection bias as a result o f the recruitment process. Since the study
only recruited from the patients in the community-based clinic, there were many groups
not reached by the study. Another limitation was the sample size. Fowler et al.
acknowledged that inferences about perceptions and behavior are more difficult with a
small sample. Small sample sizes can skew statistics and lead to a limited
generalizability of the study to the larger population. Also, since it seems the
participants only used one clinic for the study, this could limit the ability to generalize
the study to the larger population, especially to other socioeconomic groups. Finally,
the researchers also addressed the fact that there was not any follow-up data collected
about the reasons any o f patients had for refusing dementia screening. The researchers
recommended future studies include further testing o f instruments, such as the PRISMPC, to attempt to determine whether patients who are already experiencing some
cognitive impairment perceive screening differently from those without any cognitive
impairment (Fowler et al., 2012).
Berres, Krumm, Mistridis, Monsch, and Taylor (2015) performed a longitudinal
study with the intention o f modeling the longitudinal course o f different
neurophysiological functions preceding the diagnosis o f mild cognitive impairment due
to Alzheimer’s disease. Berres et al. specifically wanted to determine the average time
before a mild cognitive impairment diagnosis that each neurophysiological and clinical
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variable diverged from the course o f a neurologically healthy individual. The ability to
identify the type and sequence o f cognitive decline before a mild cognitive impairment
diagnosis is crucial to understanding the pathogenesis o f Alzheimer’s disease (Berres et
al., 2015). It is also very important in initiating much needed therapeutic interventions.
The study focused on patients during the period where cognitive impairments were not
yet manifested in daily life. If Alzheimer’s disease could be predicted in this period, it
would greatly improve the ability to implement disease-modifying interventions. While
patients’ (who will eventually be diagnosed with Alzheimer’s disease) cognitive
performance in preclinical mild cognitive impairment stage is still normal, according to
diagnostic criteria, their neurophysiological function will inevitably begin to decline
when compared to individuals who remain cognitively healthy (Berres et al., 2015).
According to Berres et al. (2015), there have been very few studies to examine the
cognitive functioning o f individuals preceding a diagnosis o f mild cognitive
impairment.
Berres et al. (2015) did not appear to have any hypothesis on the study.
However, the researchers did list information from preceding studies that was
applicable to this study. Previous studies seemed to be in agreement that verbal and
visual episodic memory appeared to be the first and most affected cognitive functions in
preclinical mild cognitive impairment. According to those studies, verbal and visual
episodic memory could decline as early as 7 to 10 years prior to a diagnosis o f mild
cognitive impairment. According to Berres et al. (2015), all o f these studies reinforced
the importance o f the subsequent dementia diagnosis when researching the pattern o f
cognitive decline in preclinical mild cognitive impairment.
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Baseline testing was conducted on patients from 1997 to 2001. This testing
included a clinical physical exam, medical history questionnaire, neurophysiological
evaluation, and assessment o f depression to ensure that all participants were completely
physically and mentally healthy. The study followed 87 participants from 1997 to
2013. The participants were reevaluated every 2 years after the initial baseline
testing. These réévaluations consisted o f a comprehensive neurophysiological
examination. An informant, a person close to the participant who could give valuable
insight into any changes since the previous assessment, was also consulted every 2
years. This informant step helped uncover slight changes in the participant that only
someone present in day-to-day life would notice (Berres et al., 2015).
This study utilized the longitudinal BASEL project (Basal Study on the Elderly).
After the initial examination visit, at each visit the participants were evaluated using an
identical version o f the Consortium to Establish a Registry for Alzheimer’s DiseaseNeuropsychological Assessment Battery (CERAD-NAB). The CERAD-NAB is a
comprehensive neuropsychological assessment. The informants were given the
IQCODE to fill out about the participants at every evaluation. This 16-item
questionnaire asks the informant to compare the participant’s present cognitive function
to their function 2 years prior. The IQCODE is scored on a scale o f 1 to 5 with 1 being
much improved and 5 being much worse. The study analyzed changes in both the
participants’ and the informants’ scores o f the 27 participants who were later diagnosed
with mild cognitive impairment compared to the 60 participants who remained
cognitively intact even after the study’s completion (Berres et al., 2015).
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The statistical analysis o f the study was done with cubic splines, an alternative
cubic function for analysis. Cubic splines were used because simple linear, quadratic,
and cubic functions were not sufficient due to the portions o f function being nearly
linear or even consistent at some intervals since many o f the participants had little or no
change throughout the study (Berres et al., 2015). All areas assessed in patients who
remained neurologically intact (NC-NC) increased or stayed the same throughout the
study. According to Berres et al., the following results were given for NC-MCI
participants. Verbal delayed recall initially decreased slightly— around 8 years prior to
MCI diagnosis— but drastically decreased around 2 years before diagnosis. Verbal
savings followed an almost identical pattern. Verbal encoding, visual episodic delayed
recall, and visual savings performance declined approximately 4 years before an MCI
diagnosis. Verbal discriminability and executive fimctions declined approximately 2
years prior to diagnosis. In NC-MCI participants, a decline in semantic fluency was
statically noted approximately 4 years before the MCI diagnosis. A very gradual
decline was noted in constructional praxis fimctioning around 6 years prior to the MCI
diagnosis. A decline was noted in psychomotor speed around 2 years prior to MCI
diagnosis. In language assessment with the Boston naming test and with the IQCODE
questionnaire, a very mild variation was seen in both 2 years before the mild cognitive
impairment diagnosis. Finally, a statistically significant difference was not noted
between NC-NC and NC-MCI participants in phonemic fluency prior to the MCI
diagnosis (Berres et al., 2015).
Berres et al. (2015) concluded that this study definitely indicated that using a
complete neurophysiological evaluation can bring neurological decline to light before
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mild cognitive diagnosis criteria is met. However, they also point out some areas o f
needed improvement to the study. First, Berres, et al. indicated that the study should be
recreated with a larger sample. A small sample size always carries the risk o f an
inability to generalize the results to the larger population. Another limitation listed was
the sample used was one o f convenience, so the results might be less likely to be
generalizable to the population as a whole. Berres et al. suggested that future research
be conducted to determine whether changes in scores on neuropsychological testing
provide more sensitive markers o f future MCI diagnosis than cross-sectional scores as
well as the optimal combination of neuropsychological test scores, CSF, PET, and MRI
measures to predict progression to Alzheimer’s disease.
In conclusion, the purpose o f this study was to determine primary care
providers’ adherence to the recommendations established by the USPSTF and the
guidelines published by the Alzheimer’s Association. With nearly 5 million Americans
currently diagnosed with Alzheimer’s disease and dramatic increases expected over the
next 30 years, the need for a more rapid and efficient screening tool is becoming more
imperative. This chapter detailed review o f literature specific to research on screenings
for the early detection o f mild cognitive impairment. After review o f the above
literature, it is concluded that annual cognitive screenings would be beneficial in
enhancing overall patient health and quality-of-life outcomes, lessening caregiver strain,
and decreasing armual healthcare costs.
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CHAPTER III
Methodology
The purpose o f this study was to determine if and how often primary care
providers adhere to the guidelines recommended by the USPSTF and the Alzheimer’s
Association pertaining to screening for mild cognitive impairments. Mild cognitive
impairment is a mild decline in single or multiple cognitive domains and indicates a
significant risk o f progression to dementia or Alzheimer’s disease. The Alzheimer’s
Association guidelines dictate that all patients should be screened on an annual basis—
regardless o f whether they are exhibiting signs o f cognitive impairment (Alzheimer’s
Association, 2013). The USPSTF recommends screening all adults in the primary care
setting aged 65 years or older who have no signs or symptoms o f mild cognitive
impairment. (USPSTF, 2014). Aiming to identify self-reported compliance with the
guidelines, the current researchers conducted a web-based study using a questionnaire
created specifically to gather and analyze information fi*om the providers. The current
study helped to determine whether responding providers are screening for MCI and, if
so, what screening methods are being utilized. This chapter will discuss the design and
implementation o f the study, the population and sample studied, the method o f data
collection, and analysis o f the findings.
Design of the Study
A quantitative descriptive study design was utilized for this research. Beck and
Polit (2017) stated that the purpose of descriptive research is “to observe, describe, and
document aspects o f a situation as if naturally occurs and sometimes to serve as a
starting point for a hypothesis generation or theory development” (p. 206). Descriptive
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research is popular in healthcare settings due to its focus on observation and description
and not on manipulation or experimentation. Since the purpose o f the study was to
deduce whether or not providers are screening without interfering with their process or
test a hypothesis, the current study design was the most appropriate. This study utilized
a web-based survey on SurveyMonkey, Inc. to gather and analyze data. The data
gathered included the following: demographic data, likelihood to screen, current
screening practices, factors that increase likelihood to screen, barriers to screening, and
screening criteria. The current researchers assessed the providers’ compliance with
guidelines for screening through a web-based survey, since this method increased the
pool of providers available to the study. The web-based survey was not limited
geographically as a compliance audit or chart review.
Protection of Human Subjects
Permission to conduct the study was obtained from the Institutional Review
Board o f Mississippi University for Women (see Appendix A). Human subjects were
used when providers were asked to complete a survey questionnaire indicating current
cognitive screening practices utilized in the clinical primary care setting. The
guidelines used for proper screening were those set by the USPSTF in screening for
cognitive impairments in patients age 65 years or older in the primary care setting (see
Appendix B). During data collection, intense caution was taken to protect participants’
anonymity. To ensure this anonymity remained intact, a non-traceable survey was
utilized via SurveyMonkey, Inc. The information obtained was used only for this
research project. This information remained closely guarded, stored only in a secure
location, and deleted after data collection was completed. The SurveyMonkey, Inc.
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account was deleted upon completion o f the research project. As stated by
SurveyMonkey Inc.’s website policy, at the time that the account was deleted the
collected data were automatically removed from the website’s server.
Instrumentation
The online survey utilized SurveyMonkey, Inc. to host the survey during the
study and maintain the data collection throughout the duration o f the research. The
survey utilized a series o f researcher-developed questions (see Appendix F) specifically
tailored to this research. The researchers used this survey to collect data from primary
care providers in Mississippi and other surrounding U.S. states and territories regarding
their self-reported compliance with the recommendations for screening for MCI. Data
collected on the survey included demographic data, current screening practices,
likelihood to screen, factors that increase likelihood to screen, barriers to screening,
screening tools used, and whether the provider’s current place o f employment has
specific screening guidelines.
This survey was comprised o f multiple-choice questions, with two questions
having the option for multiple answers. Questions 1-4 elicited responses concerning
demographic data including state o f residence, area o f practice, title o f provider, and age
o f provider. Questions 5 and 6 pertained to the first research question and elicited
responses concerning current screening practices and likelihood to screen. Questions 7
and 8 pertained to the second research question and attempted to discover factors that
increase likelihood to screen and barriers to screening. Questions 7 and 8 had the
option for the participant to select multiple answers if more than one option was
relevant to them. Questions 9 and 10 pertained to the third research question and
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elicited responses concerning screening tools used and whether the participant’s current
place o f employment has specific screening guidelines in place. The options listed in
the factors that increased likelihood to screen, barriers to screening, and screening tools
used were chosen based on current literature and prior research on MCI screening. This
survey did not undergo any psychomotor testing but had face validity determined by a
panel of expert researchers.
Setting of the Study
The setting for this study was primary care providers in Mississippi and other
surrounding U.S. states and territories. The research was conducted via a web-based
survey available to any primary care providers reached by the survey. The survey was
distributed through SurveyMonkey, Inc. protocols and through posting by the
researchers to social media outlets such as Facebook, Inc. and provider-specific groups.
To reduce the likelihood of unqualified subjects completing the survey, the provider
groups chosen on social media outlets were closed-groups open only to licensed
providers. The members o f the groups were introduced to the study, invited to complete
the survey at their discretion, and asked to share the survey with their qualified
colleagues if possible.
Population and Sample
The population for this study included primary care providers from Mississippi
and other surrounding U.S. states and territories. The survey generated a convenience
sample o f providers who agreed to participate by answering the web-based survey. This
sample was reached via postings on social media outlets and word of mouth. The
researchers studied approximately 100 surveys from providers at primary care clinics in
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the state of Mississippi and other surrounding U.S. states and territories. The survey
was available on SurveyMonkey, Inc. from March 26, 2018, to May 25, 2018.
Methods of Data Collection
After reviewing available options, the research team settled upon creating a
questionnaire through SurveyMonkey, Inc. Several local primary care providers were
presented with an opportunity to participate in the study. The research team also made
the survey available on social media outlets to local providers. Providers who agreed to
participate were given a thorough explanation o f the study, and any and all questions
were answered regarding the nature and reason for the research project and data
collection. Providers who agreed to participate were instructed to complete a brief
questionnaire through the SurveyMonkey, Inc. website. The information collected from
the survey remained anonymous, and no identifying data related to the provider or the
provider’s practice was available in any fashion.
Methods of Data Analysis
Data were compiled upon completion o f the surveys. The website utilized for
the survey, SurveyMonkey, Inc., compiled the analysis. Upon completion o f the
analysis, data were transferred to another source o f data collection, such as Microsoft
Excel. Findings were broken down using percentages, descriptive statistics, and central
tendency.
Other
At the end o f the survey, an option was provided to leave contact information,
including an email address for participants who would like to be updated with the
findings o f the study. Once all data were collected and measured, providers who
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participated in the study and elected to leave their contact information were sent a thank
you letter and the findings yielded from the research. A copy o f the outline o f the
research project and the guidelines, which were followed during the project, were also
provided.
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CHAPTER IV
Results
With an increasing number o f Americans over the age o f 65 years diagnosed
with various forms o f cognitive impairment, patients and patients’ families take on
substantial financial and emotional burdens o f managing a diagnosis o f cognitive
impairment. Over 10 years ago, the CDC estimated an average o f approximately $600
million was needed to manage a patient with Alzheimer’s disease living within an
assisted-living and/or nursing facility. With cost o f treatment steadily rising and quality
o f life diminishing for adults with cognitive impairment, the U.S. Government
mandated cognitive screenings o f patients the age o f 65 years during annual wellness
visits in order to increase early diagnosis and treatment o f age-related dementias (CDC,
2011).
Over 100 primary healthcare providers were anonymously surveyed via a webbased program to compute the following information: the amount o f primary providers’
compliance in completing cognitive impairment screenings o f older adults, any
probable barriers decreasing provider adherence o f implementing annual cognitive
testing o f older adults, and the preferred methods and tools utilized for cognitive
impairment screening o f those ages 65 years and older. The following chapter will
discuss the results o f this study and display primary care providers’ adherence to the
USPSTF and the Alzheimer’s Association’s recommendations and guidelines
advocating for annual cognitive impairment screening on patients aged 65 years or
greater.
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Profile of Study Participants
The target sample population for this study included primary care providers
practicing in the southeast region o f the United States. To reduce unqualified subjects
who were healthcare providers not practicing in primary care, this study’s anonymous,
web-based survey was advertised on voluntary, closed-groups on social media outlets
for licensed primary care providers. After participants in this study voluntarily
completed a brief anonymous survey, members o f the closed-groups were asked to
share the survey with their qualified colleagues at their discretion.
Over 100 participants completed the survey. Qualified subjects consisted o f
primary care providers, including physician assistants, certified nurse practitioners, and
physicians practicing in family medicine and/or internal medicine in primarily the
southeast region. While maintaining anonymity, the initial three questions o f the survey
provided disqualifying demographics in requesting participants’ state o f primary
practice, professional title, and primary area o f practice. With these screening questions
in place, the majority o f the study participants were identified as certified nurse
practitioners in family practice working in Mississippi.
Statistical Results
Primary care providers’ adherence to the USPSTF guidelines were examined by
an anonymous survey o f 101 providers fi"om all over the country, but primarily in
Mississippi and the surrounding states. The results are addressed below.
The providers who took the survey reported their professional title. In regard to
the type o f provider in the sample (A =101), 13 were medical doctors (MD), 84 were
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nurse practitioners (NP), and 4 were physician assistants (PA). The results for the
number o f responses from each of the three categories are shown in Figure 1.

What is your professional title?
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Figure 1. Professional title o f survey responders.

Figure 2 demonstrates the area o f practice of each provider who responded to
the survey. When the answers on the following questions were compiled and the data
analyzed, only answers from family practice, internal medicine, and geriatrics/long-term
care were used in the data analysis. This distinction was made because the providers
are practicing in the emergency room or urgent care for mainly acute issues and are not
held to the same screening standards. The answers associated with the urgent care and
emergency room providers will not be included in any o f the following data. The
results revealed 66 family practice, 15 internal medicine, 12 geriatrics/long-term care, 7
urgent care, and 1 emergency room response. Figure 2 displays a compilation of the
responses to the question regarding primary area o f practice.
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What is your primary area of practice?
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Figure 2. Area o f practice.

The third question elicited the age of the provider responding to the survey.
There were four categories given for age. Group 1 was ages 21-35 years. Group 2 was
ages 36-50 years. Group 3 was ages 51-65 years, and Group 4 was ages 65 years and
older. The age distribution of the providers who responded to the survey is shown in
Figure 3.
What is your age?
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The remaining questions in the survey examined the screening practices o f the
providers who responded. When asked which response best described screening
practices for mild cognitive impairment in patients age 65 years and older, 55 providers
responded that, I screen patients i f they or their fam ily mention a concern over memory
problems or a decline in ability to perform ADLs. A total o f 29 providers responded
that, I screen every patient aged 65 years and older every year at their wellness visit,
and 10 providers responded that I do not screen patients fo r mild cognitive impairment.
See Figure 4 for these findings.

Which response best describes your screening practices for mild
cognitive impairment in patients age 65 and older?

I do not screen %
patients for Mild \
Cognitive
impairment.

I screen every
patient aged 65 and
older every year at
their wellness...

I screen patients
if they or their
family mention a
concern over mem.

Figure 4. Screening practices.

The providers were also asked, “If a patient over 65 years of age comes into
your clinic without any obvious signs o f cognitive impairment, how likely are you to
screen this patient for mild cognitive impairment?” Their responses were divided into
four categories: (1) I will not screen, (2) I am not likely to screen, (3) I am somewhat
likely to screen, and (4) I will very likely screen. The responses were as follows: 15
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providers chose Iw ill not screen, 43 providers chose I am not likely to screen, 25
providers chose I am somewhat likely to screen, and 11 providers chose Iw ill very likely
screen. Ihese results are demons Ira Led in Figure 5.

If a patient over 65 years of age comes into your clinic without any obvious
signs of cognitive impairment, how likely are you to screen this patient for
mild cognitive impairment?
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Figure 5. Likelihood to screen.

Providers were asked which factor/factors make them more likely to screen
patients over 65 years o f age for mild cognitive impairment. They were instructed to
choose all relevant answers with an option to choose Other and describe a specific
answer not listed above. The option. Patient has not been screened in at least 12
months, was chosen 23 times; the option, Patient’s fam ily mentions deterioration or
change in p atient’s behavior, was chosen 72 times; the option. Patient appears
somewhat lost in the conversation, was chosen 69 times; the option. Patient admits to
forgetfulness or memory loss issues, was chosen 69 times; the option. Guidelines that
dictate how often a patient should be screened, was chosen 33 times; and Other was
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chosen two times with the responses as Personality changes and A ll o f the above.
These results are displayed in Figure 6.

Which factor/factors make you more likely to screen patients over 65 years
of age for mild cognitive impairment?
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Figure 6. Factors increasing likelihood o f screening.

Providers were asked which factor/factors make you less likely to screen
patients over 65 years of age for mild cognitive impairment. They were instructed to
choose all relevant answers and given the option to choose Other and describe a specific
answer. The choice Concerns over unnecessary testing was chosen 24 times; the choice
Lack o f clear guidelines on when and how to screen was chosen 31 times, the choice
Lack o f clear guidelines as to which screening tool to use was chosen 31 times, and the
choice Lack o f adequate time with each patient was chosen 65 times. The choice Other
was chosen 10 times with some responses being: I started from the beginning testing
this age group. No concerns, able to tell detailed medical (history) and recent events
well. Concerns that patients may be offended or upset by screening. Patient refusal,
(Patient) worries over consequences o f a dementia score. And No real treatment or
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cure and Insurance reimbursement is so poor and we have so many we have to see to
make any money. These results are displayed in Figure 7.

Which factor/factors make you less likely to screen patients over 65
years of age for mild cognitive impairment?
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Figure 7. Factors decreasing likelihood of screening.

In order to determine the preferred screening tool for MCI, the providers were
asked the following question: W hen/if you screen for mild cognitive impairment, and
what screening tool do you use most often? The responses were as follows: Mini Mental
State Examination was chosen 57 times. Short Portable Mental Status Questionnaire
was chosen 2 times, Mini-Cog was chosen 16 times, clock test was chosen 6 times, and
3-word recall test was chosen 9 times. The remaining 3 providers chose Another
screening tool and inserted the following 3 answers: MoCA, Animal fluency, and We
actually use a combination o f these-in yearly wellness exams, use 3-word recall and
clock test. I f there is an acute issue, use mini mental exam. The Health Risk Assessment
tool was not chosen by any provider, and 4 providers chose I do not use any screening
tools. These results are displayed in Figure 8.
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W hen/if you screen for mild cognitive impairment, what screening
tool do you use most often?
Another screening
tool
{do not use any
screening too b ^
3 Word Recall Test
Clock Test

Mini-Cog

Mini Mental State
Examination

Short Portable"
Mental Status
Questionnaire

Figure 8. Screening tool preference.

The providers were asked if their current clinic or current place of employment
had set guidelines in place for screening for mild cognitive impairment. O f the 94
responses used to analyze the data, 27 responded yes and 67 responded no. Those
results are displayed in Figure 9.

Does your current clinic/place of employment has set guidelines
in place for screening for mild cognitive impairment?

Yes

No

Figure 9. Guidelines at current place o f employment.
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The final question was added as an option at the end o f the survey. The question
consisted o f the option for participants to leave their email address if they wished to
receive the results o f the survey. This question was optional, and participants could
choose to end the survey without entering a response. If provided, email addresses were
not associated with any previous answers, which protected the anonymity o f the survey.
O f the 101 providers surveyed, 18 chose to leave their email address and were sent the
results at the conclusion o f data analysis.
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CHAPTER V
Summary, Conclusions, and Recommendations
Mild cognitive impairment (MCI) is a mild decline in a single domain or
multiple cognitive domains. A diagnosis of MCI drastically increases a person’s risk of
eventually developing Alzheimer’s disease. More than 16 million people in the U.S.
live with some form of cognitive impairment. Age is the biggest risk factor for
developing cognitive impairment, and advances in technology and medicine are
allowing people to live longer than ever. The projected increase o f this disease
incidence is 13.2 million by the year 2050 (CDC, 2011), thereby increasing the
healthcare strain and economic burden. In 2007, the CDC reported approximately $647
million as the average cost for a government-funded (i.e. Medicaid) nursing facility to
adequately care for an individual with Alzheimer’s disease (Wiese & Williams, 2015).
Alzheimer’s disease is not reversible; therefore, early detection, diagnosis, and
treatment o f MCI are imperative. Unfortunately, patients who are developing cognitive
impairment or who have dementia usually do not receive a formal diagnosis. Studies
indicated that most primary care providers were unaware o f cognitive impairments in
> 40% o f their cognitively impaired patients. Another study revealed that > 50% of
patients with dementia received no clinical cognitive screening by a primary care
provider. With efforts to increase early diagnosis and treatment o f age-related
dementias, the U.S. Government initiated the National Alzheimer’s Project Act, which
required routine cognitive screening o f adults over the age o f 65 years (Wiese et al.,
2014). According to the USPSTF, screening was recommended on a yearly basis and
applies to community-dwelling adults in the general primary care population who are
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older than the o f 65 years and have no signs or symptoms o f cognitive impairment. The
CMS amended their recommendations for the Annual Wellness Visit (AWV) effective
January 1, 2011, to include guidelines for screening for cognitive impairment during the
AWV (CDC, 2011). Over 5 years after the initiation o f new guidelines warranting
cognitive screening o f older adults over 65 years o f age, three questions justified
investigation:
1. Do primary care providers conduct mild cognitive impairment screenings
in older adults?
2. What provider-generated barriers may decrease the likelihood o f cognitive
screening in older adults during visits with primary care providers?
3. What screening methods do primary care providers use to detect mild
cognitive impairment?
The purpose o f this research study was to answer these questions. A
quantitative descriptive study design was utilized for this research. The research team
utilized a researcher-created, web-based survey on Survey Monkey Inc. to gather
information from primary care providers in Mississippi and other southern U.S. states
and territories. The information gathered included providers’ screening practices,
likelihood to screen, factors that increased or decreased likelihood o f screening, and
clinic screening guidelines. The results gathered will be used to increase provider
knowledge and improve patient outcomes.
This chapter contains the details o f a research study that was created with the
hope o f helping primary care providers understand the importance o f routinely and
consistently screening for and diagnosing cognitive impairment as early as possible.
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The summary and discussion o f the findings, the limitations o f the study, conclusions o f
the study, and the implication o f the findings are analyzed within the chapter.
Recommendations for future research and compliance with suggested screening
guidelines in primary care practice based on the conclusions o f this study are also listed.
Summary of Findings
Over 100 primary healthcare providers, including physicians, physician
assistants, and nurse practitioners, were anonymously surveyed via a web-based
program to compute the following: (a) primary providers’ compliance in completing
cognitive impairment screenings o f older adults, (b) probable barriers decreasing
provider adherence o f implementing annual cognitive testing o f older adults, and (c)
the preferred methods and tools utilized for cognitive impairment screening o f those
ages 65 years and older. O f the 101 surveys completed, 83.17% were submitted by
nurse practitioners, 12.87% were physicians, and 3.96% were physician assistants. O f
the survey takers, 65.35% practiced in primary care settings and 14.85% were in an
internal medicine setting. The remaining 19.8% o f survey takers practiced in urgent
care, geriatrics, long-term acute care, or emergency room settings. Survey results
indicated that only 28.71% o f providers routinely screened patients aged 65 years and
older every year at their wellness visit, and 58.42% only screened if the patient or a
family member voiced concern over memory problems or a decline in the ability to
perform ADLs.
Surprisingly, even with the current guidelines in place to screen every patient 65
years or older for MCI at their AWV, 44.55% o f providers answered that they were not
likely to screen for MCI if the patient presented with no obvious signs o f MCI, and only
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12.87% answered that they were very likely to screen the patient. Eighty percent o f
providers answered that the patient’s family member mentioning deterioration or
changes in the patient’s behavior was the biggest factor in choosing to screen a patient
for MCI, and 72.22% answered that the biggest factor deterring them from routinely
and consistently screening patients was lack o f adequate time with the patient. The
Mini Mental State Examination was the most popular screening tool used by 57.43% o f
providers.
Discussion of Findings
In one o f her first research studies on the correlation o f behavior to enhancing
health promotion, Nola Pender found that many individuals would utilize prevention
and health-promoting services when made available to their community. Although the
research focus was on the behavioral influences affecting the utilization o f nurse
practitioners as opposed to physicians, the study revealed most o f the sample population
agreed to partake in health-promoting services when offered by any healthcare provider
(Pender & Pender, 1980). This finding would later become the HPM ’s theoretical claim
stating, “Families, peers, and healthcare providers are important sources o f
interpersonal influence that can increase or decrease commitment to and engagement in
health-promoting behaviors” (Pender, 2011, p. 5). The current study addressed the
significance o f healthcare provider commitment to and engagement in positive
healthcare outcomes, especially regarding cognitive screening in older adults.
The findings o f the current researchers were similar to those o f Fowler et al.
(2015) in that the current study also revealed primary care providers are lacking in their
assessment o f MCI. Fowler et al. (2015) aimed to determine if identifying patients wdth
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mild cognitive impairment could result in a change in providers’ approach to treatment
or if an early diagnosis could impact the progression o f cognitive decline. Therefore,
the findings o f each study were congruent, and each study demonstrated a need for
primary care providers to screen for MCI regardless o f available time or standardized
tool.
Muller et al. (2017) concluded there is a need to develop fast, easy, noninvasive, and inexpensive diagnostic tools to accurately detect people with cognitive
impairment and dementia. The current researchers found that 72.22% o f the providers
surveyed stated that time was the determining factor in not screening for cognitive
impairment. Although there are significant data found related to the importance o f early
screening and diagnosis o f mild cognitive impairment, providers continue to find less
and less time for screenings related to the number o f patients to be seen to meet
reimbursement goals. For that reason, Muller et al. (2017) and the current study echo
similar findings in the need for a standardized, rapid, and inexpensive diagnostic tool to
be used in the primary care setting.
Malmstrom et al. (2015) found that primary care providers frequently do not
properly identify persons with cognitive dysfunction because no gold standard
screening tool currently exists to detect cognitive dysfunction. Because dementia and
cognitive impairment interfere with patients’ ADLs, the lack o f consistent cognitive
screening decreases the change o f early diagnosis and possibly increases the likelihood
o f detrimental effects and/or events. Similarly, the current researchers found that
34.44% o f providers stated they did not screen because there is a lack o f standardized
tools. The current study and the reviewed literature agreed in that, if given a
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standardized tool, primary care providers will be able to enhance the patient’s
continuity in the healthcare setting, as well as provide patients and their families with
the confidence and support needed to accept early screening.
Although not addressed in the study’s questionnaire and research, Fowler et al.
(2 0 1 2 ) recognized another aspect in barriers to completing routine cognitive
assessment. Fowler et al. (2012) performed a cross-sectional study to determine
primary care patients’ perceptions of dementia screening and to evaluate the possibility
o f an association between their perceptions and their willingness to undergo screening.
In the current study, when asked about factors making it less likely for providers to
screen patients 65 years o f age and older, one participant specified that (Patient)
worries over consequences o f a dementia score. A nd No real treatment or cure. While
patient perception was not originally considered in the design o f the present study,
Fowler et al. (2012) discussed significant reasoning for further investigation into this
component.
Regardless o f identified barriers, the current study and literature reviewed
demonstrated significant need for early cognitive screening in adults age 65 years and
older. According to Pender’s work with the Health Promotion Model, the nursing
discipline is responsible for linking the person and environment to promote behavioral
changes leading to optimal health (Pender, 2011). Therefore, it is important to consider
the outcome o f the patient’s well-being. Whether lack o f education, lack o f time, non
standardized screening tools, or negative patient perceptions, it is imperative for the
primary care provider to treat the patient physically and psychosocially in order to
produce the best possible outcome.
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Limitations
Although well-constructed to obtain primary care providers’ adherence to the
current guidelines regarding cognitive screening in older adults, the current study
presented with several limitations, which may have decreased the generalizability of its
findings. The federal government issued guidelines requiring annual cognitive screening
o f older adults, however no gold standard screening tool existed for detecting cognitive
impairment; therefore, this study’s results o f the primary care providers’ utilization and
competency o f a single screening tool could not be accurately measured. In lacking a
single cognitive screening tool, the researchers were unable to uniformly measure and
critique study participants. In addition to the absence o f an exemplar cognitive
screening tool, there was no benchmark screening instruments with a high specificity
and/or sensitivity for diagnosing MCI. Most cognitive screening tools detected
generalized cognitive impairment and not specifically MCI, which required further
assessment and possible referral to a specialist for a more accurate diagnosis.
The validity o f the research was affected by the small sample size and
geographical location. The research project was only implemented as a survey and was
posted on several social platforms for primary care providers. The sample size was
made up o f only 101 primary care providers’ responses. Additionally, posting on social
media platforms allows for providers from many states to have access to the survey.
The majority o f respondents were from Mississippi; however, several other states were
represented. Thus, the small sample size and geographical location limited the amount
and number o f samples that could be reviewed, narrowing our field o f research and
generalizability.
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Another key limitation within the study was that not all o f the providers
surveyed were primary care providers. O f the respondents, 7.62% did not work in a
primary care setting. O f the 7.62%, 0.99% worked in an emergency room setting and
6.93% worked in an urgent care setting. Working in settings outside the primary care
setting could potentially affect the intended results, as emergency/urgent care settings
are not required to test for cognitive impairment on a routine basis. Another limitation
was the possibility o f inadequate reporting by the healthcare providers. Without a
uniform cognitive screening tool and a substantial number o f primary providers
excluded in the convenience sample, this research study proposed several limitations,
which may have affected the generalizability o f the study's findings. Furthermore,
collecting data in a period o f 30 days may have limited the amount o f surveys that could
have been obtained.
Conclusions of the Findings
The goal o f the current study was to determine primary care providers’
adherence to the guidelines established by the USPSTF for mild cognitive impairment
screenings. According to the results, the researchers determined adherence to the
guidelines established by the USPSTF were inadequate. The results revealed that only
12.87% of primary care providers surveyed screen according to the recommendations o f
the USPSTF. Consequently, 28.71% o f the primary care providers surveyed stated they
do not screen at all for MCI. Based on these results, the researchers concluded that
compliance to recommended screenings established by USPSTF among primary care
providers is insufficient and there was a great need for further education on this topic.
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Implications
The purpose o f this study was to determine primary care providers’ adherence to
USPSTF and the Alzheimer’s Association’s recommendation and guidelines advocating
annual cognitive impairment screening on patients ages 65 years or greater. Primary
care providers, including nurse practitioners and advanced practice nurses, have the
potential to take an aggressive approach to MCI detection and treatment by adhering to
USPSTF recommendations. This current study utilized Nola Pender’s Health
Promotion Model (HPM) as a guide to identifying the perceived barriers to action and
perceived self-efficacy o f primary providers’ nonadherence to the national guidelines
requiring annual cognitive screening o f older adults. Through surveying primary care
providers, this study incorporated the theoretical assumptions and propositions o f the
HPM to promote compliance with the national standard o f routine cognitive screening
in the geriatric population.
Based on the findings o f this study, there is a great need for further education of
the USPSTF guidelines and the Alzheimer’s Association recommendations for routine
screenings for MCI in the primary care setting. As nurse practitioners are often the first
access to health care in rural areas, this education o f early screenings is o f great
importance. In 2007, the Centers for Disease Control and Prevention (CDC) found
approximately $647 million as the average cost for a government-funded (i.e. Medicare)
nursing facility to adequately care for an individual with Alzheimer’s disease (Wiese &
Williams, 2015). With adequate routine screenings and early diagnosis, providers can
decrease the risk o f complications related to MCI and decrease the costs o f caring for
individuals with cognitive impairments later in diagnosis. Advance practice nurses, as
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well as other providers, not only have the ability to change outcomes for patients; but
they have the responsibility also to educate their patients, families, and colleagues about
the significance o f early screening fur MCI.
The CMS recommends indulging cognitive assessment screening for early
detection o f MCI as a part of the requirements o f the annual wellness visit for adults
ages 65 years and older (see Appendix D). Even though CMS recommends cognitive
screenings annually, they do not specify what screening approach to use. The federal
government issued guidelines requiring annual cognitive screening o f older adults;
however, no gold standard screening tool existed for detecting cognitive impairment. In
addition to the absence o f an exemplar cognitive screening tool, there were no
benchmark screening instruments with a high specificity and/or sensitivity for
diagnosing MCI. Most cognitive screening tools detected generalized cognitive
impairment and not specifically MCI, which required further assessment and possible
referral to a specialist for a more accurate diagnosis. Due to the stated findings, further
implications for standardized cognitive impairment screening and scoring across
different disciplines in the medical field would provide better continuity in care for
patients and decrease prevalence o f delayed diagnosis o f MCI.
Recommendations
Based on the significant findings o f this study, recommendations for future
study should be discussed. It is important to consider whether or not providers are
influenced in screening for MCI. Payer source should be identified in those patients
screened to identify a trend. It would be interesting to identify whether or not providers
are considering the reimbursement versus the long-term benefit prior to screening
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patients for MCI. Another argument could lie in the outcomes o f those identified as
having an MCI. Once identified, research could include plan o f care after diagnosis.
Researchers could evaluate the aggressiveness o f treatment once the provider makes the
diagnosis. Lastly, one aspect to consider when performing future research is the
provider’s awareness o f the recommended guidelines. Research aimed at identifying
whether or not providers are aware o f current recommendations for screening for MCI
could foster fruitful research data for long-term planning. As previously discussed
regarding implications, a standardized assessment tool is vital to continuity o f care
between providers and prevention/treatment o f MCI. With proper education and an
appropriate assessment tool, patients would experience less decline in cognitive
abilities, increased independence and safety, a decrease in caregiver burden, a decrease
in the progression o f dementia, and an increased chance o f maintaining baseline
cognitive status.
As discussed, implications for future research were a vital outcome o f this study.
While the study findings are significant, without further data, the motivation to increase
awareness is minimal. The outcomes o f this study indicate that further research for
MCI screening in the primary care setting by nurse practitioners and physicians is
warranted. The study raised the following aforementioned topics for future research.
Further investigation into providers’ awareness o f current guidelines, deterring payor
sources, the impact o f time to screen, and the availability o f screening tools would yield
more gainful data for future implications.
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Preface
The U.S. P reventive S ervices Task Force (U SP S TF) m a ke s reco m m e nd a tion s a b o u t th e e ffectiveness o fs p e d h c p reventive care se rv ic es fo r p atie nts w ittio u t re la te d sig n s o r
sym ptom s.
it trases its recom m ertdations on th e e vide n ce o f both the b e n e fits a n d h arm s o f tite s e rvice a n d a n a ssessm en f o f the balance. The U S P S T F does n o t co n s id e r the co sts o f
p ro viding a service in this a sse ssm e n t
The U S P S TF re cognizes th a t d in ic a i d e d s io n s in volve m o re co nsid e ra tion s tha n evidence alone. C lin id a n s sh ou ld und erstan d the e v id e rx e b u t in dividualize d e d s io n m akirtg to
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Rationale
Importance
D em entia affects approxim ately 2.4 to 5 .5 million A m ericans. Its p revalence in cre a se s with ag e, to 5% in p e rso n s a g e d 71 to 79 y e a rs, 24% In th o se a g e d 80 to 89 y e a rs, and
37% In th o se older ttian 90 y ears. Mild cognitive im pairm ent (MCI) is different from dem entia in th at th e cognitive im pairm ent is not se v e re en ough to interfere with instrum ental
activities of daily life. It is difficult to estim ate th e p revalence of MCI, an d estim a te s ran g e widely, from 3% to 42% in adults a g e d 65 y e a rs an d older.

Detection
The U SPSTF found a d e q u a te evidence th at so m e screening tools h av e sufficiently high sensitivity a n d specificity to b e dinicaliy useful in identifying dem entia.

Benefits o f Detection and Early Intervention
T he U SPSTF found in ad eq u ate direct ev idence on th e benefits of screening for cognitive Im pairm ent Evidence sh o w s th at sev eral drug th erap ies an d nonpharm acologic
Interventions have a small effect on cognitive function m e a s u re s In th e sh o rt term for patien ts with mild to m o d erate dem entia, but th e m agnitude of th e clinically relevant benefit
Is uncertain. The USPSTF found a d e q u ate evidence th at interventions targ eted to caregivers h av e a small effect on m e a su re s of caregiver burden and d e p re ssio n , but the
m agnitude of the clinically relevant benefit is uncertain. The USPSTF found no published ev idence on th e effect of screening on decision m aking or planning by patients,
clinicians, o r caregivers.

Harms o f Detection and Early Intervention or Treatment
T he U SPSTF found Inadequate evidence on th e h arm s of screening for cognitive impairm ent a n d of nonpharm acologic interventions. It found a d e q u ate evid en ce th at
acetylcholinesterase inhibitors (AChEis) a re a sso c ia te d with a d v e rse effects, so m e of which a re serious, including central n ervous sy stem disturbances a n d arrhythmia.
Gastroirrtestinai sym ptom s a re also comm on.

USPSTF Assessment
T he U S PSTF concludes th at th e evidence on screening for cognitive im pairm ent is lacking a n d that th e balan ce of benefits a n d h arm s cannot b e determ ined.

h ttp s ://w w w .u s p re v e n tlv e s e rv ic e s ta s k fo rc e .O rg /P a g e /D o c u m e n t/R e c o m m e .te m e n tF in a i/c o g n itiv e -im p a irm e n t-ln -o ld e r-a d u U s -s c re e n in g # c o n s ld e r
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Clinical C onsiderations
Patient Population Under Consideration
This recommendation applies to universal screening with formal screening instruments in community-dwelling adults in the general primary care population who are older than
age 65 years and have no signs or symptoms of cognitive impairment. Early detection and diagnosis of dementia through the asse ssm e n t of patient-, family-, or physicianrecognized signs and symptoms, som e of which may be subtle, are not considered screening and are not the focus of this recommendation.

Suggestions for Practice Regarding the I Statement
Potential Preventable B urden

The prevalence of dementia in th e United States is 5% in persons aged 71 to 79 years, increasing to 24% in those aged 80 to 89 years and 37% In those older than 90 years^> ^
The prevalence of older adults with MCI is difficult to estim ate b ecau se of differences in the definition of MCI and m ethods used in studies; estim ates range widely, from 3% to
42% in adults a g e 65 years and older. Approximately 40% to 50% of older adults report subjective memory symptoms. The rate of progression of MCI to dementia is uncertain
2

Although the evidence on routine screening is insufficient, there may be important reasons to identify early cognitive impairment. In addition to its potential to help patients make
diagnostic and treatm ent decisions, including treatm ent of reversible c a u se s of dementia and m anagem ent of comorbid conditions, early recognition of cognitive impairment
allows clinicians to anticipate problems patients m ay have in understanding and adhering to recommended therapy. This Information may also be useful to patients and their
caregivers and family m em bers in anticipating and planning for future problems that may develop a s a result of progression of cognitive impairment. Although the overall
evidence on routine screening is insufficient, clinicians should remain alert to early signs or symptoms of cognitive impairment (for example, problems with memory or language)
and evaluate as appropriate. The National Institute on Aging h as information on the detection and m anagem ent of cognitive impairment for patients and clinicians, including a
database of tools to detect cognitive impaintient (available at www.nia.nih.govThis link goes offsite. Click to read the external link disclaimer).
Potential Harms

Information about th e harnis of screening, including labeling and the effect of false-positive results, is limited. Acetylcholinesterase inhibitors are associated with adverse effects,
som e of which are serious, including central nervous system disturbances and bradycardia. Gastrointestinal symptoms are also common. Information about the harms of
nonpharmacologic interventions is limited, but th ese harm s are assum ed to be small. Exercise interventions are not associated with serious adverse effects.
Costs
The cost of screening varies depending on the screening instrument. Som e instmments take little time and are free to th e public. The most widely studied instnjment, the MiniMental State Examination (MMSE), tak es approximately 10 minutes to administer and is not free. Total health, long-term, and hospice care costs for dementia in the United
States were an estimated $183 billion in 2011. Medicare and Medicaid pay approximately 40% to 70% of th ese costs, representing $130 billion. These costs do not include the
estimated $202 billion in uncom pensated care that infonnai caregivers provide annually^.
Current Practice

At present, diagnosis of dementia primarily occurs a s a result of a clinician's suspicion of patient symptoms or caregiver concerns and not a s a result of routine fornial screening.
As much a s 29% to 76% of patients with dementia or probable dementia in the primary care setting are u n d ia g n o s e d ^ , in 2011, Medicare added detection of cognitive
impainnent to the new annual w ellness visit benefit, and th e Alzheimer's Association has published guidance on how to implement this benefit.

Assessment of Risk
Increasing age is th e strongest known risk factor for cognitive impairment. The e4 allele of the apolipoprotein E gene is a reported risk factor for Alzheimer disease. Other
reported risk factors for cognitive impairment include cardiovascular risk factors (such a s diabetes, tobacco use, hypercholesterolemia, hypertension, and the metabolic
syndrome), head traum a, learning disabilities (such a s Down syndrome), depression, alcohol abuse, physical frailty, low education level, low social support, and having never
been married.
Several dietary and lifestyle factors have been associated with decreased risk for dementia; th ese factors have weaker supporting evidence than th o se previously mentioned.
Adequate folic acid intake, low saturated fat intake, longer-chain w-3 fatty acids, high fruit and vegetable intake, MedKemanean diet, m oderate alcohol intake, educational
attainment, cognitive engagem ent, and participation in physical activity are all associated with d ecreased risk for dementia.

Screening Tests
Screening tests for cognitive impairment in the clinical setting generally include asking patients to perform a series of task s that a s se s s at least 1 cognitive domain (memory,
attention, language, and visuospatial or executive functioning). Blood tests and radiology examinations a re not currently u sed a s screening tests but are often used after a
positive screening result to confirm the diagnosis of dementia and determine its subtype. Although optimum sensitivity and specificity of the MMSE probably vary depending on
the patient's age and education level, a large body of literature suggests that a general cut point of 23/24 or 24/25 (score considered ‘positiveTnegative’) is appropriate for most
primary care populations.
Other instruments with more limited evidence include the Clock Drawing Test, Mini-Cog Test, Memory Impainnent Screen, Abbreviated Mental Test, Short Portable Mental
Status Questionnaire, Free and Cued Selective Reminding Test, 7-Minute Screen. Telephone Interview for Cognitive Status, and Informant Questionnaire on Cognitive Decline
in the Elderly. Each o f th ese te s ts has reasonable perfonnance in som e studies, but estim ates of sensitivity and specificity vary, and the optimum diagnostic threshold or cut
point for many of th ese instalm ents is unclear. For infom ation on all instruments reviewed by the USPSTF, including the Montreal Cognitive Screening A ssessm ent, the St.
Louis University Mental Status examination, and other instruments with 2 or fewer studies, s e e the full evidence report (available at wwww. uspre ventiveserviceslaskforce org)^.

Treatment and Interventions
Treatment of cognitive impairment focuses on several signs and symptoms, including quality-of-life, cognition, mood, and behavioral impairments.
Several pharmacologic and nonpharmacologic interventions aim to prevent, slow, or reverse cognitive impainnent in older adults or improve caregiver burden and depression.
Pharmacologic treatm ents approved by the U.S. Food and Doig Administration include AChEls and memantine. Nonpharmacologic interventions include cognitive training,
lifestyle behavioral interventions, exercise, educational interventions, and multidisciplinary care interventions. Several interventions focus on the caregiver and aim to improve
caregiver morbidity and delay institutionalization of persons with dementia.

Other Approaches to Prevention
The USPSTF has published recommendations related to several of th e risk factors for cognitive impairment, including counseling on tobacco cessation, alcohol use, healthful
diet, physical activity, and falls prevention and screening for high cholesterol, hypertension, and depression (available at wwww.uspreventlveservicestaskforce.org).

https://w w w .uspreventiveservicestaskforce.org/Page/Docum ent/Recom me..le m en tF inal/cogn itive-im pairm ent-in-old er-adu lts-screening#co nside r
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O ther C o n sid eratio n s
Reseai c/i Needs and Caps
More research on screening for and treatm ent of MCI is needed. Evidence on the effect of screening and early detection of mild to m oderate dem entia on decision making,
planning, or other important patient outcom es is a critical gap in the evidence. Given th e lack of evidence that treatm ent affects long-term cognitive outcom es for mild to
m oderate dem entia, its effect on decision making and planning could b e th e most compelling reaso n for screening. However, no studies provided information on this effect. More
research on the harm s of screening is needed. R esearch on new interventions that ad d ress th e changing n e e d s of patients and families and interventions that clearly have an
effect on the long-term clinical course of mild to m oderate dem entia are also critically needed.

D iscussion
D iscussion
Burden o f Disease
Dem entia is an acquired condition characterized by a decline in at least 2 cognitive dom ains (loss of memory, attention, language, and visuospatial or executive functioning) that
is severe enough to affect sociai or occupational functioning^. Patients with dem entia m ay also exhibit behavioral and psychological symptoms. The major dem entia syndrom es
in older adults include Alzheimer disease, vascular dem entia, frontotemporal dem entia, dem entia with Lewy bodies, Parkinson d ise a se with dem entia, and dem entia of mixed
c a u se (8). Mild cognitive impairment Is different from dem entia in that the cognitive impairment is not sev ere enough to interfere with instnim ental activities of daily life.
Dem entia affects approximately 2.4 to 5.5 million Americans, but its prevalence is difficult to determ ine becau se of differences in definitions an d populations u sed in studies (8 10). Age is the m ost important risk factor. Data from large population-based surveys indicate that the prevalence of dem entia in th e United S ta te s is 5% in perso n s ag ed 71 to 79
years, 24% in th o se ag ed 80 to 89 y ears, and 37% in th o se older than 90 years*^. Prevalence varies by race; prevalence in adults ag ed 71 years and older in 1 large study w as
21.3% for blacks and 11.2% for w hites’'''. The prevalence of Alzheimer d isease in Hispanics is approximately 1.5 tim es that se en in th e white p o p u latio n ""'^ . Dem entia also
affects more wom en than men. In p ersons ag ed 71 years and older, approximately 16% of wom en have dem entia com pared with 11% of m en; th e se differences are primarily
explained by w om en's longer life expectancy rather than any sex -b ased risk factors
Alzheimer d isease accounts for 60% to 80% of all dem entia, frontotemporal dem entia
accounts for 12% to 25%, 10% to 20% is considered vascu lar dem entia, 5% to 10% is considered dem entia with Lewy bodies, an d 10% to 30% is considered dem entia with
mixed cause®'
It is difficult to estim ate the prevalence of MCI, and estim ates range widely, from 3% to 42% in adults ag ed 65 y ears and older, depending on th e population
and diagnostic criteria used'® ' '^ .

Scope o f Review
In 2003, the USPSTF concluded th at th e evidence w a s insufficient to recom m end for o r against routine screening for dem entia in older adults. To update its recom m endation,
the USPSTF comm issioned a system atic review of the evidence on screening for cognitive impairment, including dem entia and MCI. The evidence review gathered evidence on
the benefits, harm s, and test perform ance of screening instruments to detect cognitive impairment in older adults and th e benefits and harm s of commonly u sed treatm ent and
m anagem ent options for older adults with MCI or early dem entia and their caregivers. Important potential benefits included decision making, cognitive function, physical function,
quality of life, safety, and caregiver burden. The USPSTF reviewed a significant am ount of evidence, including available studies on caregiver burden and future planning (the full
evidence report is available at wwww.uspreventiveservicestaskforce.org)'. The review focused on screening adults in th e general primary care population and m an ag em ent of
screen-detected patients with cognitive Impairment, excluding delirium. The review on treatm ent and m anagem ent focused on studies of adults with mild to m oderate dem entia
be c au se th ese are th e patients m ost likely to be identified by screening.

Accuracy o f Screening Tests
The review identified 55 studies on instalm ents that screen for cognitive impainnent. Forty-six of th e studies provided evidence on th e sensitivity and specificity of screening for
dem entia, and 27 provided evidence on MCI. Included studies had to u se a diagnostic reference standard (such a s the D iagnostic a n d Statistical M anual o f M e n ta l DisonJers,
Third or F o ig th E dition) o r criteria from th e National institute of Neurological Disorders and Stroke and the Alzheim er's D isease and Related Disorders Association (now known
a s the Alzheimer's Association). T h e se studies w ere conducted in primary c are-relev an t populations, and m ost instruments w ere brief (slO minutes) and adm inistered in a
clinical setting. Studies on self-adm inistered instruments w ere also reviewed.
Screening instruments evaluated in more than 2 studies include the MMSE, Clock Drawing Test, verbal fluency tests, Informant Q uestionnaire on Cognitive Decline in the
Elderly, Memory Impairment Screen, Mini-Cog Test, Abbreviated Mental Test, and Short Portable Mental S tatu s Questionnaire. The MMSE w as the most evaluated instalm ent,
with 25 published studies. The MMSE is a 30-point instrument with 11 items. It h a s been studied in various populations; the m ean age of participants ranged from 69 to 95
y ears, the m ean prevalence of dem entia ranged from 1.2% to 38.0%, and education level also varied widely but w as not always reported. For the most commonly reported cut
points (23/24 o r 24/25 [scorn considered 'positiveTnegativeT), the pooled sensitrvity from 14 studies (involving 10,185 participants) w as 88.3% (95% Cl, 81.3% to 92.9% ) and
specificity w a s 86.2% (95% Cl, 81.8% to 8 9 .7 % )''^ . The other Instruments w ere studied in far few er studies (4 to 7 studies each), had limited reproducibility in primary c a r e relevant populations, and had unknown optimum cut points. Sensitivity and specificity ranged widely in th ese studies.

Effectiveness of Early Detection and Treatment
No trials evaluated th e direct effect of screening for cognitive impairment by comparing screen ed and u nscreened older adults and reporting important patient outcom es,
including decision-making outcom es. The review identified more than 130 studies on several interventions for m anaging or treating mild to m oderate dem entia, including
pharm acologic and nonpharm acological interventions. Pharmacologic interventions in duded U.S. Food and Drug A dm inistratiorr-approved m edications for th e treatm ent of
Alzheimer d isease with the purpose of preventing or delaying cognitive im painnent (AChEls and mem antine), m edications for cardiovascular risk reduction for vascular
dem entia, nonsteroidal anti-inflammatory dntgs, gonadal steroids, and dietary supplem ents. The review also considered evidence on nonphannacologic interventions, including
interventions aimed primarily at the caregiver or p atient-caregiver dyad and at th e patient (such a s cognitive training, rehabilitation, or stimulation, with or without motor skills
training interventions; exercise inten/entions; multidisciplinary care imerventions involving a sse ssm e n t and care coordination; an d education-only interventions).
Fifty-four trials provided evidence on A ChEls for th e treatm ent of mild to m oderate Alzheimer d isease (donepezil, galantam ine, rivastigmine, and tacrine), including 4 trials of
persons with MCI. Ten additional trials reported on m em antine in persons with m oderate dem entia. Many studies reported differences in s c o re s on the Alzheim er's D isease
/Assessm ent Scale-Cognitive S ubscale (ADAS-cog). The /AD/AS-cog is a validated instrument that a s s e s s e s memory, attention, orientation, language, an d praxis. S c o res range
from 0 to 70, with higher sco res signifying greater cognitive impairment; a ch an g e of 4 points or more is commonly accepted to be clinically significant for patients with mild to
m oderate dem entia. Acetylcholinesterase inhibitors and m em antine improved global cognitive function by approximately 1- to 3-point differences on the ADAS-cog. A m eta
analysis of 7 rivastigmine trials reported a 3-polnt difference on th e ADAS-cog (-3 .0 6 [95% Cl, -4 .4 8 to -1.65]; f = 92.6%). Only 4 trials w ere conducted in perso n s with MCI
and reported global cognitive function'® "^'. T h ese trials of donepezil and galantam ine generally show ed a small but unclear clinical effect on global cognitive function. Only one
half of the trials reported global physical function; findings w ere inconsistent and sparsely reported. Few studies reported outcom es beyond 6 m onths. Longer-term studies w ere
generally consistent with studies of shorter duration and dem onstrated statistically significant small improvements of unknown clinical importance.
The review considered 26 studies th at evaluated other m edications or supplem ents, including low-dose aspirin, 3-hydroxy-3-methylglutaryl coenzym e A reductase inhibitors (or
"statins'^, nonsteroidal anti-inflammatory drugs, gonadal steroids, and dietary supplem ents, and did not find any evidence that th e se m edications or supplem ents provided a
benefit in global cognitive or physical function in p ersons with mild to m oderate dem entia o r M C I'.

h ttp s://w w w .uspreven tiveservicestaskfo rce.org/P age/D o cum e nt/R e com m e..tem entF ina l/cognitive -im p airm e nt-in -older-a dults-scree ning ffconsid er
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Tfie review identified 59 studies ttiat evaluated th e effect of nonpharm acological interventions aim ed a t th e caregiver or both th e patient an d caregiver. Most of th e s e trials
evaluated interventions that included an educational com ponent d esig n ed to in crease caregiver skills. Although th e a p p ro a c h e s to education in th e interventions varied, th ere
w a s a generally co n sisten t finding of a small benefit on caregiver bu rd en an d d ep ressio n ou tco m es in p e rso n s caring for patients with m o d erate dem entia. The clinical m eaning
of the c h a n g e s in caregiver burden and d ep ressio n is unknown but on a v e ra g e is probably small at best. Ten stu d ies on e x ercise interventions w ere reviewed; the clinical effect
of th e s e results on im portant o u tco m es is uncertain b e c a u s e of the limited n u m ber of trials a n d variability in studied populations, exercise interventions, an d reported outcom es.
Fifteen cognitive intervention trials provided so m ew h at inconsistent evidence that cognitive stimulation with o r without cognitive training s e e m s to improve global cognitive
function m e a su re s in the short term for p erso n s with MCI or dem entia. However, the m agnitude and certainty of th e dinicai benefit is difficult to determ ine b e c a u s e of the limited
num ber of trials, dinicai an d statistical heterogeneity com bined, an d im predsion of results.

Potential Harms o f Screening and Treatment
No studies reported on d ire d or indirect harm s from false-positive or false-negative results, psychological harm s, u n n e c essa ry diagnostic testing, or labeling. O n e study
provided so m e information on the potential h arm s of screening for cognitive impairm ent in primary care, in this study of 3573 older adults, approxim ately o n e half of patients who
had a positive screening result for cognitive impairm ent (207 out of 434 patients) d e d in e d a formal diagnostic work-up for d em entia. Only 233 out of 3573 p artid p an ts initially
d e d in e d to b e screened^^'
A dverse effects from AC hEls are comm on. W ithdrawal or discontinuation ra te s in stu d ies of AC hEis w ere 14% for donepezil an d rivastigmine an d 17% for g alantam ine. Serious
a d v e rse effects from th e s e m edications se em to occur with similar frequency a c ro ss the different AChEls. Bradycardia an d a d v e rse effects related to b radycardia (such a s falls
and syncope) m ay result from taking AChEls. Tacrine, which h ad very high discontinuation ra te s in trials, h a s an uncom m on but serio u s ad v erse effect of liver toxidty. Tacrine is
no longer u sed in the United S ta te s for this reaso n . In trials, m em antine did not differ from placebo in th e p erc e n tag e of withdrawals from m edication d u e to a d v e rse or serious
ad v e rse effed s. E vidence on the h arm s of nonpharm acologic interventions in patients with dem entia or their careg iv ers is limited.

Estimate o f Magnitude o f Net Benefit
T he U SPSTF found no evidence on the d ire d benefits and h arm s of screening for cognitive impairm ent and therefore considered the indired e vidence on screen in g accuracy,
early treatm ent, and harm s. Evidence is a d e q u ate that so m e screening tools c a n accurately identify dem entia. T reatm ent of mild to m o d erate dem entia with several drug
th erap ies and nonpharm acologic interventions results in small im provem ents in m e a su re s of cognitive fu ndion a n d caregiver outcom es, but the dinicai significance of th e s e
im provem ents is uncertain. T h e USPSTF found no published ev idence on th e e ffe d of screening on d e d sio n making or planning by patients, d in id a n s, or caregivers. Evidence
on the harm s of screening and nonpharm acologic interventions is in ad eq u ate. The U SPSTF found a d e q u ate evid en ce th at AC hEls a re a s s o d a te d with a d v e rse e ffe d s, som e of
which are serious. Overall, the U SPSTF w as unable to estim ate th e b a la n c e of benefits and harm s of screening for cognitive impairment.

How Does Evidence Fit With Biological Understanding?
D em entia is the m anifestation of various pathophysiologic c h a n g es in th e brain; therefore, th e developm ent of early interventions that result in an important dinicai e ffe d on all
ty p es of dem entia is difficult. The e x a d c au sal m echanism for m any ty p es of dem en tia is unknown. Most dem entia in th e United S ta te s is a result of Alzheim er d ise a se , which is
th e target of m ost U.S. Food an d Drug Adm inistration-approved d rugs for dem entia. Given that c u n e n t th era p ie s for dem entia do not s e e m to a ffe d th e long-term progression of
mild to m oderate cognitive impairment, th e ho p e is for e ffedive interventions th at can help patients an d careg iv ers p rep are for dealing with d em entia sym ptom s.

Response to Public Comment
A draft version of this recom m endation statem en t w a s p o sted for public com m ent on the U SPSTF W eb site from 5 N ovem ber to 2 D ecem ber 2013. S everal com m ents ag re e d
with the insuffidency of th e evidence. A few com m en ts d isag reed with th e recom m endation, an d so m e com m ents e x p re sse d confusion about th e m eaning of an I sta te m e n t and
how it m ay a ffe d early d e te d io n . The recom m endation contains su g g estio n s for practice regarding the I sta te m e n t an d n o tes that, although evid en ce on routine screen in g is
insuffident, there m ay b e important rea so n s to identify eariy cognitive impairm ent in sp e d fic d rcu m sta n c e s. O th er com m ents req u ested darification on th e m eaning of screening
and for whom th e recom m endation is intended; in resp o n se , information w a s ad ded to th e recom m endation. A few com m ents provided evidence on additional risk fa d o rs for
cognitive impairm ent a n d su g g e ste d additional rese a rch gaps; th e s e w ere ad d e d to the Clinical C onsiderations s e d io n . T h e im portance of v ascu lar c a u s e s of dem entia w a s
m entioned in a few com m ents, and information on USPSTF recom m endations related to vascular risk fa d o rs w a s ad ded.

U pdate of P re v io u s USPSTF R e co m m en d atio n
This reœ m m endation u p d a te s th e 2003 U SPSTF recom m endation on screen in g for dem entia. This u p dated recom m endation differs from th e 2003 recom m endation in that it
considers the evidence on screening for and treatm en t o f MCI in addition to dem entia an d how screening a ffe d s d e d s io n making and planning. The current evid en ce review
found much m ore information on the test perform ance of screen in g instrum ents than in 2003, and th e U SPSTF c o n d u d e d th at th ere is now a d e q u a te infomnation on th e test
perform ance of so m e screening tools. Similar to the findings of th e 200 3 ev idence review and recom m endation, th e U SPSTF found th at pharm acologic treatm en ts result in small
benefits of unknown dinicai significance and co n d u d e d ag ain that th e overall ev idence is insuffident to m ake a recom m endation on screening.

R e co m m e n d a tio n s of O th ers
In 2011, M edicare be g a n covering the d e te d io n of cognitive im pairm ent a s a p art of th e new annual w ellness visit benefit. In 2013, th e Alzheimeris A sso d atio n published
guidance on the d e te d io n of cognitive impairm ent during the annual w elln ess visit an d recom m ended an algorithm involving a health risk a s se s s m e n t, patient observation, and
u n stru d u red questioning. The Alzheimeris A sso d atio n recom m ends th e u s e of a brief s tru d u re d a s se s s m e n t (such a s th e G eneral P rad itio n er A sse ssm e n t of Cognition, MiniCog Test, Memory Impairm ent S creen, Alzheim er D isease 8-item inform ant Interview, o r th e sh o rt version of th e Informant Q uestionnaire o n Cognitive D ed in e in the Elderly) if
sig n s or sym ptom s of cognitive impairment a re p rese n t o r if an informant is not available to confimn th e a b s e n c e of sig n s or symptoms^^.

M em bers of th e U.S. P reventive S e rv ic e s Task F orce
M em bers of the U.S. Preventive S ervices Task Force at the tim e this recom m endation w a s finaiizedt are Virginia A. Moyer, MD, MPH, Chair (Anterican Board of Pediatrics,
C hapel Hill, North Carolina); Michael L. LeFevre, MD, MSPH, Co-Vice C hair (University of Missouri School of Med id ne, Columbia, Missouri); Albert L. Siu, MD, MSPH, Co-Vice
C hair (Mount Sinai School of M edidne, New York, an d J a m e s J. P e te rs V eterans Affairs Medical Center, Bronx, New York); Linda Ciofu B aum ann, PhD, RN (University of
W isconsin, M adison, W isconsin); S u sa n J. Curry, PhD (University of Iowa C ollege of Public Health, Iowa City, Iowa); Mark Ebell, MD, MS (University of G eorgia, Athens,
G eorgia); F ra n d sc o A.R. G arcia, MD, MPH (Pim a County D epartm ent of Health, Tucson, Arizona); Je ss ic a Herzstein, MD, MPH (Air P ro d u d s, Allentown, Pennsylvania);
Douglas K. O w ens, MD, MS (V eterans Affairs Palo Alto Health C are System , Palo Alto, and Stanford University, Stanford, California); William R. Phillips, MD, MPH (University of
W ashington, Seattle, W ashington); and Michael P. Pignone, MD, MPH (University of North Carolina, C hapel Hill, North Carolina). Form er U SPSTF m em b ers R o san n e Leipzig,
MD, PhD, Kirsten Bibbins-Domingo, MD, PhD, an d Adelita G on zales C antu, PhD, RN, also contributed to th e developm ent of this recom m endation.
t For a list of cument Task Force m em bers, go to w w w .usprevenfiveservicestaskforce.org/m em bers.htm .
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General
Guideline Title
Alzheimer's Association recomm endations for operationalizing the detection
of cognitive impairment during the Medicare Annual Wellness Visit in a
primary care setting.

Bibliographic Source(s)_______________________
I Cordell CB, Borson S, Boustani M, Chodosh J, Reuben D, V erghese J,
Thies W, Fried LB, Medicare Detection of Cognitive Impairment
Workgroup. Alzheimer's Association recom m endations for
operationalizing the detection of cognitive Impairment during the
Medicare Annual Wellness Visit in a primary care setting. Alzheimers
Dement. 201 3 Mar;9(2): 1 4 1-5 0. [61 references] PubMed

Guideline Status
This is the current release of the guideline.

Recommendations
Major Recommendations
Recom m ended Algorithm for Detection of Cognitive Impairment
During the Annual W ellness Visit (AWV)
Incorporating A sse ssm e n t of Cognition During the AWV
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The Alzheimer's Association Medicare Annual W ellness Visit Algorithm
for A sse ssm e n t of Cognition for consistency ( s e e Figure 1 in the
original guideline docum ent) illustrates a step w ise process. The
process is intended to d etect patients with a high likelihood of having
dem entia. The AWV algorithm includes both structured a s s e s s m e n ts
discussed previously (in the original guideline docum ent) and other
less structured patient- and informant-based evaluations. By
assessin g and documenting cognitive status on an annual basis
during the AWV, clinicians can more easily determ ine gradual
cognitive decline over time in an Individual patient—a key criterion for
diagnosing dem entia due to Alzheimer's d isea se and other
progressive conditions affecting cognition.
For patients with a previous diagnosis of mild cognitive impairment
(MCI) or dem entia, this should be docum ented and included in their
AWV list of health risk factors. Annual unstructured and structured
cognitive a s s e s s m e n ts could be used to monitor significant ch a n g es in
cognition and potentially lead to a new diagnosis of dem entia for
th o se with MCI or new care recom m endations for th o se with
dem entia.
Detection of Cognitive Impairment During the AWV—Initial Health
Risk A sse ssm e n t (HRA) Review, Conversations, and Observations
The first step in detection of cognitive impairment during the AWV
( s e e Figure 1, Step A in the original guideline docu m ent), involves a
conversation betw een a clinician and the patient and, if present, any
family m em ber or other person who can provide collateral
information. This introduces the purpose and content of the AWV,
which includes: a review of the HRA; observations by clinicians
(medical and associated staff); acknow ledgm ent of any self-reported
or informant-reported concerns; and conversational queries about
cognition directed toward the patient and others present. If any
concerns are noted, or if an informant is not present to provide
confirmatory information, further evaluation of cognition with a
structured tool should be performed.
Patient completion of an HRA is a required elem en t of the AWV and
can be accomplished with the help of a family m em ber or other
knowledgeable informants, including a professional caregiver.
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Published Centers for Medicare and Medicaid Services (CMS) guidance
offers healthcare professionals flexibility as to the specific format,
q uestions, and delivery m ethods that can be used for an AWV HRA.
The following questions may be suitable for the AWV HRA and have
been tested and evaluated in the general population through the
Behavioral Risk Factor Surveillance S ystem or presented as HRA
exam p le questions:
1. During the past 12 m onths, have you experienced confusion or
m emory loss that is happening more often or is getting worse?
2. During the past 7 days, did you need help from others to perform
everyday activities such as eating, getting dressed, grooming,
bathing, walking, or using the toilet?
3. During the past 7 days, did you need help from others to take care of
things such as laundry and housekeeping, banking, shopping, using
the teleph one, food preparation, transportation, or taking your own
medications?

A noted deficit in activities of daily living (ADLs) ( e .g ., eating and
dressing) or instrumental activities of daily living (lADLs) ( e .g .,
shopping and cooking) that cannot be attributed to physical
limitations should prompt concern, as there is a strong correlation
b etw een decline in function and decline in cognitive status across the
full spectrum of dem entia. In addition to clinically observed concerns,
any patient- or informant-reported concerns should trigger further
evaluation. Positive resp o n ses to conversational queries, such as
"Have you noticed any ch an ge in your m em ory or ability to com plete
routine tasks, such as paying bills or preparing a meal?" should be
followed up with a structured a s s e s s m e n t of cognition.
Upon realizing the tim e constraints of a typical primary care visit, if
no cognitive concerns surface during the initial evaluation and this
information is corroborated by an informant, the clinician may elect
not to perform a structured cognitive a s s e s s m e n t and a ssu m e that
the patient is not currently d em en ted. This approach is supported by
studies in populations with low rates of dem entia that s u g g e s t the
a b sen ce of m em ory difficulties reported by informants and patients
reduces the likelihood that dem entia is present.

90

Structured Cognitive A sse ssm e n t Tools for Use with Patients and
Informants During the AWV
The second step in detection of cognitive impairment during the AWV
( s e e Figure 1, Step B in the original guideline docum ent) requires
cognitive a s s e s s m e n t using a structured tool. Based on syn th esis of
data from the six review articles previously discussed (in the original
guideline docu m ent), patient tools suitable for the initial structured
a s s e s s m e n t are the General Practitioner A sse ssm e n t of Cognition
(GPCOG), Mini-Cog, and Memory Impairment Screen (MIS).
Recognizing that there is no single optimal tool to d etect cognitive
impairment for all patient populations and settin gs, clinicians may
select other brief tools to use in their clinical practice, such as th o se
listed in Table 3 in the original guideline docum ent. The 15 brief tools
listed were evaluated in multiple review articles (p assed through at
least two review search criteria for tools possibly suited for primary
care) or are used in the Veterans Administration (VA). Tools listed in
Table 3 in the original guideline docum ent are subject to the
inclusion/exclusion criteria of each review and do not represent the
entire listing of the > 1 0 0 brief cognitive a s s e s s m e n t tools that may
be suitable for primary care practices.
If an informant is present, defined a s so m e o n e who can a ttest to a
patient's ch an ge in m em ory, language, or function over tim e, it is
suitable to use the Eight-item Informant Interview to Differentiate
Aging and Dementia (AD8), the informant com p onent of the GPCOG,
or the Short Informant Questionnaire on Cognitive Decline in the
Elderly (IQCODE), during the AWV.
Primary Care Workflow Considerations
According to the algorithm, any patient who d o es not have an
informant present should be a s s e s s e d with a structured tool. For such
patients (and for practices that im plem ent structured a s s e s s m e n ts
during all AWVs), completion of this structured a s s e s s m e n t can be
administered by trained medical staff as the first step for cognitive
impairment detection. This could improve office efficiency. To
increase acceptance of a structured a ss e s s m e n t, the reason provided
to the patient can be normalized with a sta te m e n t such as, "This is
som ething I do for all of my older patients as part of their annual
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visit." When the initial a s s e s s m e n t prompts further evaluation,
explanation of results should be deferred until a more com prehensive
evaluation has been com pleted. "There are many reasons for not
getting every answ er correct. More evaluation will help us determ ine
that," is an exam p le sta tem en t that may encourage patients to
pursue further testing.
Full Dementia Evaluation
Patients with a s s e s s m e n ts that indicate cognitive impairment during
the AWV should be further evaluated to determ ine appropriate
diagnosis ( e .g ., MCI, Alzheimer's d isea se) or to identify other cau ses.
As reflected in the algorithm ( s e e Figure 1, Step C in the original
guideline d ocum ent), initiation of a full dem entia evaluation is outside
the scop e of the AWV, but can occur in a separate visit either on the
sa m e day, during a newly scheduled visit, or through referral to a
specialist. Specialists who have expertise in diagnosing dem entia
include geriatricians, geriatric psychiatrists, neurologists, and
neuropsychologists. The two-visit approach has been cited as a tim eeffective process to evaluate su sp ected dem entia in primary care and
is con sistent with the tw o-step approach widely used in epidemiologic
research on dem entia. Regardless of th e timing and setting, clinicians
are encouraged to counsel patients to include an informant in the
diagnostic process.
C om ponents of a full dem entia evaluation can vary depending on the
presentation and include te sts to rule in or out the various c a u se s of
cognitive impairment and establish its severity. Diagnostic
evaluations include a com plete medical history; a s s e s s m e n t of
multiple cognitive dom ains, including episodic m em ory, execu tive
function, attention, language, and visuospatial skills; neurologic exam
(gait, motor function, reflexes); ADL and lADL functioning;
a s s e s s m e n t for depression; and review for medications that may
adversely affect cognition. Standard laboratory te sts include thyroidstimulating hormone (TSH), com plete blood count (CBC), serum B 1 2 ,
folate, com plete metabolic panel, and, if the patient is at risk, testing
for sexually transmitted d ise a s e s (human im munodeficiency virus,
syphilis). Structural brain imaging, including m agnetic resonance
imaging (MRI) or com puted tom ography (CT), is a supplem ental aid
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in th e differential diagnosis of dem en tia, especially if neurologic
physical exam findings are noted. An MRI or CT can be especially
informative in th e following ca ses: dem entia that is of recent o n set
and is rapidly progressing; younger o n se t dem entia ( < 6 5 years of
a g e); history of head trauma; or neurologic sym p to m s su ggestin g
focal d isease.

Clinical Algorithm(s)
An algorithm titled "Alzheimer's Association Medicare Annual W ellness
Visit Algorithm for A sse ssm e n t of Cognition" is provided in the
original guideline docum ent.

Scope
Disease/Condition(s)
Cognitive impairment

Guideline Category
Diagnosis
Evaluation
Risk A sse ssm e n t
Screening

Clinical Specialty
Family Practice
Geriatrics
Internal Medicine
Neurology
Nursing
Psychiatry
Psychology

Intended Users
Advanced Practice Nurses
Nurses
Physician A ssistants
Physicians
Psychologists/Non-physician Behavioral Health Clinicians
Social Workers
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Guideline Objective(s)
To provide primary care physicians with guidance on cognitive
a s s e s s m e n t during the Annual W ellness Visit (AWV) and when referral
or further testing is needed

Target Population
Medicare beneficiaries during their Medicare Annual W ellness Visit
(AWV)

Interventions and Practices Considered
1. Conversation betw een clinician and patient/informant
2. Patient completion and clinician review of a Health Risk A sse ssm e n t
(HRA)
3. Use of a structured a s s e s s m e n t tool, including:
•

General Practitioner A sse ssm e n t of Cognition (GPCOG)

•

Mini-Cog

•

Memory Impairment Screen (MIS)

•

Eight-item Informant Interview to Differentiate Aging and
Dementia (AD8)

•

Short Informant Questionnaire on Cognitive Decline in the
Elderly (IQCODE)

4. Full dementia evaluation (outside the scope of the Medicare Annual
W ellness Visit [AWV])

Major Outcomes Considered
•

Cognitive level

•

Functional level

Methodology
Methods Used to Collect/Select the Evidence
S earch es of Electronic D atabases

Description of Methods Used to Collect/Select
the Evidence
A MEDLINE (PubMed) search conducted in October 2 0 1 1 , using the
key words "screening or detection of dem entia or cognitive
impairment," yielded over 5 00 publications. To narrow the search to
tools more applicable to the Annual W ellness Visit (AWV), the
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workgroup sou ght to determ ine w hether the literature offered a
co n se n su s regarding brief cognitive a s s e s s m e n t during time-limited
primary care visits.
The workgroup focused on system atic evidence review (SER) studies
published since 2 0 0 0 , resulting in four studies by Lorentz et al.,
Brodaty et al., Holsinger et al., and Milne et al. Although each SER
had a similar objective—to determ ine which tools w ere best for
administration during primary care visits—different comparison
criteria to select the tools w ere applied ( s e e Table 1 in the original
guideline docum ent). Two other studies were also considered relevant
to the d evelopm en t of the workgroup recom m endations: Ismail et al.
conducted a literature review designed to identify widely used and
m ost promising new er brief cognitive tools being used in primary care
and geriatrics, and an SER by Kansagara and Freeman of six brief
cognitive a s s e s s m e n t tools that could se rv e as possible alternatives
to the Mini-Mental S tate Examination (MMSE) for u se by the U.S.
Department of Veterans Affairs (VA). Neither study w as designed to
determ ine which brief tool is the "best," but both provided evidence
related to primary care use and performance characteristics of brief
a s s e s s m e n ts of cognition ( s e e Table 1 in the original guideline
docum ent).

Number of Source Documents
The workgroup focused on system atic evidence review (SER) stud ies
published since 2 0 0 0 , resulting in four studies. Two other studies
w ere also considered relevant to the d evelop m en t of th e workgroup
recom m endations.

Methods Used to A ssess the Quality and
Strength of the Evidence
Not Stated

Rating Schem e for the Strength of the
Evidence
Not applicable

95

Methods Used to Analyze the Evidence
S ystem atic Review

Description of the Methods Used to Analyze
the Evidence
S ystem atic Review
The workgroup's research included comparing five system atic
evidence reviews (SERs) of brief dem entia screening tools published
since 2 0 0 0 and a 2 0 1 0 literature review of newer brief a s se ssm e n ts
of cognition. The workgroup's research focused on determining if
there w as a co n sen su s am ong the published SERs as to which tool is
m ost suited for primary care and if there were any com m on results
across the publications.

Methods Used to Formulate the
Recommendations
Expert C onsensus

Description of Methods Used to Formulate the
Recommendations
Not S tated

Rating Schem e for the Strength of the
Recommendations
Not applicable

Cost Analysis
A formal cost analysis was not performed and published cost an alyses
w ere not reviewed.

Method of Guideline Validation
Not stated

Description of Method of Guideline Validation
Not applicable
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Evidence Supporting the
Recommendations
Type of Evidence Supporting the
Recommendations
The recom m endations are supported by system atic evid en ce reviews
and a literature review.

Benefits/Harms of Implementing
the Guideline Recommendations
Potential Benefits
•

Detection of cognitive impairment during the Medicare Annual
Wellness Visit

•

Establishment of a baseline for longitudinal a s s e s s m e n ts for th o se
with normal a ss e s sm e n ts

Potential Harms
Not stated

Qualifying S ta tem en ts
Qualifying Statem ents
•

There are limitations to th e se recom m endations. They are based on
a s s e s s m e n t of recom m endations from review articles and on expert
opinion, not on a new, com prehensive review of original research to
define the optimal approach to detection of cognitive impairment or
review of emerging technologies that could assist in testing ( e .g ., use
of online or electronic tablet applications). Further complicating
system atic evidence reviews (SERs) of brief cognitive a s s e s s m e n t
tools is that sensitivity and specificity will vary depending on the
dementia prevalence of the study population, the tool(s) used, and
the cut score selected for each tool. Brodaty et al. recognized that
published research concerning cognitive impairment screening tools
is uneven in quantity and quality. The literature also is lacking in
comparative validity of brief cognitive a s s e s s m e n t tools in loweducation or illiterate populations.
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•

The Alzheimer's Association Medicare Annual W ellness Visit Algorithm
for A sse ssm e n t of Cognition is based on current validated tools and
comm only used rule-out a ss e s sm e n ts. The use of biomarkers (e .g .,
cerebrospinal fluid [CSF] tau and beta amyloid proteins, amyloid
tracer positron em ission tomography scans) was not considered as
th e se m easures are not currently approved or widely available for
clinical use.

Implementation of the Guideline
Description of Implementation Strategy
An im plementation strategy w as not provided.

Implementation Tools
Chart D ocum entation/Checklists/Form s
Clinical Algorithm
Patient R esources
Resources
For information about availability, s e e the A vailability o f Com panion
D o cu m en ts and P atien t R eso u rces fields below.

Institute of Medicine (lOM)
National Healthcare Quality Report
Categories
lOM Care Need
Living with Illness

lOM Domain
Effectiveness
P atient-centeredness

Identifying Information and
Availability
Bibliographic Source(s)_______________________
I Cordell CB, Borson S, Boustani M, Chodosh J, Reuben D, V erghese J,

j Thies W, Fried LB, Medicare Detection of Cognitive Impairment
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instructional v ideos, are available from the Alzheimer's Association
Web site

Patient Resources
A variety of resources for patients concerned with cognitive decline
and their families and caregivers are available from the Alzheimer's
Association Web site
Please note: This patient information is intended to provide health professionals with
information to share with their patients to help them better understand their health and their
diagnosed disorders. By providing access to this patient information, it is not the intention of
NGC to provide specific medical advice for particular patients. Rather we urge patients and
their representatives to review this material and then to consult with a licensed health
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professional for evaluation of treatm ent options suitable for them as well as for diagnosis and
answers to their personal medical questions. This patient information has been derived and
prepared from a guideline for health care professionals included on NGC by the authors or
publishers of that original guideline. The patient information is not reviewed by NGC to
establish whether or not it accurately reflects the original guideline's content.

NGC Status
This NGC sum m ary w as completed by ECRI Institute on S ep tem b er
27, 2 0 1 3 . The Information w as verified by the guideline d eveloper on
October 22, 2 01 3 .

Copyright Statem ent
This NGC sum m ary is based on the original guideline, which is subject
to the guideline developer's copyright restrictions.

Disclaimer
NGC Disclaimer
The National Guideline Clearinghouseâ„(t (NGC) d o es not develop,
produce, approve, or endorse the guidelines represented on this site.
All guidelines summarized by NGC and hosted on our site are
produced under the auspices of medical specialty so cieties, relevant
professional associations, public or private organizations, other
governm ent a gen cies, health care organizations or plans, and similar
entities.
Guidelines represented on the NGC Web site are subm itted by
guideline d evelopers, and are screened solely to determ ine that they
m eet the NGC Inclusion Criteria.
NGC, AHRQ, and its contractor ECRI Institute make no warranties
concerning the content or clinical efficacy or effectiven ess of the
clinical practice guidelines and related materials represented on this
site. Moreover, the view s and opinions of developers or authors of
guidelines represented on this site do not necessarily sta te or reflect
th o se of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or
hosting of guidelines in NGC may not be used for advertising or
commercial en d orsem en t purposes.
Readers with questions regarding guideline content are directed to
contact the guideline developer.
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APPENDIX D
The ABC’s of the Medicare Annual Wellness Visit

KNOWLEDGE

« RESOURCES

' TRAINING

THE ABCs OF THE ANNUAL WELLNESS VISIT (AWV)

T arget A u d ien ce: M edicare Fee-For-SenÂ ce Program
{also known a s Original M edicare)

The Hyperlink Table, at the end of this docum ent,
provides the com plete URL for each hyperlink.

CRT codes, descriptions and other data only are o^yrighf 2016 American Medical Association. Ail Rights Reserved. Applicable FARS/HHSAR apply. CRT is a
registered trademark of the American Medical Association. Applicable FARS.'HHSAR Restrictions Apply to Government Use. Fee schedules, relative value units,
conversion factors and/or related components are not assigned by the AMA, are not part of CRT, and the AMAis not recommending their use. The AMA does not
direcdty or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
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%

:

V v - ;.%

rippiL iprp

w

wm i i i 3 #

0 ^oiictMW )*# m 0301

ccg

#<icm ncm

D Have not received an Initial Preventive Physical Examination (IPPE) or AWV within the past 1 2 months

Kiwi#*
elements of all subsequent AWVs. You must provide all elem ents of the AWV prior to submitting a claim for the AWV.
NOTE: OIL^11?K©ipmiL*I

B

#

I

Æ

D

2 2 p l M t 1 I L t N i ^ ^ £ S i y i D G #03»#

HEALTH RISK ASSESSMENT (HRA)
The AWV includes a Health Risk A ssessm ent (HRA). The following tables include a brief summary of the minimum elem ents in the
f0
%
n p < p f l üî Xng$n t t © ( F r a m e w o r k for Patient-Centered Health Risk A ssessm ents
publication r o Q I l t i m ) g P 0 l i p ^

D
D The history of HRAs
D A sample HRA
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MLN Educational Tool vjfe-‘

INITIAL AWV COMPONENTS: APPLIES THE FIRST TIME A BENEFICIARY RECEIVES AN AWV
A cquire Benefica-y lif cr ra t im
E lem ents
□ Administer HRA

0 <OKO$t1ll#WE#

Ü"(IMPWW

should take no more than 20 minutes
D Account for and tailor to the)éommunication needs of underserved populations, persons

D

$KaD*()d€Dlf^S
0

Demographic data

0

Self-assessm ent of health status

0

Psychosocial risks

0 iyi^«noc^
and walking

D ■o n p p »
□ Establish a list of current providers
and suppliers
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■:v '"The ABCs of the Annual Vlfellness Visit (AWV)

Acquire Beneficar y Ilf r a t loi (oont.)

n H E iH n i
medical/family history
D Past medical and surgical history, including experiences with illnesses, hospital stays,
operations, allergies, injuries, and treatments
0 Use of, or exposure té, medications and supplements,)ihcluding calcium and vitamins
□ O ftk#
factors for depression, including
current or past experiences with
depression or other mood disorders
□ om
* D IE K >
ability and level of safety

of depression, which you may select from various available standardized screening tests
designed for this putjiose and recognizeif by national professional medical organizations

a screening questionnaire from various available screening questions or standardized
questionnaires recognized by national professional medical organizations to assess, at a
0 ) # D 4 0 % B D # ) d G ] lf tD
0 Ability to successfully perform ADLs
0 Fall risk
D Hearing impairment
D Home safety
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Begin A ssessm en t

□ A ssess
D Height, weight, body m ass index (or waist circumference, if appropriate), and
blood pressure
0 Other routine m easurem ents as deem ed appropriate based on medical and family history
□ Detect Ëiy cognitive impairment the

«♦♦fih*

n p w K fH ;# # : ( ( M M

)* ;m iiip H W K :

friends, caretakers, or others
C ounsel Beneficary

□ Establish a written screenMg
a checklist for the next 5 to 10 years,
as appropriate

( i « ? ♦ ip i o i w v p ^ o e
D Age-appropriate preventive services Medicare covers

D Recom mendations from the United States Preventive Services Task Force (USPSTF)
and the Advisory CommMee on Immunization Practices (ACIP)
D

preventive ièrvices covered by Medic&e
□ Establish a list of risk factors and
conditions for which the primary,
secondary, or tertiary interventions
are recommended or underway for
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C ounsel B eneficyy (oont.)

□ Furnish personalized health advice
referrals to health education or
preventive counseling services
or programs

□ Furnish, at the discretion of the
benefica-y , advance care
planning services

« p f t n p G ® € f i g w œ i æ i i p f r tip i^ ip iiW t c m n w
D Community-based lifestyle interventions to reduce health risks and promote self0

Fall prevention

0

Nutrition

0

Physical activity

0

Tobacco-use cessation

0

Weight loss

Q Future care décrions that may need to be made
D m

jg } ^ i P L o i r o r R

D Explanation of advance directives, which may involve the completion of standard forms
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SUBSEQUENT AWV COMPONENTS: APPLIES FOR ALL SUBSEQUENT AWVs AFTER A
BENEFICIARY’S FIRST AWV
Acquire Updated Benefica-y itf dra t loi

□ Update HRA
should take no more than 20 minutes

idiL>0i>»O€Dii)B
0
0
0

Demographic data
Self-assessment of health status
Psychosocial risks

0

□ Update the list of current providers
and suppliers

Include curiént provMers and suppliers regularly involved in providing medical care to

□ tiiaiLiEtWilE»’
medical/family history
0 Past medical and surgical history, including experiences with illnesses, hospital stays,
operations, allergies, injuries, and treatments
D Use of, or exposure to, medications and supplements, including calcium and vitamins

medicare^\
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■ H im j
Degin Assessm ent

cipnpf a

□ A ss e ss

□ Weight (or waist circumference, if appropriate) and blood pressure
D Other routine measurem ents as deem ed appropriate based on medical and
family history
□ Detect any ibgnitive impairment

«♦♦nk* ♦flLcjppygr»» np##nL)W)iai
D»enD30

ipiw»

friends, caretakers, or others

Counsel Beneficary

□ Update the written screeMng

IIL*

‘ IP T P »3^ n ic flp liL O e

Q Age-appropriate preventive services Medicare covers
0

R ecom m endation from the USPSTF and the ACIP
preventive services covered by Medicare

□ Update the list of risk factors and ^
conditions for which primary,
secondary, or tertiary interventions
are recommebiüed or underway for
« J L flip tiJ E E

Page 8 of 17

ICN 905706 April 2017

* p a i4 c m .£ »
0

Mental health conditions

Q OXcfegBJO C I T ip » 3 4 » ie p W tL
□

îO p D n p c c »

eiiLQÇnc>2S

109

* The ABCs of the Annual Wellness Visit (AWV)

> . T ; . J

*4

:.. r-

' kf r, -

'• i

C ounsel B eneficdy (oont.

□ Furnish personiflized health advice
appropriate, to health education or
preventive counseling services
or programs

□ Furnish, at the discretion of the
b eneficary , advance care
planning services
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0 Community-based lifestyle interventions to reduce health risks and promote self0 3 # l p i i # 2 m a . iDwi! ♦
0

Fall prevention

0

Nutrition

0

Physical activity

0

Tobacco-use cessation

0

Weight loss

D Future care décrions that may need to be made
D
^ ip in iT O ijiL
0 Explanation of advance directives, which may involve the completion of standard forms
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AWV CODING, DIAGNOSIS, AND BILLING
Coding
AWV HCPCS Codes and Descriptors

G0438
G0439

Annual wellness visit, includes a personalized prevention plan of service (PPS),
subsequent visit

Diagnosis
You must report a diagnosis code when submitting a claim for theifWV. Since you are not required to document a specific diagnosis

PîILOTîll^t

DLOEBOilDX ip tffr

IPS)^

Billing

«'îippiL?^€3^ p rp

^ iOCEEDÎiP(pE

D Physiciaê(a doctor of medicine or osteopathy)
0 Medical professional (including a health educator, registered dietitian, nutrition professional, or other licensed practitioner), or a team
of medical professionals whfiàre directly supervised ly a physician (doctor of medicine or osteopathy)

é-fippiL0$mm»tss3e»ïpiçiOTiiHtsûi»
CPT only copyright 2016 American Medical Association. All rights reserved.
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ADVANCE CARE PLANNING (ACP) AS AN OPTIONAL ELEMENT OF AN AWV
ACP is theiface-to-face conversation between a physician (or other qualifie health care prd essi anal ) aid a henef id ly t odisoiss t he
benefica y s wishes and preferences for medical treatment if he or she were unable to speak or make decisions in the future. You can
provide the ACP at the time of the AWV, at the benefica y s discretion.

Coding
Use the following CPT codes to fii d a m for ACP as an optional element of an AWV.
ACP CPT C odes and Descriptors
ACP CPT C odes
99497

< Billing C ode Descriptors
Advance care planning including the explanation and discussion of advance directives such
as standard forms (with completion of such forms, when performed), by the physician or
other qualifie health care proâessional; firt 30 minutes, face-to-face with the patient, family
member(s), and/or surrogate
Advance care planning including the explanation and discussion of advance directives
such as standard fcrms (with completion of such forms, when performed), by the physician
or other qualifie heal th care pr des si anal ; s c h aldit'anal 30 rhnjtes (lid s e p a rd ë y in
addition to code for primary procedure)

99498

Diagnosis
You must report a diagnosis code when submitting a claim for ACP as an optional element of an AWV. Since you are not required to
document a specific diagnosis code for ACP as an optional elem ent of an AWV, you may choose any diagnosis code consistent with a
benefica y s exam.

CPT only copyright 2016 American Medical Association. All rights reserved.

d le d ic a r^
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Billing

é^nppiL»m . c p ^ n p i 4QMKsmi#L*'WiL(^

^ ^ )»)(a

D Provided on the sam e day as the covered AWV

0 Furnished by the sS n e provider as the covered AWV

0

eigWMiiaimie)

D

9 # # i"

The deductible and coinsurance for ACP are waived only once per year, when it is billed with the AWV. If the AWV billed with ACP is
denied for exceeding the once per year limit, the deductible and coinsurance will be applied to the ACP.
NOTE: The deductible and coinsurance apply when ACP is provided outside the covered AWV.

FREQUENTLY ASKED QUESTIONS (FAQs)
What are the other Medicare Part B preventive services?
D Alcohol Misuse Screening and Counseling

D

rnpdpip

D Cardiovascular Disease Screening Test
D Colorectal Cancer Screening

D Counseling to Prevent Tobacco Use
D Depression Screening
D Diabetes Screening
D Diabetes Self-Management Training (DSMT)

CPT only copyright 2016 American Medical Association. All rights reserved.
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;ï
D Glaucoma Screening
Q Hepatitis C Virus (HCV) ScreenMg

0f
###()=
D iwem#iiyKi]i(pi#mi mpm ^

æ *#

D
D IPPE (also called the "Welcome to Medicare Preventive Visit”)
D Medical Nutrition Therapy (MNT)
Q Prostate Cancer Screening
0 Screening for Cervical Cancer with Human Papillomavirus (HPV) Tests
0 Screening for Lung Cancer with Low Dose Computed Tomography (LDCT)

D

itpm %tH#

D Screening Mammography
D Screening Pap Tests
D Screening Pelvic Examination (includes a clinical breast examination)
D Ultrasound Screening for Abdominal Aortic Aneurysm (AAA)
ft Preventive Services Educational Tool for additional resources on Medicare preventive services.

Who is eligible for the AWV?

rippiiiipp a a n-

m ocm

coverage period, and who have not had either an IPPE or an AWV within the past 12 months. Medicare pays for only one first AWV
per benefica-y p r liË im md me subsequent AWV per year thereafter.
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The ABCs of the Annual Wellness Visit (AWV)

Is the AWV the same as a benefica*y s yearly physical?
No. The AWV is not a routine physical checkup that some seniors may
practitioner. Medicare does not cover routine physical examinations.

PREPARING ELIGIBLE MEDICARE
BENEFICIARIES FOR THE AWV

Are clinical laboratory tests part of the AWV?

for their AWV by encouraging them to come prepared with the

No. The AWV does not include any clinical laboratory tests, but you
may make referrals for such tests as part of the AWV, if appropriate.

D Medical records, including immunization records

Do deductible or coinsurance/copayment
apply for the AWV?

Q Family health history, in as much detail as possible
0 A full list of medications and supplements, including calcium
and vitamins - how often and how much of each is taken

No. Medicare waives both the coinsurance or copayment and the

Ü A full list of current providers and suppliers involved in
providing care

ip

WEZQ

Can I bill an electrocardiogram (EKG) and the
AWV on the same date of service?
Generally, you may provide other medically necessary services on the same date of service as an AWV. The deductible and
coinsurance/copayment apply ior these other medically neclssary services.

How do I know if a benefica-y d ready g>t H d 1er firs AWV from another provider and
know whether to bill for a subsequent AWV even though this is the firt AWV I provided i
to this benefica*^
You have different options for accessing AWV eligibility information depending on where you practice. You may access the information
through the Health Insurance Portability and Accountability Act (HIPAA) Eligibility Transaction System (HETS) or through the provider
call center Interactive Voice Responses (IVRs). CMS suggests providers checKwith their Medicare Administrative Contractor (MAC)
€ • rtpi* î S O K ï *
MAC for more information.
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RESOURCES
The Medicare Preventive Services w ebpage lists educational products for Medicare Fee-For-Service providers and their staff about
preventive services, coverage, coding, billing, payment, and claim filig frm edures.
AWV R esources

42 Code of Federal Regulations 410.15
(policy governing AWV service)
CMS Provider Minute; Preventive
Services
(pointers to help you submit correct
documentation and avoid claim denials)
Medicare B enefits 1 icy M nual

GPO.gov/fdsys/pkg/CFR-2016-title42-vol2/pdf/CFR-2016-title42-vol2-part410-subpartB.pdf
Youtube.com/watch?v=-tuMWM4KeZg&feature=youtu,be&list=PLaV7m2zFKpigbl UvmChI Q2cBKi1 SGk-V

Chapter 15
CMS.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf

Medicare Claims Processing Manual

Chapter 12, Section 30.6.1.1
CMS.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c12.pdf
Chapter 18, Section 140
CMS.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm1G4c18.pdf

MLN Guided Pathways: Provider
SpecificMdi care R souroes

CMS.gov/Outreach-and-Education/Medicare-Leaming-Network-MLN/MLNEdWebGuide/
Downloads/Guided_Pathways_Provider_SpecificBookl é .pdf

MLN Matters® Article MM7079,
Annual W ellness Visit (AWV),
Including Personalized Prevention Plan
Services (PPPS)

CMS.gov/Gutreach-and-Education/Medicare-Leaming-Network-MLN/MLNMattersArticies/
Downloads/MM7079.pdf
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: MLN Educational Tool -

AWV Resources (cont.)

MLN Matters Article MM9271, Advance
Care Planning (AGP) as an Optional
Element of an Annual \Afellness Visit (AWV)
MLN Matters Article MM10000, Billing for
Advance Care Planning (AGP) Claims

CMS.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/
Downloads/MM9271.pdf
CMS.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/
Downloads/MM 10000.pdf

MLN Matters Article SE1338, Improve
Your Patients’ Health with the Initial
Preventive Physical Examination (IPPE)
and Annual Wellness Visit (AWV)
MLN Matters Articles on Medicarecovered Preventive Services

CMS.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/
Downloads/SE1338.pdf

Preventive Services Educational Tool

CMS.gov/Outreach-and-Educatlon/Medicare-Learning-Network-MLN/MLNProducts/MLNPublications-ltems/CMSI 243319.html

Resources for Medicare
B eneficais R iblistioi

CMS.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/MLNPublications-ltems/ICN905183.html
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Hyperlink Table

The ABCs of the Initial Preventive
Physical Examination (IPPE)

https://www.cms.gov/Outreach-and-Education/Medicare-Leaming-Network-MLN/
MLNProducts/MLN-Publlcations-ltems/CMS1243320.html

Advisory Committee on Immunization
Practices

https://www.cdc.gov/vaccines/acip

ACIP
Framework for Patient-Centered Health
Risk A ssessm ents Publication

https://www.cdc.gov/policy/hst/HRA/FramewcrkForHRA.pdf

Medicare Preventive Services W ebpage https://www.cms.gov/Medicare/Prevention/PrevntlonGenlnfo
Preventive Services Educational Tool

https://www.cms.gov/Medicare/Prevention/PrevntionGenlnfo/medicare-preventive-services/
MPS-QuickReferenceChart-1 .html

United States Preventive Services
Task Force
USPSTF
Your MAC

https://www.uspreventiveservicestaskforce.org

https://www.cms.gov/Research-Statistlcs-Data-and-Systems/Monitoring-Programs/
Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-lnteractive-Map

Medicare Learning Network® Product Disclaimer
The Medicare Learning Network®, MLN Connects®, and MLN Matters® are registered trademarks of the U.S. Department of Health & Human Services (HHS).
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APPENDIX E
A lzheim er’s Association Cognitive Assessm ent Toolkit

g

alzheimeT’s % association'
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OVERVIEW

The A lzheim er's A ssociation - d edicated to fueling the ad v an cem en t of early d etectio n and diagnosis of
d em en tia - h a s developed an easy-to-im plem ent p rocess to a s s e s s cognition during th e M ed icare A nnual
W elln ess Visit. D eveloped by a group of clinical d em en tia experts, th e recom m ended p ro cess outlined on
p age 4 allow s you to efficiently identify p atien ts w ith probable cognitive im pairm ent w h ile giving you th e
flexibility to ch oo se a cognitive a s s e ss m e n t tool th a t w orks b e st for you and your p atien ts.
This C ognitive A sse ssm e n t Toolkit contains:
• The M edicare Annual W elln ess Visit Algorithm for A ssessm e n t of Cognition, incorporating p atien t
history, clinician o bserv ation s, and co ncern s ex p ressed by th e p atien t, fam ily or caregiver
• T hree v alid ated p atien t a s s e ss m e n t tools: th e G eneral P ractitioner A ssessm e n t of C ognition (GPCOG),
th e M em ory Im pairm ent S creen (MIS) and th e Mini-Cog™. All tools:
> Can be ad m inistered in 5 m inutes or less
> Are equal to or superior to th e M ini-M ental S ta te Exam (MMSE) for d etectin g d em en tia
> Are easily ad m inistered by m edical staff m em bers w ho are not physicians
> Are relatively free from ed ucation al, lang uage a n d /o r cultural bias
• T hree validated inform ant a s s e ss m e n t of p a tien t tools: th e S hort Form of th e Inform ant Q uestionnaire
on Cognitive D ecline in th e Elderly (Short IQCODE), th e Eight-item Inform ant Interview to D ifferentiate
Aging and D em entia (AD8) and th e GPCOG
• The "A lzheim er's A ssociation R ecom m endations for O perationalizing th e D etection of Cognitive
Im pairm ent During th e M edical A nnual W elln ess Visit in a Prim ary C are S ettin g ,"as published in th e
journal A lzheim er's and D em entia.
For m ore inform ation on th e d etectio n, diag no sis and tre a tm e n t of A lzheim er's d ise a se , a s w ell as direct
ac ce ss to p atien t and caregiver reso urces, p le a se visit our (Health C are P ro fession als and A lzheim er's c e n ter
a t alz.org/hcps.

800.272.39001alz.org
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ALZHEIMER'S ASSOCIATION
Medicare Annual Wellness Visit Algorithm for Assessment of Cognitfon^^'

A.

R eview HRA, clinician observation, self-rep o rted concerns, re sp o n se s to q ueries

S ign s/sy m p tom s p resen t
Inform ant av ailable to confirm

B.* C onduct brief stru ctu red a s s e ss m e n t
• P atien t A ssessm en t: M ini-Cog or GPCOG or MIS
• Inform ant a s s e s s m e n t of p atien t; S hort IQCODE, AD8 or GPCOG
Follow-up during su b se q u en t AWV
Brief assessment(s) triggers concerns: P atient: M ini-Cog
<3 or GPCOG <5 (5-8 score is ind eterm inate w itho ut inform ant)
or M IS<4 or Inform ant: Short IQCODE > 3.38 or AD8 > 2 or
GPCOG inform ant score <3 w ith p a tie n t score <8

C. R efer OR C onduct full D em entia Evaluation

No one tool is recognized as th e b est brief a s s e ss m e n t to d eterm in e if a full d em en tia evaluation is
n eeded . Som e providers re p e a t p atie n t a s s e ss m e n t w ith an a lte rn a te tool (e.g., SLUMS, or MoCA)
to confirm initial findings before referral or initiation of full d em en tia evaluation.

AD8 = Eight-item Inform ant Interview to D ifferentiate Aging and D em entia; AWV = A nnual W elln ess
Visit; GPCOG = G eneral P ractitioner A ssessm en t of Cognition; HRA = H ealth Risk A ssessm ent; MIS
= M em ory Im pairm ent S creen; MMSE = Mini M ental S tatu s Exam; MoCA = M ontreal Cognitive
A ssessm ent; SLUMS = St. Louis U niversity M ental S ta tu s Exam; Short IQCODE = S hort Inform ant
Q uestionnaire on C ognitive D ecline in th e Elderly

Cordell CB, Borson S, B oustani M, C hodosh J, R euben D, V erghese J , e t al. A lzheim er's A ssociation
recom m endations for operationalizing th e d etectio n of cognitive im pairm ent during th e M edicare
Annual W elln ess Visit in a prim ary care setting . Alzheimers Dement. 2013;9(2):141-150. A vailable a t
h ttp ://do w nlo ad.jo urnals.elsev ierhealth .eo m /pd fs/jou rn als/1 55 2-52 60 /P IIS l5 52 52 60 12 02 50 10 .pd f.
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Patient name:

Date:

GPCOG S c re e n in g T e s t
Step 1: Patient Examination
Unless specified, each question should only be asked once

Name and Address for subsequent recall test
1.

7 am going to give you a name and address. After I have said it, I want you to repeat
it. Remember this name and address because I am going to ask you to tell it to me
again in a few minutes: John Brown, 42 West Street, Kensington." (Allow a maximum

of 4 attempts).
Time Orientation
2.

]Miat is the date? (exact only)

Correct

Incorrect

□ □

Clock Drawing - use blank page
3.

Please mark in all the numbers to indicate
the hours of a clock (correct spacing required)

4.

Please mark in hands to show 10 minutes past
eleven o’clock (11.10)

□ □
□ □

information
5.

Can you tell me something that happened in the news recently? ,----- ,
(Recently = in the last week, if a general answer is given,
I_ _ I
eg “war”, “lot of rain”, ask for details. Only specific answer scores).

,— ,

I

I

Recall
6.

What was the name and address I asked you to remember

John
Brown
42
West (St)
Kensington
(To get a total score, add the number of items answered correctly
Total correct (score out of 9)

/9

If patient scores 9, no significant cognitive Impairment and further testing not necessary
If patient scores 5-8, more information required. Proceed with Step 2, informant section.
If patient scores 0-4, cognitive impairment is indicated. Conduct standard investigations.
© University of New South W ales a s rep resen ted by th e D em entia Collaborative R e se arc h C entre - A sse ssm e n t and Better Ca re;
Brodaty at al. JA G S 2002; 50:530-534
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informant Interview
Date:
Informant’s name:
Informant’s relationship to patient, i.e. informant is the patient’s:

These six questions ask how the patient is compared to when s/he
was well, say 5 - 10 years ago
Com pared to a few years ago:

Don’t
Yes

No

Know

■ Does the patient have more trouble remembering things
that have happened recently than s/he used to?

[ | |

| ]

[

■ Does he or she have more trouble recalling conversations
a few days later?

[ | |

| |

[

■ When speaking, does the patient have more difficulty in
finding the right word or tend to use the wrong words
more often?

___

___

___

-----

-----

N/A

Is the patient less able to manage money and financial
I
I I
I I
I I
I
affairs (e.g. paying bills, budgeting)?--------------------------------- I----- ' I----- > I---- 1-- '---- 1
Is the patient less able to manage his or her medication-------i----- 1 i----- 1 i---- 1--i---- 1
independently?--------------------------------------------------------------I- ---- 1 I- ---- 1 I---- 1-- I- --- 1
Does the patient need more assistance with transport
(either private or public)?

□□□□

(if the patient h a s difficulties d u e only to physical problem s, e g bad leg, tick no')

(To get a total score, add the number o f items answered ‘no’, ‘don’t know’ or ‘N/A’) ___
Total score (out of

6 ) _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ I_ _ I

If patient scores 0-3, cognitive impairment is indicated. Conduct standard investigations.
© U niv ersity o f N e w S o u th W a le s a s r e p r e s e n te d b y th e D e m e n tia C o lla b o ra tiv e R e s e a rc h C e n tre —A s s e s s m e n t a n d B e tte r C a re ;
B ro d a ty e t ai, J A G S 2 0 0 2 ; 5 0 :5 3 0 -5 3 4
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MEMORY IMPAIRMENT SCREEN (MIS)
Instructions for Administration
1. Show patient a sheet of paper with the 4 items to be recalled in 24-point or greater uppercase
letters (on other side), and ask patient to read the items aloud.
2. Tell patient that each item belongs to a different category. Give a category cue and ask patient to
indicate which of the words belongs in the stated category (eg, "Which one is the game?"). Allow
up to 5 attempts. Failure to complete this task indicates possible cognitive impairment.
3. When patient identifies all 4 words, remove the sheet of paper. Tell patient that he or she will be
asked to remember the words in a few minutes.
4. Engage patient in distractor activity for 2 to 3 minutes, such as counting to 20 and back, counting
back from 100 by 7, spelling WORLD backwards.
5. FREE RECALL — 2 points per word: Ask patient to state as many of the 4 words he or she can
recall. Allow at least 5 seconds per item for free recall. Continue to step 6 if no more words have
been recalled for 10 seconds.
6 . CUED RECALL— 1 point per word: Read the appropriate category cue for each word not recalled

during free recall (eg, "What was the game?").

Word

> --

g Free recall (2 pts.)

Checkers

Game

Saucer

Dish

Telegram

Message

Red Cross

Organization

Cued R ecall (1 pts)

The maximum sco r e for th e MIS is 8.
• 5-8 No cognitive impairment
• < 4 Possible cognitive impairment

Copyright <S> 1999Albert Einstein College of Medicine. AH rights reserved

800.272.3900 | alz.org'

alzheim er’s

association

125

WORD LIST

CHECKERS
SAUCER
TELEGRAM
RED CROSS

Copyright (£> 1993 Albert Einstein College of Medicine. All rights reserved.

800.272.3900 | alz.org'
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M ini-C og'

In s tru c tio n s for A d m in is tra tio n & Scoring
ID:.

D a te :.

S tep 1: T hree W ord R e g is tra tio n
Look d irectly a t p e rso n a n d say, “P le a se listen carefully. I am going to sa y th r e e w o rd s th a t I w a n t you to re p e a t b a ck
to m e now a n d try to re m e m b e r. The w o rd s are [se le c t a list of w o rd s from th e v e rsio n s below]. P le a s e sa y th e m for
m e now.” If th e p e rso n is u n a b le to re p e a t th e w o rd s a fte r th r e e a tte m p ts , m ove on to S te p 2 (clock draw ing).
T he follow ing a n d o th e r w ord lists have b e e n u se d in o n e o r m ore clinical stu d ie s .’'^ For re p e a te d a d m in istra tio n s,
u se of a n a lte rn a tiv e w ord list is re c o m m e n d e d .

V ersion 1

V ersion 2

V ersion 3

V ersion 4

V ersion 5

V ersion 6

B a n an a
S u n rise
C hair

L ea d er
S e a so n
Table

Village
K itchen
Baby

River
N ation
F inger

C ap tain
G a rd en
P ic tu re

D a u g h te r
H eav en
M o u n ta in

S tep 2: C lock D ra w in g
Say: “Next, I w a n t you to draw a clock for m e. First, p u t in all of th e n u m b e rs w h ere th e y go.” W hen t h a t is c o m p le te d ,
say: “Now, s e t th e h a n d s to 10 p a s t 11.”
U se p re p rin te d circle (se e next p a g e ) for th is e xercise. R e p e a t in s tru c tio n s a s n e e d e d a s th is is n o t a m em o ry te s t.
Move to S te p 3 if th e clock is n o t c o m p le te w ithin th re e m in u te s.

S tep 3: Three W ord Recall
Ask th e p e rso n to recall th e th re e w o rd s y ou s ta te d in S te p l. Say: “W h at w ere th e th re e w o rd s I a sk e d you to
re m e m b e r? ” R ecord th e w ord list v ersio n n u m b e r a n d th e p e rs o n ’s a n sw e rs below.
W ord L ist Version:

P e rs o n ’s A nswers:

S co rin g
Word Recall:

fO-"i points)

1 point for each word sp o n ta n eo u sly recalled w ith ou t cueing.

Normal clock = 2 points. A norm al clock has all n u m b ers placed in th e correct
se q u e n c e and approxim ately correct position (e.g., 12, 3, 6 and 9 are in a n ch o r
Clock Draw;

fo or 2 points)

positions) with no m issing or d u p licate n um b ers. H and s are pointing to th e 11
an d 2(11:10). Hand length is n ot scored.
Inability or refusal to draw a clock (abnorm al) = 0 points.

Total sco re = Word Recall score + Clock Draw score.

Total Score;

fO-S points)

A c u t p oint of <3 on th e Mini-Cog™ h as been validated for d e m e n tia screenin g ,
b u t m any individuals with clinically m eaningful cognitive im pairm en t will score
higher. W hen g re a te r sensitivity is d esired, a c u t point of <4 is re com m end ed as
it may indicate a need for fu rth er evaluation of cognitive sta tu s .

M ini-C og™ © S. B o r s o n . All r ig h t s r e s e r v e d . R e p r in te d w ith p e r m i s s i o n o f t h e a u t h o r s o le ly f o r c lin ic a l a n d e d u c a t i o n a l p u r p o s e s .
M ay n o t b e m o d if ie d o r u s e d fo r c o m m e r c ia l, m a r k e tin g , o r r e s e a r c h p u r p o s e s w i t h o u t p e r m i s s i o n o f t h e a u t h o r C so o b @ u w .e d u ).
V. 01.19.16
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Clock D rawing

ID:

Date:
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Short Form of the Informant Questionnaire on Cognitive
Decline in the Elderly (Short IQCODE)^

by A. F. Jorm
Centre for Mental Health Research
The Australian National University
Canberra, Australia

There is no copyright on the Short IQCODE. However, the author appreciates being
kept informed of research projects which make use of it.

Note: As used in published studies, the IQCODE was preceded by questions to the
informant on the subject's sociodemographic characteristics and physical health.
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Now we want you to remember what your friend or relative was like 10 years ago and
to compare it with what he/she is like now. 10 years ago was in 20__.* Below are
situations where this person has to use his/her memory or intelligence and we want
you to indicate whether this has improved, stayed the same or got worse in that
situation over the past 10 years. Note the importance o f comparing his/her present
performance with 10 years ago. So if 10 years ago this person always forgot where
he/she had left things, and he/she still does, then this would be considered "Hasn't
changed much". Please indicate the changes you have observed by circling the
appropriate answer.
Compared with 10 years ago how is this person at:
1

2

3

4

5

1. Remembering things about
family and friends e.g.
occupations, birthdays,
addresses

Much
improved

A bit
improved

Not much
change

A bit
worse

Much
worse

2. Remembering things that
have happened recently

Much
improved

A bit
improved

Not much
change

A bit
worse

Much
worse

3. Recalling conversations a
few days later

Much
improved

A bit
improved

Not much
change

A bit
worse

Much
worse

4. Remembering his/her
address and telephone number

Much
improved

A bit
improved

Not much
change

A bit
worse

Much
worse

5. Remembering vriiat day and
month it is

Much
improved

A bit
improved

Not much
change

A bit
worse

Much
worse

6. Remembering where things
are usually kept

Much
improved

A bit
improved

Not much
change

A bit
worse

Much
worse

7. Remembering where to find
things which have been put in
a different place from usual

Much
improved

A bit
improved

Not much
change

A bit
worse

Much
worse

8. Knowing how to work
familiar machines around the
house

Much
improved

A bit
improved

Not much
change

A bit
worse

Much
worse

130

13

9. Learning to use a new
gadget or machine around the
house

Much
improved

A bit
improved

Not much
change

A bit
worse

Much
worse

10. Learning new things in
general

Much
improved

A bit
improved

Not much
change

A bit
worse

Much
worse

11. Following a story in a book
or on TV

Much
improved

A bit
improved

Not much
change

A bit
worse

Much
worse

12. Making decisions on
everyday matters

Much
improved

A bit
improved

Not much
change

A bit
worse

Much
worse

13. Handling money for
shopping

Much
improved

A bit
improved

Not much
change

A bit
worse

Much
worse

14. Handling financial matters
e.g. the pension, dealing with
the bank

Much
improved

A bit
improved

Not much
change

A bit
worse

Much
worse

15. Handling other everyday
arithmetic problems e.g.
knowing how much food to
buy, knowing how long
between visits fi'om family or
friends

Much
improved

A bit
improved

Not much
change

A bit
worse

Much
worse

16. Using his/her intelligence
to understand what's going on
and to reason things through

Much
improved

A bit
improved

Not much
change

A bit
worse

Much
worse

*The original tool w as published in 1994.
The Alzheimer's Association updated the year 19__ as published in the original tool to 20
.
Tool Reference: Jonn AF. A short form o f the Inform ant Questionnaire on Cognitive Decline in the
Elderly (IQCODE): developm ent and cross-validation. Psychol M ed 1994; 24: 145-153.
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ADS Dementia Screening interview

Remember, “Yes, a change” indicates that
there has been a change in the last several
years caused by cognitive (thinking and
memory) problems.

Patient ID#:
CS ID#:___
Date:

YES,
A change

NO,
No change

N/A,
Don’t know

1. Problems with judgment (e.g.,
problems making decisions, bad
financial decisions, problems with
thinking)
2. Less interest in hobbies/activities

3. Repeats the same things over and
over (questions, stories, or
statements)
4. Trouble learning how to use a tool,
appliance, or gadget (e.g., VCR,
computer, microwave, remote control)
5. Forgets correct month or year
6. Trouble handling complicated financial
affairs (e.g., balancing checkbook,
income taxes, paying bills)
7. Trouble remembering appointments
8. Daily problems with thinking and/or
memory

1

TOTAL AD8 SCORE

Adapted from Galvin JE et al, The AD8, a brief informant interview to detect dementia. Neurology 2005:65:559-564
Copyright 2005. The AD8 Is a copyrighted Instrument of the Alzheimer's Disease Research Center, Washington University, St. Louis, Missouri.
All Rights Reserved.
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The AD8 Administration and Scoring Guidelines
A spontaneous self-correction is allowed for all responses without counting as an error.

The questions are given to the respondent on a clipboard for self—administration or can be read
aloud to the respondent either in person or over the phone. It is preferable to administer the AD8
to an informant, if available. If an informant is not available, the AD8 may be administered to the
patient.
When administered to an informant, specifically ask the respondent to rate change in the
patient.
When administered to the patient, specifically ask the patient to rate changes in his/her ability
for each of the items, w ith o u t attributing causality.
If read aloud to the respondent, it is important for the clinician to carefully read the phrase as
worded and give emphasis to note changes due to cognitive problems (not physical problems).
There should be a one second delay between individual items.
No timeframe for change is required.
The final score is a sum of the number items marked “Yes, A change”.

Interpretation of the AD8 (Adapted from Galvin JE et al. The AD8, a brief informant interview to detect dementia,
Neurology 2005:65:559-564)

A screening test in itself is insufficient to diagnose a dementing disorder. The AD8 is, however,
quite sensitive to detecting early cognitive changes associated many common dementing illness
including Alzheimer disease, vascular dementia, Lewy body dementia and frontotemporal
dementia.
Scores in the impaired range (see below) indicate a need for further assessment. Scores in the
“normal" range suggest that a dementing disorder is unlikely, but a very early disease process
cannot be ruled out. More advanced assessment may be warranted in cases where other
objective evidence of impairment exists.
Based on clinical research findings from 995 individuals included in the development and
validation samples, the following cut points are provided;
□ 0 - 1 ; Normal cognition
□ 2 or greater; Cognitive impairment is likely to
R#ck»ver O p e ra to r C h a ra c te ris tie s (ROC) c u r v e t o r A 0 8
be present
Administered to either the informant (preferable) or the
patient, the AD8 has the following properties;
□ Sensitivity > 84%
□ Specificity > 80%
□ Positive Predictive Value > 85%
□ Negative Predictive Value > 70%
□Area under the Curve; 0.908; 95%CI; 0.8880.925

I

133

16

Copyright 2005. The Eight-item informant Interview to Differentiate Aging and Dementia is a
copyrighted instrum ent of W ashington University, St. Louis, Missouri. All Rights R eserved.
Permission Statement
W ashington University grants perm ission to u se and reproduce th e Eight-item Informant Interview to
Differentiate Aging and Dementia exactly a s it a p p e ars in the PDF available h ere without

modification or editing of any kind solely for end u ser u se in investigating dem entia in clinical care or
research in clinical care or re search (the “P u rp o se”). For the avoidance of doubt, the P urpose d o es
not include the (i) sale, distribution or transfer of th e Eight-item informant Interview to Differentiate
Aging and Dementia or copies thereof for any consideration or comm ercial value; (ii) th e creation of

any derivative works, including translations; and/or (ill) u se of the Eight-item Informant Interview to
Differentiate Aging and Dementia a s a marketing tool for the sale of any drug. All copies of the AD8

shall include the following notice: “Reprinted with perm ission. Copyright 2005. The Eight-item
Informant Interview to Differentiate Aging and Dementia is a copyrighted instrum ent of W ashington

University, St. Louis, Missouri. Ail Rights R eserved.” P le a se contact m orrisi@ abraxas.w ustl.edu for
u se of the Eight-item Informant Interview to Differentiate Aging and Dementia for any other intended
purpose.
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A lzheim er’s Association recom mendations for operationalizing
the detection of cognitive impairment during the M edicare Annual
Wellness Visit in a primary care setting
Cyndy B. Cordell^'*, Soo Borson^^, Maiaz Boustani'^’®’^^,Joshua Chodosh® *’, David Reuben*’,
Joe Verghese’, William Thies®, Leslie B. Frie(f’*^; for the Medicare Detection
of Cognitive Impairment Workgroup
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Abstract

The Patient Protection and Affordable Care Act added a new Medicare benefit, the Annual
Wellness Visit (AWV), effective January 1, 2011. The AWV requires an assessment to detect cog
nitive impairment The Centers for Medicare and Medicaid Services (CMS) elected not to recom
mend a specific assessment tool because there is no single, universally accepted screen that
satisfies all needs in the detection of cognitive impairment. To provide primary care physicians
with guidance on cognitive assessment during the AWV, and when referral or further testing is
needed, the Alzheimer’s Association convened a group of experts to develop recommendations.
The resulting Alzheimer’s Association Medicare Annual Wellness Visit Algorithm for Assessment
of Cognition includes review of patient Health Risk Assessment (HRA) information, patient ob
servation, unstructured queries during the AWV, and use of structured cognitive assessment tools
for both patients and informants. Widespread implementation of this algorithm could be the first
step in reducing the prevalence of missed or delayed dementia diagnosis, thus allowing for better
healthcare management and more favorable outcomes for affected patients and their families and
caregivers.
© 2013 The Alzheimer’s Association. All rights reserved.

Keywords:

Annual Wellness Visit; AWV; Cognitive impairment; Assessment; Screen; Dementia; Alzheimer’s disease;
Medicare; Agorithm; Patient Protection and Affordable Care Act

1. Introduction
T he Patient Protection and Affordable Care Act o f 2010
added a new M edicare benefit, the Annual Wellness Visit

•Corresponding author. Tel.: 312-335-5867. Fax; 866-699-1246.
E-mail address: cyndy.cordeII@alz.org

(AWV), effective January 1, 2011. The AWV includes
routine m eastnem ents such as height, weight, and blood
pressure; a review of m edical and family history; an assess
m ent to detect cognitive im pairm ent; and establishm ent of
a list o f current m edical providers, m edications, and sched
ule for future preventive services. In addition, during the first
AWV only, beneficiaries are to be screened for depression (if

1552-5260/$ - see front matter © 2013 The Alzheimer’s Association. A l rights reserved.
http://dx.doi.org/10.1016/j.jalz.2012.09.011
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not com pleted under a separate M edicare benefit) and for
functional difficulties using nationally recognized appropri
ate screening questions or standardized questionnaires. Al
though the U.S. Preventive Services Task Force (USPSTF)
in 2003 concluded that there was insufficient published evi
dence o f better clinical outcom es as a result of routine
screening for cognitive im pairm ent in older adults, the
Task Force recognized that the use o f cognitive assessm ent
tools can increase the detection of cognitive im pairm ent
[1]. As per the Centers for M edicare and M edicaid Services
(CMS) regulation, the AWV requires detection o f cognitive
im pairm ent by “ ... assessment o f an individual’s cognitive
function by direct observation, with due consideration o f in
form ation obtained by way of patient report, concerns raised
by fam ily members, friends, caretakers, or others” [2]. Dur
ing the public com m ent period, several organizations, in
cluding the Alzheim er’s Association, noted that the use of
a standardized tool for assessm ent of cognitive function
should be part of the AWV.
These com m ents are supported by a num ber of studies
showing that cognitive im pairm ent is unrecognized in
27% -81% o f affected patients in prim ary care [3-7]. The
use o f a brief, structured cognitive assessm ent tool
correctly classifies patients with dem entia or mild
cognitive im pairm ent (MCI) m ore often than spontaneous
detection by the patients’ own prim ary care physicians
(83% vs 59%, respectively) [8].
In response to concerns submitted during public comment,
CM S elected not to recom m end a specific tool for the final
AWV benefit because “There is no nationally recognized
screening tool for the detection of cognitive im pairm ents at
the present tim e...” [9]. However, CMS recognizes that with
out clarification, the full intended benefits o f the AWV cogni
tive assessm ent may not be realized [10]. CM S is working
with other governmental agencies (e.g.. National Institutes
on A ging) on recom m endations for use of specific tools.
Understanding that, under the present regulation, each
healthcare provider who conducts an AWV would have to
determ ine how best to “detect cognitive im pairm ent,” the
A lzheim er’s Association convened the M edicare Detection
o f Cognitive Im pairm ent Workgroup to develop recom m en
dations for operationalizing the cognitive assessm ent com 
ponent in prim ary care settings. This workgroup was
com prised o f geographically dispersed U SA experts w ith
published works in the field of detecting cognitive im pair
m ent during primary care visits. The focus on prim ary care
was deliberate, as m ost M edicare beneficiaries will receive
their AWV in this setting.

2. Guiding principles for recommendations
2.1. Consensus on general principles
Based on their expertise, the workgroup agreed on the fol
lowing general principles to guide the developm ent o f rec
om m endations for cognitive assessment:

• Detection o f cognitive im pairm ent is a stepwise, itera
tive process.
• Inform al observation alone by a physician is not suffi
cient (i.e., observation w ithout a specific cognitive
evaluation).
• Detection of cognitive im pairm ent can be enhanced by
specifically asking about changes in memory, lan
guage, and the ability to com plete routine tasks.
• Although no single tool is recognized as the “gold stan
dard” for detection o f cognitive im pairm ent, an initial
structured assessm ent should provide either a baseline
for cognitive surveillance or a trigger for further eval
uation.
• Clinical staff can offer valuable observations o f cogni
tive and functional changes in patients who are seen
over time.
• Counseling before and after cognitive assessm ent is an
essential com ponent o f any cognitive evaluation.
• Inform ants (fam ily member, caregiver, etc.) can pro
vide valuable inform ation about the presence of
a change in cognition.
2.2.

Principles specific to the AWV

• The AWV requires the com pletion o f a H ealth Risk A s
sessment (HRA) by the patient either before or during
the visit. The HRA should be reviewed for any reported
signs and symptoms indicative o f possible dementia.
• The AWV will likely occur in a primary care setting.
Tools for initial cognitive assessm ents should be brief
(< 5 min), appropriately validated, easily adm inistered
by non-physician clinical staff, and available free of
charge for use in a clinical setting.
• If further evaluation is indicated based on the results of
the AWV, a m ore detailed evaluation of cognition
should be scheduled for a follow-up visit in primary
care or through referral to a specialist.

3.

Review of available brief tools for use during the AWV

3.1. Workgroup review process
Although there is no single cognition assessment tool that
is considered to be the gold standard, there is a plethora of
tools in the literature. A M EDLINE (PubM ed) search con
ducted in October 2011, using the key words “screening or
detection of dementia or cognitive impairment,” yielded
over 500 publications. To narrow the search to tools more
applicable to the AWV, the workgroup sought to determine
whether the literature offered a consensus regarding brief
cognitive assessment during tim e-lim ited primary care visits.
The workgroup focused on system atic evidence review
(SER) studies published since 2000 resulting in four studies
by Lorentz et al, Brodaty et al, Holsinger et al, and M ilne et al
[11—14]. Although each SER had a sim ilar objective— to
determine which tools were best for adm inistration during
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primary care visits— different com parison criteria to select
the tools were applied (Table 1). Two other studies were
also considered relevant to the developm ent o f the w ork
group recom m endations: Ismail et al [15] conducted a litera
ture review designed to identify widely used and most
prom ising new er brief cognitive tools being used in primary
care and geriatrics, and an SER by Kansagara and Freeman
[16] o f six brief cognitive assessm ent tools that could serve
as possible alternatives to the M ini-M ental State Exam ina
tion (M M SE) for use by the U.S. Departm ent o f Veterans
Affairs (VA). N either study was designed to determ ine which
brief tool is the “best,” but both provided evidence related to
prim ary care use and perform ance characteristics of brief
assessm ents o f cognition (Table 1).
3.2. Workgroup review results

1 H
i E#

I.

I-I

îÉ

O f the five publications that focused specifically on
identifying b rie f cognitive assessm ents m ost suitable or
m ost used in prim ary care settings [11-15], all selected
the M em ory Im pairm ent Screen (M IS), and four o f these
publications [11,12,14,15] also selected the G eneral
P ractitioner A ssessm ent o f Cognition (G PCO G ) and the
M ini-Cog (Table 2).
The follow ing attributes o f the GPCOG, M ini-Cog, and
the MIS contributed to their selection as most suited for rou
tine use in prim ary care:
• Requires 5 minutes or less to administer.
• Is validated in a prim ary care or com m unity setting.
• Is easily administered by m edical staff m em bers who
are not physicians.
• Has good to excellent psychom etric properties.
• Is relatively firee from educational, language, and/or
culture bias.
• Can be used by clinicians in a clinical setting w ithout
paym ent for copyrights.

•5 S
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Charging a fee for clinical use o f brief cognitive assess
m ent tool has becom e an issue because o f increased enforce
m ent o f the M M SE copyright. First published in 1975 [17],
the M M SE copyright is now held by Psychological Assess
m ent Resources, Inc., which charges a fee for each use (for
exact fees see www.parinc.com ). The com parative SER
within the VA [16] evaluated alternatives to the proprietary
M M SE, including the GPCOG and the M ini-Cog, along
with four other brief tools (Table 2). The M ini-Cog and
M IS are copyrighted, but the owners, Soo Borson, MD,
and A lbert Einstein CoUege o f M edicine, respectively, allow
free use by clinicians as clinical tools with distribution re
strictions for other entities (e.g., com m ercial com panies).
The GPCOG has sim ilar use rules.

3.3. Patient structured cognitive assessment tools
recommended fo r AWV
In alignm ent w ith the w orkgroup’s guiding principles
and supported by data in the six selected SER s/review s,
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Table 2
Brief cognitive assessment tools evaluated in multiple review articles
Assessment Tool
7-Minule Screener
AMT
CAMCOG
CDT
GPCOG
Mi ni-Cog
MIS
MMSE
MoCA
RUDAS
SAS-SI
SBT (BOMC, 6-CIT)
SPMSQ
STMS
T&C

Lorentz et al,
2002 [11]

Brodaty et al,
2006 [12]

Holsinger et al,
2007 [13]

Milne et al,
2008 [14]

Ismail et al,
2010 [15]

X

X
X
X
X
Most suited
Most suited
Most suited
X

X
X
Suited^
Suited^
X
X
Suited*
Suited*
Suited*

X
X

X

X
Most suited
Most suited
Most suited
X

X
X
X
X
X

X
X
X
X
X

X
X
X

X
Most suited
Most suited
Most suited
X

X
X

X
Most suited
Most suited
Most suited
X
X
X

Kansagara and
Freeman, 2010* [16]

X
X

X

X
X

Abbreviations: 6-CIT, 6-Item Cognitive Impairment Test; AMT, Abbreviated Mental Test; BOMC, 6-item Blessed Orientation-Memory-Concentration Test;
CAMCOG, Cambridge Cognitive Examination; CDT, Clock Drawing Test; GPCOG, General Practitioner Assessment of Cognition; MIS, Memory Impairment
Screen; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; RUDAS, Rowland Universal Dementia Assessment; SAS-SI, Short
and Sweet Screening Instrument; SBT, Short Blessed Test; SLUMS, St Louis Mental Status; SPMSQ, Short Portable Mental Status Questionnaire; STMS, Short
Test of Mental Status; T&C, Time and Change Test
X = assessment reviewed, but not identified as most suited for general use in primary care.
Suited — tool appropriate for the following clinical issue: f available time is not limited; f available time is limited; and § cognitive impairment is at least
moderate. Most suited — tool identified as most suited for routine use in primary care.
•Kansagara and Freeman evaluated six tools, including the SLUMS, which was not evaluated in any other review.

the GPCOG , M ini-Cog, and MIS are b rie f structured
tools that are suitable fo r assessm ent o f cognitive func
tion during the AWV. Each tool has unique benefits.
T he G PCO G has patient and inform ant com ponents
that can be used alone or together to increase specificity
and sensitivity [18]. The M ini-Cog has been validated in
population-based studies and in com m unity-dw elling
older adults heterogeneous with respect to language, cul
ture, and education [19-22]. The MIS is a verbally
adm inistered w ord-recall task that tests encoding as
w ell as retrieval [23], and is an option for patients who
have m otor im pairm ents that prevent use of paper and
pencil.

3.4. Structured cognitive assessment tools fo r use with
informants
C ognitive assessm ent com bined w ith inform antreported data im proves the accuracy o f assessm ent
[2 4 -2 7 ]. I f an inform ant is present during the AWV,
use o f a structured inform ant tool is recom m ended.
S im ilar to cognitive assessm ent tools for use with
patients, there is no single “gold standard” inform ant
tool; how ever, relatively few b rie f inform ant tools
have been validated in com m unity and/or prim ary care
settings. B rief tools appropriately validated include the
S hort IQ C O D E [25], the ADS [28], w hich can be ad
m inistered in-person or by telephone, and the aforem en
tioned GPCO G [18], w hich has both patient and
inform ant com ponents.

4. R ecom m ended alg o rith m fo r d etection of cognitive
im p a irm e n t d u rin g th e AWV

4.1. Incorporating assessment o f cognition during the
AWV
The A lzheim er’s Association M edicare Annual W ellness
Visit Algorithm for Assessm ent o f Cognition for consistency
(Figure 1) illustrates a stepwise process. The process is in
tended to detect patients with a high likelihood o f having de
m entia. The AWV algorithm includes both structured
assessm ents discussed previously and other less structured
patient- and inform ant-based evaluations. By assessing and
docum enting cognitive status on an annual basis during the
AWV, clinicians can more easily determ ine gradual cogni
tive decline over tim e in an individual patient— a key crite
rion for diagnosing dem entia due to A lzheim er’s disease and
other progressive conditions affecting cognition.
F or patients with a previous diagnosis o f M CI or dem en
tia, this should be docum ented and included in their AWV
list o f health risk factors. Annual unstructured and structured
cognitive assessm ents could be used to m onitor significant
changes in cognition and potentially lead to a new diagnosis
o f dem entia for those with MCI or new care recom m enda
tions for those with dementia.

4.2. Detection o f cognitive impairment during the AWV —
initial HRA review, conversations, and observations
The first step in detection of cognitive impairment during
the A W V (Fig. 1, Step A), involves a conversation between
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Medicare Annual Wellness Visit (HCPCS codes G0438 or G0439)
Review HRA (especially reports of functional deficits), clinician observations, and selfreported concerns; and query patient and, if available, informant
Yes

No

Signs/symptoms of cognitive
impairment present
No

Informant
confirm

Yes
Conduct brief structured assessment
Patieiu Assessment: GPCOG ot Mini-Cog or MIS
Informant assessment of patient: AD8 or GPCOG or Short IQCODE

Brief assessment(s) triggers concerns:
Patient: GPCOG <5 (5-8 score is indeterminate without
informant) or Mini-Cog s3 or MISs4
Informant: AD8 &2 or GPCOG informant score s3 with
patient score <8 or Short KJCODE s3.38

Follow-up during
subsequent AWV

No

Yes

Refer for full dementia evaluation or
Conduct fun dementia evaluation
If informant is available during AWV can follow up same day as AWV and bUl for E/M service with
CPT codes 99201-99215. If not, schedule new visit for evaluation and request presence of
family/companion to facilitate assessment.
* No one tool is recognized as the best brief assessment to determine if a full dementia evaluation is
needed. Alternate tools (eg. MMSE. SLUMS, or MoCA) can be used at the discretion of the clinician.
Some providers use multiple brief tools prior to referral or initiation of a full dementia evaluation.
A W V = A nnua] W elln ess V isit; G P C O G = G eneral P ra ctitioner A ssessm ent o f C ognition; H R A » H ealth R isk A ssessm ent;
MTS a M em o ry Im pairm ent S creen ; M M S E = M ini M ental S tatu s E xam ; M oC A = M o ntreal C og n itiv e A ssessm ent; S L U M S =
St. L o u is U niversity M ental S tatu s E x am ; S hort IQ C O D E = short Inform ant Q uestionnaire on C ognitive D ec lin e in the E lde rly

Fig. 1. Alzheimer’s Association Medicare Annual Wellness Visit Algorithm for Assessment of Cognition.

a clinician and the patient and, if present, any family member
or other person who can provide collateral information. This
introduces the purpose and content of the AWV, which in
cludes: a review o f the HRA; observations by clinicians
(medical and associated staff); acknowledgment of any selfreported or informant-reported concerns; and conversational
queries about cognition directed toward the patient and others
present. If any concerns are noted, or if an informant is not
present to provide confirmatory information, further evalua
tion of cognition with a structured tool should be performed.
Patient completion of an HRA is a required element o f the
AWV and can be accomplished with the help of a family m em 
ber or other knowledgeable informants, including a profes
sional caregiver. Published CMS guidance offers healthcare
professionals flexibility as to the specific format, questions,
and delivery methods that can be used for an AWV HRA
[29], The following questions may be suitable for the AWV
HRA and have been tested and evaluated in the general popu

lation through the Behavioral Risk Factor Surveillance System
or presented as HRA example questions:
1. During the past 12 m onths, have you experienced con
fusion or memory loss that is happening m ore often or
is getting worse [30]?
2. During the past 7 days, did you need help with others
to perform everyday activities such as eating, getting
dressed, groom ing, bathing, walking, or using the toi
let [29]?
3. During the past 7 days, did you need help from others
to take care of things such as laundry and housekeep
ing, banking, shopping, using the telephone, food
preparation, transportation, or taking your own m edi
cations [29]?
A noted deficit in activities of daily living (ADLs) (e.g.,
eating and dressing) or instrum ental activities o f daily living
(lADLs) (e.g., shopping and cooking) that caimot be
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attributed to physical lim itations should prom pt concern, as
there is a strong correlation betw een decline in function and
decline in cognitive status across the full spectrum o f dem en
tia [31]. In addition to clinically observed concerns, any pa
tient- or inform ant-reported concerns should trigger further
evaluation [13]. Positive responses to conversational
queries, such as “Have you noticed any change in your m em 
ory or ability to complete routine tasks, such as paying bills
or preparing a m eal?” should be followed up with a struc
tured assessm ent o f cognition.
U pon realizing the tim e constraints o f a typical primary
care visit, if no cognitive concerns surface during the initial
evaluation and this inform ation is corroborated by an infor
m ant, the clinician may elect not to perform a structured cog
nitive assessm ent and assume that the patient is not currently
dem ented. This approach is supported by studies in popula
tions with low rates of dem entia that suggest the absence of
memory difficulties reported by inform ants and patients re
duces the likelihood that dem entia is present [32,33].

4.3. Structured cognitive assessment tools fo r use with
patients and informants during the AWV
The second step in detection o f cognitive im pairm ent dur
ing the AWV (Figure 1, Step B) requires cognitive assess
m ent using a structured tool. Based on synthesis o f data
from the six review articles previously discussed, patient
tools suitable for the initial structured assessm ent are the
GPCOG, Mini-Cog, and MIS.
Recognizing that there is no single optim al tool to detect
cognitive im pairm ent for all patient populations and set
tings, clinicians may select other brief tools to use in their
clinical practice, such as those listed in Table 3. The 15 brief
tools listed were evaluated in m ultiple review articles
(passed through at least two review search criteria for tools
possibly suited for prim ary care) or are used in the VA. Tools
listed in Table 3 are subject to the inclusion/exclusion crite
ria o f each review and do not represent the entire listing of
the > 1 0 0 brief cognitive assessm ent tools that m ay be suit
able for prim ary care practices.
If an inform ant is present, defined as som eone who can
attest to a patient’s change in memory, language, o r function
over tim e, it is suitable to use the AD8, the inform ant com 
ponent o f the GPCOG, or the Short IQCODE, during the
AWV.

4.4. Primary care workflow considerations
A ccording to the algorithm , any patient who does not
have an inform ant present should be assessed w ith a struc
tured tool. For such patients (and for practices that im ple
m ent structured assessm ents during all AWVs), com pletion
o f this structured assessment can be adm inistered by trained
m edical staff as the first step for cognitive im pairm ent detec
tion. This could improve office efficiency. To increase ac
ceptance of a structured assessm ent, the reason provided to

the patient can be norm alized with a statem ent such as,
“This is something I do for all o f my older patients as part
of their annual visit.” W hen the initial assessm ent prompts
further evaluation, explanation of results should be deferred
until a more comprehensive evaluation has been completed.
“T here are many reasons for not getting every answer cor
rect. M ore evaluation will help us determ ine that,” is an ex
am ple statem ent that m ay encourage patients to pursue
further testing.

5. Full dementia evaluation
Patients with assessm ents that indicate cognitive im 
pairm ent during the AWV should be further evaluated to
determ ine appropriate diagnosis (e.g., M CI, A lzheim er’s
disease) or to identify other causes. As reflected in the algo
rithm (Figure 1, Step C), initiation of a full dem entia evalu
ation is outside the scope o f the AWV, but can occur in
a separate visit either on the same day, during a newly sched
uled visit, or through referral to a specialist. Specialists who
have expertise in diagnosing dem entia include geriatricians,
geriatric psychiatrists, neurologists, and neuropsychologists.
The tw o-visit approach has been cited as a tim e-effective
process to evaluate suspected dem entia in primary care
[34] and is consistent with the tw o-step approach widely
used in epidem iologic research on dementia. Regardless of
the tim ing and setting, clinicians are encouraged to counsel
patients to include an inform ant in the diagnostic process.
Com ponents o f a full dem entia evaluation can vary de
pending on the presentation and include tests to rule in or
out the various causes o f cognitive im pairm ent and establish
its severity. Diagnostic evaluations include a com plete m ed
ical history; assessm ent of m ultiple cognitive domains, in
cluding episodic memory, executive function, attention,
language, and visuospatial skills; neurologic exam (gait, m o
tor function, reflexes); ADL and lA D L functioning; assess
m ent for depression; and review for medications that may
adversely affect cognition. Standard laboratory tests include
thyroid-stim ulating horm one (TSH), com plete blood count
(CBC), serum B 1 2 , folate, com plete m etabolic panel, and,
if the patient is at risk, testing for sexually transm itted dis
eases (human imm unodeficiency virus, syphilis). Structural
brain imaging, including m agnetic resonance imaging
(M RI) or computed tom ography (CT), is a supplemental
aid in the differential diagnosis o f dem entia, especially if
neurologic physical exam findings are noted. An M RI or
CT can be especially informative in the following cases: de
m entia that is o f recent onset and is rapidly progressing;
younger onset dem entia (< 6 5 years o f age); history of
head traum a; or neurologic symptom s suggesting focal
disease.

6. Discussion
Unfortunately, up to 81 % of patients who m eet the crite
ria for dem entia have never received a docum ented diagnosis
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Table 3
Key advantages and limitations of brief cognitive assessment tools evaluated in multiple reviews and/or for use in the VA
Assessment*

Time ( —min)

Advantages

Limitations

7-Minute Screener [48]

7-12

AMT [49]

5-7

•
•
•
•

•
•
•
•
•

CAMCOG [50]

20

• Tests many separate domains (7)

Little or no education bias
Validated in primary care
Easy to administer
Verbal memory test (no writing/drawing)

Difficult to administer
Complex logarithmic scoring
Education/language/culture bias
Limited use in US (mostly used in Europe)
Does not test executive function or visuospatial
skills
• Difficult to administer
• Long administration time
• Lacks standards for administration and scoring

CDT [51]

<1

• Very brief administration time
• Minimal education bias

GPCOG^ [18]
Patient
Informant

2-5
1-3

Mini-Cogt [8, 19]

2-4

MIS [23.52]

4

MMSE [17]

7-10

• Developed for and validated in primary care
• Informant component useful when initial
complaint is informant-based
• Little or no education bias
• Multiple languages accessible at www.gpcog.
com.au
• Developed for and validated in primary care
and multiple languages/cultures
• Little or no education/language/race bias
• Short administration time
• Verbal memory test (no writing/drawing)
• Little or no education bias
• Most widely used and studied worldwide
• Often used as reference for comparative eval
uations of other assessments
• Required for some drug insurance reimbtuse-

MoCAt [53]

10-15

• Designed to test for mild cognitive impairment
• Multiple languages accessible at www.
mocatestorg
• Tests many separate domains (7)

RUDAS [54]

10

• Designed for multicultural populations
• Little or no education/language bias

SAS-SI [55]

10

• Detected dementia better than netirupsychologic testing in a coinmunity population

« Does not test executive function or visuospatial
skills
• Education/age/language/culture bias
• Ceiling effect (highly educated impaired subjects
pass)
• Proprietary— unless used from memory, test needs
to be purchased at www.parinc.com
• Best performance for at least moderate cognitive
impairment
• Lacks studies in general practice settings
• Education bias (<12 years)
■ Limited use and evidence due to published data
relatively new (2005)
a Admin time >10 min
a Validated in Australian community
a Limited use and evidence due to published data
relatively new (2004)
a Does not test memory
a Lacks data on any education/language/culture

SBT (BOMC^ and
6-CIT) [56.57]

4-6

• Verbal test (no writing/drawing)

a

SLUMSt [58]

7

• Patient component scoring has an indeterminate
range that requires an informant score to assess as
pass or fail
• Informant component alone has low specificity
• Lacks data on any language/culture biases
• Use o f different word lists may affect failure rates
• Some study results based on longer tests with the
Mini-Cog elements reviewed independently

a
a

SPMSQ [59]

3 -4

» No education bias
• Tests many separate domains (7)
• Available at; http://aging.slu.edu/pdfsurveys/
mentalstatus.pdf
• Verbal test (no writing/drawing)

a

a

a
a

STMS^ [60]

T&C [61]

5

• Validated in primary care
• Tests many separate domains (7)

a

<1

• Very brief administration time
• Little or no education bias

a

a

Education/language/cultural/race bias
Scoring can be cumbersome
Does not test executive function
Limited use and evidence due to published data
relatively new (2006)
Studied in VA geriatric clinic (predominantly white
Scoring can be cumbersome
Does not test short-term memory
Education/language/race bias
Studied in relatively educated subjects, may not be
applicable to general population
Strong language/cultural bias

Abbreviations: 6-CIT, 6-Item Cognitive Impairment Test; AMT, Abbreviated Mental Test; BOMC, 6-item Blessed Orientation-Memcny-Concentration Test;
CAMCOG, Cambridge Cognitive Examination; CDT. Clock Drawing Test; GPCOG, General Practitioner Assessment of Cognition; MIS, Memory Impairment
Screen; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; RUDAS, Rowland Universal Dementia Assessment; SAS-SI, Short
and Sweet Screening Instrument; SBT, Short Blessed Test; SLUMS, St Louis University Mental Status; SPMSQ, Short Portable Mental Status Questioimaire;
STMS, Short Test of Mental Status; T&C, Time and Change Test.
♦References provide descriptions of assessments.
% rief tools used in the VA healthcare system reviewed by Kansagara and Freeman.
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[35]. D elayed or m issed diagnosis deprives affected individ
uals o f available treatments, care plans, and services that can
im prove their sym ptoms and help m aintain independence.
Studies show that interventions tailored to patients with de
m entia can improve quality o f care, reduce unfavorable
dem entia-related behaviors, increase access to community
services for both the patient and their caregivers, and result
in less caregiver stress and depression [36-42], Early
diagnosis o f dem entia also provides fam ilies and patients
an opportunity to plan for the future w hile the affected
individual is still able to participate in the decision-m aking
processes.
Early detection and medical record docum entation may
im prove medical care. The m edical record could inform
all clinicians, including those who may be managing com or
bidities on a sporadic basis, that treatm ent and care should be
adjusted to accom m odate cognitive im pairm ent. According
to a 2004 M edicare beneficiary survey, am ong patients
w ith dem entia, 26% had coronary heart disease, 23% had di
abetes, and 13% had cancer [43].
It is im portant to note that the unstructured and structured
cognitive assessm ents being recom m ended for the AWV are
only the first steps in diagnosing dem entia, and cognitive as
sessment is best as an iterative process. For example, clini
cians concerned with HRA inform ation about decline in
function may proceed directly to a structured assessment
o r continue to query the patient for additional information;
a self-reported memory concern coupled with a failed struc
tured cognitive assessm ent should always result in a full de
m entia evaluation.
N ot all who are referred for further assessm ent will u l
tim ately receive a dem entia diagnosis. In a U SA prim ary
care population aged > 65 years (N = 3340), 13% failed
a b rief screen for cognitive im pairm ent and approxi
m ately half (n = 227) agreed to be further evaluated
for dem entia [7]. A m ong the 107 patients ultim ately d i
agnosed w ith dem entia, 81% were newly diagnosed
based on the absence o f any m edical record o f dem entia,
thus facilitating appropriate m edical and psychosocial in
terventions [7].
Despite the m any advantages o f early dem entia diagno
sis, several barriers to diagnosis still exist. These include
physician concerns of the time burden resulting from testing
and counseling [35] and stigm a concerns among physicians,
patients, and caregivers [35,44,45]. Despite these barriers,
successful w idespread im plem entation of a brief cognitive
assessm ent has been reported. M cCarten et al [22] evaluated
the M ini-Cog for routine cognitive assessm ent o f veterans
presenting for primary care. O f the 8342 veterans ap
proached, > 96% agreed to be assessed and those that failed
the brief assessm ent exhibited no serious reactions upon dis
closure o f test results.
T he AWV provides an unprecedented opportunity to
overcome current barriers and initiate discussions about cog
nitive function among the growing population m ost at risk

for A lzheim er’s disease. Detection o f cognitive im pairm ent
during the AWV is further supported by previously pub
lished quality indicators that state all vulnerable elders (de
fined as persons > 65 years who are at risk for death or
functional decline) should be evaluated annually for cogni
tive and functional status [46].
There are lim itations to these recom m endations. They
are based on assessm ent o f recom m endations from review
articles and on expert opinion, not on a new, comprehensive
review o f original research to define the optim al approach
to detection o f cognitive im pairm ent or review o f emerging
technologies that could assist in testing (e.g., use of online
or electronic tablet applications). Further com plicating
SERs o f brief cognitive assessm ent tools is that sensitivity
and specificity will vary depending on the dem entia preva
lence o f the study population, the tool(s) used, and the cut
score selected for each tool. Brodaty et al [12] recognized
that published research concerning cognitive im pairm ent
screening tools is uneven in quantity and quality. The liter
ature also is lacking in com parative validity o f brief cogni
tive assessm ent tools in low-education or illiterate
populations.
The A lzheim er’s Association M edicare Annual Wellness
Visit Algorithm for Assessm ent o f Cognition is based
on current validated tools and com m only used rule-out
assessments. The use o f biom arkers (e.g., CSF tau and
beta am yloid proteins, am yloid tracer positron em ission
tom ography scans) was not considered as these measures
are not currently approved or widely available for clinical
use.
In 2011, greater than two m illion M edicare beneficiaries
received their AWV preventive service [47]. There are no
data available as to w hat methods were used to detect cogni
tive im pairm ent or how m any beneficiaries were assessed
as having cognitive impairment. For future AWVs, the
A lzheim er’s Association M edicare Annual W ellness Visit
A lgorithm for Assessm ent of Cognition provides guidance
to primary care practices on a process to operationalize
this required AWV element. W ith w idespread im plem enta
tion o f the algorithm, the AWV could be the first step in re
ducing the prevalence o f m issed or delayed dem entia
diagnoses, thus allowing for better healthcare m anagem ent
and more favorable outcomes for affected patients and their
fam ilies and caregivers.
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( R E S E A R C H IN C O N T E X T

1. Systematic review: Our research included com paring
five system atic evidence reviews (SER) of brief de
m entia screening tools published since 2000 and
a 2010 literature review of newer brief assessm ents
of cognition. Our research focused on determ ining
if there was a consensus among the published SERs
as to which tool is most suited for primary care and
if there were any com mon results across the publica
tions.
2. Interpretation: Our research concluded there is a con
sensus in the literature concerning suitable tools for
screening for dem entia in primary care. We also reaf
firmed that many validated tools are available, and
that screening for dem entia should not be solely
based on a tool, but should be a stepwise process to
include other assessments.
3. Future directions: Further validation of existing and
emerging screening tools (e.g., iPad applications,
gait m onitoring) may result in newer tools being rec
ognized more suitable and practical for primary care
settings.
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APPENDIX F
Mild Cognitive Impairment Screening Survey
If you agree to take this survey, your answers serve as your consent. If you would like
to receive the results and implications from this study, please provide your email
address below. (Answers will not be associated with email addresses when statistics are
analyzed; survey responses will remain completely anonymous.)

Questions:
1. In what state do you primarily practice?

2. What is your professional title?
a. MD
b. NP
c. PA
3. What is your primary area of practice?
a. Family Practice
b. Internal Medicine
c. Geriatrics/Long Term Care
d. Urgent Care
e. Emergency Room
4. What is your age?
a. 21-35
b. 36-50
c. 51-65
d. 65+
5. Which response best describes your screening practices for Mild Cognitive
Impairment in patients aged 65 and older?
a. I do not screen patients for Mild Cognitive Impairment.
b. I screen patients if they or their family mention a concern over memory
problems or a decline in ability to perform AD L’s.
c. I screen every patient aged 65 and older every year at their wellness visit.
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6. If a patient over 65 years o f age comes into your clinic without any obvious
signs o f cognitive impairment, how likely are you to screen this patient for Mild
Cognitive Impairment?
a. I will not screen
b. I am not likely to screen
c. I am somewhat likely to screen
d. I will very likely screen
7. Which factor/factors make you more likely to screen patients over 65 years of
age for Mild Cognitive Impairment? *Choose all relevant answers.
a. Patient has not been screened in at least 12 months
b. Patient’s family mentions deterioration or changes in patient’s behavior
c. Patient appears somewhat “lost” in the conversation
d. Patient admits to forgetfulness or memory loss issues
e. Guidelines that dictate how often the patient should be screened
f. O ther_____________
8. Which factor/factors make you less likely to screen patients over 65 years o f age
for Mild Cognitive Impairment? *Choose all relevant answers.
a. Concerns over unnecessary testing.
b. Lack o f clear guidelines as to when and how to screen
c. Lack o f guidelines as to which screening tool to use
d. Lack o f adequate time with each patient
e. O ther_____________
9. W hen/If you do screen patients for Mild Cognitive Impairment, what screening
tool do you use?
a. Mini Mental State Examination
b. Short Portable Mental Status Questionnaire (SPMSQ)
c. Mini-Cog
d. Clock Test
e. 3 Word Recall Test
f. Health Risk Assessment
g. Another screening tool
h. I do not use any screening tools
10. Does your current clinic/place o f employment have set guidelines in place for
screening for Mild Cognitive Impairment?
a. Yes
b. No

